Christopher Bull Granger
Professor of Medicine
Research:
My primary research interest is in conduct and methodology of large randomized clinical trials in heart disease. I have led a number of large international clinical studies in heart attacks, unstable angina, heart failure, and atrial fibrillation. I have lead clinical studies of blood thinners and coronary intervention for heart attacks, stroke prevention in atrial fibrillation, and prevention of heart attack for patients with coronary artery disease. I have been co-director of the Reperfusion of Acute MI in Carolina Emergency Departments (RACE) project that is a North Carolina state-wide program to improve reperfusion care for acute myocardial infarction. I serve as the Chairman of the American Heart Association Mission: Lifeline program to improve heart attack care nationally as well as the American College of Cardiology/American Heart Association guideline committee for heart attack care. I have also studied the effects of genetic variation on heart disease. I work with the National Institute of Health and the Federal Drug Administration on evaluation of heart disease and of new drugs. I have developed tools to predict which patients are at risk for death, heart attack, and need for hospitalization.
My primary research interest is in conduct and methodology of large randomized clinical trials in heart disease. I have led a number of large international clinical studies in heart attacks, unstable angina, heart failure, and atrial fibrillation. I have lead clinical studies of blood thinners and coronary intervention for heart attacks, stroke prevention in atrial fibrillation, and prevention of heart attack for patients with coronary artery disease. I have been co-director of the Reperfusion of Acute MI in Carolina Emergency Departments (RACE) project that is a North Carolina state-wide program to improve reperfusion care for acute myocardial infarction. I serve as the Chairman of the American Heart Association Mission: Lifeline program to improve heart attack care nationally as well as the American College of Cardiology/American Heart Association guideline committee for heart attack care. I have also studied the effects of genetic variation on heart disease. I work with the National Institute of Health and the Federal Drug Administration on evaluation of heart disease and of new drugs. I have developed tools to predict which patients are at risk for death, heart attack, and need for hospitalization.
Current Appointments & Affiliations
- Professor of Medicine, Medicine, Cardiology, Medicine 2007
- Professor in the School of Nursing, School of Nursing, Duke University 2015
- Member in the Duke Clinical Research Institute, Duke Clinical Research Institute, Institutes and Centers 1988
Contact Information
- 200 Morris Street, Durham, NC 27701
- Duke Box 3409, Durham, NC 27710
-
grang001@mc.duke.edu
(919) 668-8900
- Background
-
Education, Training, & Certifications
- Fellow in Cardiology, Medicine, Duke University 1988 - 1990
- Chief Medical Resident, Medicine, University of Colorado Denver, School of Medicine 1987 - 1988
- Medical Resident, Medicine, University of Colorado Denver, School of Medicine 1984 - 1987
- M.D., University of Connecticut 1984
-
Previous Appointments & Affiliations
- Associate Professor of Medicine with Tenure, Medicine, Cardiology, Medicine 2000 - 2007
- Associate Professor of Medicine, Medicine, Cardiology, Medicine 1998 - 2000
- Assistant Professor of Medicine, Medicine, Cardiology, Medicine 1993 - 1998
- Associate in the Department of Medicine, Medicine, Clinical Science Departments 1990 - 1993
- Recognition
-
In the News
-
MAY 4, 2023 Duke Today -
NOV 19, 2019 -
NOV 27, 2018 -
NOV 15, 2017 Duke Health News -
AUG 28, 2017 Duke Health News -
AUG 3, 2016 Fox News -
NOV 20, 2014 Duke Today
-
-
Awards & Honors
- "World Expert" PubMed-based algorithms. Expertscape . 2021
- "World Expert". Expertscape . 2021
- Highly Cited Researcher. Clarivate Analytics . 2021
- Robert M Califf Award for Outstanding Mentorship. Duke Clinical Research Institute . 2021
- Highly Cited Researcher. Clarivate Analytics . 2020
- ARISTOTLE trial selected as one of "Drazen's Dozen". New England Journal of Medicine. 2019
- Highly Cited Researcher. Clarivate Analytics . 2019
- Highly Cited Researcher. Clarivate Analytics. 2018
- Keynote Speaker. European Society of Cardiology Acute Cardiovascular Care. 2018
- Highly Cited Researcher. Clarivate Analytics. 2017
- Excellence in Professionalism Award, School of Medicine. Duke School of Medicine. 2016
- Highly Cited Researcher. Clarivate Analytics (formerly Thompson Reuters). 2016
- Lumen Achievement Award. Lumen Global. 2016
- AHA Gold Standard Board Award, Triangle Metro Board . American Heart Association. 2015
- Highly Cited Researcher. Thompson Reuters . 2015
- Highly Cited Researcher (top 1% of all biomedical researchers, including 3 of the 1899 clinical faculty at Duke). Thompson Reuters. 2014
- Doctor Honoris Causa. "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2013
- Top 10 Clinical Research Achievement Awards in the United States for 2012. Clinical Research Forum. 2012
- Top Ten Research Advances 2007 (RACE Program). American Heart Association. 2007
- Expertise
-
Subject Headings
- Acute Coronary Syndrome
- Adenosine
- Advance Directives
- Aged, 80 and over
- Ambulances
- American Heart Association
- Amiodarone
- Angina Pectoris
- Angina, Unstable
- Angioplasty
- Angioplasty, Balloon, Coronary
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Anticoagulants
- Antihypertensive Agents
- Antithrombins
- Aspirin
- Atherosclerosis
- Atrial Fibrillation
- Biomedical Research
- Blood Coagulation Factors
- Blood Coagulation Tests
- Blood Platelets
- Blood Pressure
- Body Mass Index
- Bundle-Branch Block
- Cardiac Care Facilities
- Cardiology
- Cardiopulmonary Resuscitation
- Cardiovascular Diseases
- Chest Pain
- Clinical Protocols
- Confidence Intervals
- Coronary Artery Disease
- Coronary Care Units
- Creatinine
- Critical Pathways
- Double-Blind Method
- Evidence-Based Medicine
- Factor Xa
- Fibrinolytic Agents
- Genome, Human
- Heart Failure
- Hemorrhage
- Hemostasis
- Heparin
- Hypertension
- Individualized Medicine
- Informed Consent
- Intensive Care
- International Normalized Ratio
- Kaplan-Meier Estimate
- Kidney Diseases
- Medication Adherence
- Medication Errors
- Monitoring, Physiologic
- Mortality
- Multivariate Analysis
- Myocardial Infarction
- Myocardial Reperfusion
- Myocardial Revascularization
- National Institutes of Health (U.S.)
- Out-of-Hospital Cardiac Arrest
- Plasminogen Activators
- Protein Kinase Inhibitors
- Proteomics
- ROC Curve
- Randomized Controlled Trials as Topic
- Registries
- Renal Dialysis
- Renal Insufficiency
- Reperfusion Injury
- Research
- Risk Assessment
- Risk Factors
- Shock, Cardiogenic
- Stroke
- Survival Analysis
- Tachycardia, Ventricular
- Thrombocytopenia
- Thromboembolism
- Thrombolytic Therapy
- Thrombosis
- Time-to-Treatment
- Tissue Plasminogen Activator
- Troponin T
- Ventricular Fibrillation
- Vitamin K
- Warfarin
- p38 Mitogen-Activated Protein Kinases
- Research
-
Selected Grants
- Stimulating Access to Research in Residency (StARR) - NHLBI awarded by National Institutes of Health 2018 - 2028
- CCC: The Regional Approaches to Cardiovascular Emergencies- Cardiac ARreSt (RACE-CARS) Cluster-Randomized Trial 1/2 awarded by National Institutes of Health 2020 - 2027
- Integrated Biostatistical Training for CVD Research awarded by North Carolina State University 2022 - 2027
- Shingrix awarded by Harvard Pilgrim Health Care, Inc. 2023 - 2025
- RECOVER Auto Dysfunction Protocol awarded by Research Triangle Institute International 2022 - 2024
- Printed Electronic Biosensors for Point-of-Care Testing of Cardiovascular Biomarkers awarded by National Institutes of Health 2019 - 2024
- Postdoctoral Training in Cardiovascular Clinical Research awarded by National Institutes of Health 2003 - 2024
- PARADISE awarded by Novartis Pharmaceuticals Corporation 2017 - 2022
- COORDINATE Diabetes Study awarded by Boehringer Ingelheim Pharmaceuticals, Inc. 2018 - 2022
- HeartRescue awarded by University of Washington 2016 - 2021
- Effect of monitoring system design on response time to cardiac arrhythmias awarded by Agency for Healthcare Research and Quality 2015 - 2021
- Prehospital Termination of Resuscitation in Out-of-Hospital Cardiac Arrest awarded by Society for Academic Emergency Medicine 2019 - 2020
- Evaluating and Improving Cardiac Arrest Resuscitation Efforts in Hemodialysis Clinics awarded by National Institutes of Health 2017 - 2020
- Janssen AF Quality Improvement Research Study awarded by Janssen Pharmaceutica, Inc. 2017 - 2019
- Implementation of Demonstration Project for Health Systems: Atrial Fibrillation(INFORM-AF) awarded by Janssen Scientific Affairs, LLC. 2016 - 2019
- Regional Systems Accelerator: Implementation of the AHA Mission (TMC) awarded by The Medicines Company 2016 - 2017
- Heart Rescue Flagship Premier Partner Program "RACE CARs" awarded by Medtronic Foundation 2013 - 2017
- HeartRescue awarded by University of Washington 2016 - 2017
- Workload effects on response time to life-threatening arrhythmias awarded by Agency for Healthcare Research and Quality 2012 - 2014
- Rare Thrombotic Diseases Clinical Research Network awarded by National Institutes of Health 2004 - 2010
- GENECARD: Gene identification in Early-Onset CAD awarded by National Institutes of Health 2003 - 2009
- DCRI CERT for Cardiovascular Therapies awarded by National Institutes of Health 1999 - 2002
-
External Relationships
- Abiomed, Inc.
- Alnylam Pharmaceutical, Inc.
- Anthos
- Bayer Healthcare Pharmaceuticals, Germany
- Boehringer Ingelheim/Lilly alliance
- Boston Scientific Corporation
- Bristol Myers Squibb
- Cardionomic
- Celecor
- FDA
- Janssen Pharmaceuticals
- Medtronic
- Merck
- Nephrosynergy
- Novartis pharmaceuticals
- Novo Nordisk
- Pfizer Inc.
- Phillips
- Reata Pharmaceuticals, Inc.
- tenacio
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of clinical trials. 2015.Full Text
-
-
Academic Articles
-
Hijazi Z, Lindbäck J, Oldgren J, Benz AP, Alexander JH, Connolly SJ, et al. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J. 2023 Jul;261:55–63.Full Text Link to Item
-
Benz AP, Hohnloser SH, Eikelboom JW, Carnicelli AP, Giugliano RP, Granger CB, et al. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. Eur Heart J. 2023 May 21;44(20):1807–14.Full Text Link to Item
-
Jering KS, Claggett BL, Pfeffer MA, Granger CB, Køber L, Lewis EF, et al. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circ Heart Fail. 2023 May;16(5):e010259.Full Text Link to Item
-
Rikken SAOF, Bor WL, Selvarajah A, Zheng KL, Hack AP, Gibson CM, et al. Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa study. Am Heart J. 2023 Apr 22;262:75–82.Full Text Link to Item
-
Pagidipati NJ, Nelson AJ, Kaltenbach LA, Leyva M, McGuire DK, Pop-Busui R, et al. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. Jama. 2023 Apr 18;329(15):1261–70.Full Text Link to Item
-
Harrington J, Carnicelli AP, Hua K, Wallentin L, Patel MR, Hohnloser SH, et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation. 2023 Apr 12;Full Text Link to Item
-
Butt JH, Claggett BL, Miao ZM, Jering KS, Sim D, van der Meer P, et al. Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial. Eur J Heart Fail. 2023 Apr 11;Full Text Link to Item
-
Lakkireddy DR, Segar DS, Sood A, Wu M, Rao A, Sohail MR, et al. Early Lead Extraction for Infected Implanted Cardiac Electronic Devices: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 Apr 4;81(13):1283–95.Full Text Link to Item
-
Barker M, Sekhon M, Krychtiuk KA, van Diepen S, Alviar CL, Granger CB, et al. Targeted Temperature Management After Out-of-Hospital Cardiac Arrest: Integrating Evidence Into Real World Practice. Can J Cardiol. 2023 Apr;39(4):385–93.Full Text Link to Item
-
Nanna MG, Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, et al. Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease. J Am Geriatr Soc. 2023 Apr;71(4):1243–9.Full Text Link to Item
-
Primary Panel, Fordyce CB, Kramer AH, Ainsworth C, Christenson J, Hunter G, et al. Neuroprognostication in the Post Cardiac Arrest Patient: A Canadian Cardiovascular Society Position Statement. Can J Cardiol. 2023 Apr;39(4):366–80.Full Text Link to Item
-
Rikken SAOF, Selvarajah A, Hermanides RS, Coller BS, Gibson CM, Granger CB, et al. Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial. Am Heart J. 2023 Apr;258:119–28.Full Text Link to Item
-
Harrington J, Piccini JP, Alexander JH, Granger CB, Patel MR. Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 Feb 28;81(8):771–9.Full Text Link to Item
-
Carnicelli AP, Keane R, Brown KM, Loriaux DB, Kendsersky P, Alviar CL, et al. Characteristics, therapies, and outcomes of In-Hospital vs Out-of-Hospital cardiac arrest in patients presenting to cardiac intensive care units: From the critical care Cardiology trials network (CCCTN). Resuscitation. 2023 Feb;183:109664.Full Text Link to Item
-
Granger CB, Pocock SJ, Gersh BJ. The need for new clinical trials of old cardiovascular drugs. Nat Rev Cardiol. 2023 Feb;20(2):71–2.Full Text Link to Item
-
Nelson AJ, Pagidipati NJ, Kelsey MD, Ardissino M, Aroda VR, Cavender MA, et al. Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design. Am Heart J. 2023 Feb;256:2–12.Full Text Link to Item
-
Hijazi Z, Benz AP, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. Eur Heart J. 2023 Jan 14;44(3):208–18.Full Text Open Access Copy Link to Item
-
Schwamm LH, Kamel H, Granger CB, Piccini JP, Katz JM, Sethi PP, et al. Predictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: A Prespecified Secondary Analysis of the STROKE AF Randomized Clinical Trial. Jama Neurol. 2023 Jan 1;80(1):99–103.Full Text Link to Item
-
Krychtiuk KA, Rader DJ, Granger CB. RNA-targeted therapeutics in cardiovascular disease: the time is now. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):94–9.Full Text Link to Item
-
Harrington J, Granger CB. Bleeding and risk for future cardiovascular events in patients with atrial fibrillation on oral anticoagulation: major bleeding is a major problem. Eur Heart J. 2022 Dec 14;43(47):4909–11.Full Text Link to Item
-
Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, et al. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 2022 Dec 6;146(23):1749–57.Full Text Link to Item
-
Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022 Dec 6;146(23):1735–45.Full Text Link to Item
-
Bagai A, Ali FM, Gregson J, Alexander KP, Cohen MG, Sundell KA, et al. Multimorbidity, functional impairment, and mortality in older patients stable after prior acute myocardial infarction: Insights from the TIGRIS registry. Clin Cardiol. 2022 Dec;45(12):1277–86.Full Text Link to Item
-
Garcia A, Lee J, Balasubramanian V, Gardner R, Gummidipundi SE, Hung G, et al. The development of a mobile app-focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials. Stat (Int Stat Inst). 2022 Dec;11(1):e470.Full Text Link to Item
-
Krychtiuk KA, Granger CB. In older men, an invitation for comprehensive CV screening did not reduce death at 5.6 y. Ann Intern Med. 2022 Dec;175(12):JC140.Full Text Link to Item
-
Jollis JG, Granger CB, Zègre-Hemsey JK, Henry TD, Goyal A, Tamis-Holland JE, et al. Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021. Jama. 2022 Nov 22;328(20):2033–40.Full Text Link to Item
-
Nelson AJ, Pagidipati NJ, Granger CB. Reply: High-Dose Statins Increase Adverse Events and Do Not Improve Survival. J Am Coll Cardiol. 2022 Oct 18;80(16):e127.Full Text Link to Item
-
Berwanger O, Pfeffer M, Claggett B, Jering KS, Maggioni AP, Steg PG, et al. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. Eur J Heart Fail. 2022 Oct;24(10):1918–27.Full Text Link to Item
-
Dubé M-P, Chazara O, Lemaçon A, Asselin G, Provost S, Barhdadi A, et al. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. Esc Heart Fail. 2022 Oct;9(5):2997–3008.Full Text Link to Item
-
Engel JR, Lindsay M, O’Brien S, Granger CB, Moore ES, Hughes T, et al. Health System Redesign of Cardiac Monitoring Oversight to Optimize Alarm Management, Safety, and Staff Engagement. J Nurs Adm. 2022 Oct 1;52(10):511–8.Full Text Link to Item
-
Rao VN, Kaltenbach LA, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, et al. The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF. J Card Fail. 2022 Oct;28(10):1487–96.Full Text Link to Item
-
Al-Khatib SM, Wojdyla DM, Granger CB, Wallentin L, Garcia DA, Hijazi Z, et al. Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Circulation. 2022 Sep 20;146(12):958–60.Full Text Link to Item
-
Amon J, Wong GC, Lee T, Singer J, Cairns J, Shavadia JS, et al. Incidence and Predictors of Adverse Events Among Initially Stable ST-Elevation Myocardial Infarction Patients Following Primary Percutaneous Coronary Intervention. J Am Heart Assoc. 2022 Sep 6;11(17):e025572.Full Text Link to Item
-
Aulin J, Hijazi Z, Lindbäck J, Alexander JH, Gersh BJ, Granger CB, et al. Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. Am Heart J. 2022 Sep;251:13–24.Full Text Link to Item
-
Cantor WJ, Tan M, Berwanger O, Lavi S, White HD, Nicolau JC, et al. Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. Am Heart J. 2022 Sep;251:1–12.Full Text Link to Item
-
Granger BB, Kaltenbach LA, Fonarow GC, Allen LA, Lanfear DE, Albert NM, et al. Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. J Card Fail. 2022 Aug;28(8):1355–61.Full Text Link to Item
-
Pol T, Hijazi Z, Lindbäck J, Oldgren J, Alexander JH, Connolly SJ, et al. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112–23.Full Text Link to Item
-
Bahit MC, Vora AN, Li Z, Wojdyla DM, Thomas L, Goodman SG, et al. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. Jama Cardiol. 2022 Jul 1;7(7):682–9.Full Text Link to Item
-
Macedo AVS, de Barros E Silva PGM, de Paula TC, Moll-Bernardes RJ, Mendonça Dos Santos T, Mazza L, et al. Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial. Am Heart J. 2022 Jul;249:86–97.Full Text Link to Item
-
Krychtiuk KA, Fordyce CB, Hansen CM, Hassager C, Jentzer JC, Menon V, et al. Targeted temperature management after out of hospital cardiac arrest: quo vadis? Eur Heart J Acute Cardiovasc Care. 2022 Jun 22;11(6):512–21.Full Text Link to Item
-
Figtree GA, Redfors B, Kozor R, Vernon ST, Grieve SM, Mazhar J, et al. Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors. Jacc Cardiovasc Interv. 2022 Jun 13;15(11):1167–75.Full Text Link to Item
-
Del Brutto VJ, Diener H-C, Easton JD, Granger CB, Cronin L, Kleine E, et al. Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial. J Am Heart Assoc. 2022 Jun 7;11(11):e023545.Full Text Link to Item
-
Pokorney SD, Granger CB. Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. Circulation. 2022 Jun 7;145(23):1705–7.Full Text Link to Item
-
Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, et al. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. J Am Coll Cardiol. 2022 May 10;79(18):1849–57.Full Text Link to Item
-
Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, et al. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. J Am Coll Cardiol. 2022 May 10;79(18):1802–13.Full Text Link to Item
-
De Caterina R, Patti G, Westerbergh J, Horowitz J, Ezekowitz JA, Lewis BS, et al. Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):227–35.Full Text Link to Item
-
Garcia A, Balasubramanian V, Lee J, Gardner R, Gummidipundi S, Hung G, et al. Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials. J Biopharm Stat. 2022 May 4;32(3):496–510.Full Text Link to Item
-
Pokorney SD, Cocoros N, Al-Khalidi HR, Haynes K, Li S, Al-Khatib SM, et al. Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial. Jama Netw Open. 2022 May 2;5(5):e2214321.Full Text Link to Item
-
Krychtiuk KA, Granger CB. In older persons at risk for dementia, a multidomain approach reduced stroke and transient ischemic attack. Ann Intern Med. 2022 May;175(5):JC55.Full Text Link to Item
-
Shavadia JS, Alemayehu W, deFilippi C, Westerhout CM, Tromp J, Granger CB, et al. Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes. J Thromb Thrombolysis. 2022 May;53(4):841–50.Full Text Link to Item
-
Granger CB, Krychtiuk KA, Gersh BJ. Personalizing Choice of CABG vs PCI for Multivessel Disease: Predictive Model Falls Short. J Am Coll Cardiol. 2022 Apr 19;79(15):1474–6.Full Text Link to Item
-
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, et al. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J Cardiol. 2022 Apr;79(4):522–9.Full Text Link to Item
-
Bhasin S, Lincoff AM, Basaria S, Bauer DC, Boden WE, Cunningham GR, et al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. Am Heart J. 2022 Mar;245:41–50.Full Text Link to Item
-
Harskamp RE, Fanaroff AC, Lopes RD, Wojdyla DM, Goodman SG, Thomas LE, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. J Am Coll Cardiol. 2022 Feb 8;79(5):417–27.Full Text Link to Item
-
Nelson AJ, O’Brien EC, Kaltenbach LA, Green JB, Lopes RD, Morse CG, et al. Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Jama Netw Open. 2022 Feb 1;5(2):e2148030.Full Text Link to Item
-
Welsh RC, Dehghani P, Lopes R, Wojdyla DM, Aronson R, Granger CB, et al. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart. 2022 Feb;9(1).Full Text Link to Item
-
Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022 Jan 25;145(4):242–55.Full Text Link to Item
-
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation. 2022 Jan 4;145(1):87–9.Full Text Link to Item
-
Attelind S, Hallberg P, Wadelius M, Hamberg A-K, Siegbahn A, Granger CB, et al. Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. Front Genet. 2022;13:982955.Full Text Link to Item
-
Fudim M, Wojdyla DM, Alexander JH, Goodman SG, Mehran R, Windecker S, et al. Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. J Am Heart Assoc. 2021 Dec 21;10(24):e023143.Full Text Link to Item
-
Carnicelli AP, Owen R, Pocock SJ, Brieger DB, Yasuda S, Nicolau JC, et al. Atrial fibrillation and clinical outcomes 1 to 3 years after myocardial infarction. Open Heart. 2021 Dec;8(2).Full Text Link to Item
-
Fabris E, Korjian S, Coller BS, Ten Berg JM, Granger CB, Gibson CM, et al. Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thromb Haemost. 2021 Dec;121(12):1562–73.Full Text Link to Item
-
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 Nov 11;385(20):1845–55.Full Text Link to Item
-
Bossard M, Gao P, Boden W, Steg G, Tanguay J-F, Joyner C, et al. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021 Nov;107(21):1739–47.Full Text Link to Item
-
Siegbahn A, Lindbäck J, Hijazi Z, Åberg M, Alexander JH, Eikelboom JW, et al. Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. J Thromb Haemost. 2021 Nov;19(11):2726–37.Full Text Link to Item
-
Perino AC, Gummidipundi SE, Lee J, Hedlin H, Garcia A, Ferris T, et al. Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart Study. Circ Arrhythm Electrophysiol. 2021 Oct;14(10):e010063.Full Text Link to Item
-
Moeller S, Hansen CM, Kragholm K, Dupre ME, Sasson C, Pearson DA, et al. Race Differences in Interventions and Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010 to 2014. J Am Heart Assoc. 2021 Sep 7;10(17):e019082.Full Text Link to Item
-
Bor WL, Zheng KL, Tavenier AH, Gibson CM, Granger CB, Bentur O, et al. Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction. Eurointervention. 2021 Aug 6;17(5):e401–10.Full Text Link to Item
-
Albers GW, Bernstein R, Brachmann J, Camm AJ, Fromm P, Goto S, et al. Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke. 2021 Aug;52(8):2715–22.Full Text Link to Item
-
Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, et al. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. Clin Res Cardiol. 2021 Aug;110(8):1234–48.Full Text Link to Item
-
DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, et al. Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. Jama. 2021 Jul 27;326(4):314–23.Full Text Link to Item
-
Nelson AJ, Pagidipati NJ, Aroda VR, Cavender MA, Green JB, Lopes RD, et al. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation. 2021 Jul 6;144(1):74–84.Full Text Link to Item
-
Goyal A, Schibler T, Alhanti B, Hannan KL, Granger CB, Blazing MA, et al. Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. Jama Netw Open. 2021 Jul 1;4(7):e2117963.Full Text Link to Item
-
Granger CB, Pokorney SD. Preventing and Managing Bleeding With Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2021 Jun 22;77(24):3002–4.Full Text Link to Item
-
Bernstein RA, Kamel H, Granger CB, Piccini JP, Sethi PP, Katz JM, et al. Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial. Jama. 2021 Jun 1;325(21):2169–77.Full Text Link to Item
-
Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021 Jun;23(6):1040–8.Full Text Link to Item
-
Nelson AJ, Pagidipati NJ, Granger CB. The SAMSON trial: using a placebo to improve medication tolerability. Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e13.Full Text Link to Item
-
Carnicelli AP, Al-Khatib SM, Xavier D, Dalgaard F, Merrill PD, Wojdyla DM, et al. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. Heart. 2021 May;107(9):713–20.Full Text Link to Item
-
Kelsey MD, Granger CB. LOW-HARM score predicted mortality in patients hospitalized with COVID-19 in Mexico. Ann Intern Med. 2021 May;174(5):JC59.Full Text Link to Item
-
Povysil G, Chazara O, Carss KJ, Deevi SVV, Wang Q, Armisen J, et al. Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. Jama Cardiol. 2021 Apr 1;6(4):379–86.Full Text Link to Item
-
Hijazi Z, Alexander JH, Li Z, Wojdyla DM, Mehran R, Granger CB, et al. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2021 Mar 23;143(12):1215–23.Full Text Link to Item
-
Carnicelli AP, Hong H, Giugliano RP, Connolly SJ, Eikelboom J, Patel MR, et al. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. Am Heart J. 2021 Mar;233:48–58.Full Text Link to Item
-
Tomasdottir M, Held C, Hadziosmanovic N, Westerbergh J, Lindbäck J, Aylward PE, et al. Risk markers of incident atrial fibrillation in patients with coronary heart disease. Am Heart J. 2021 Mar;233:92–101.Full Text Link to Item
-
Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. Circ Arrhythm Electrophysiol. 2021 Mar;14(3):e009614.Full Text Link to Item
-
Al-Khatib SM, Mulder H, Wojdyla D, Lopes RD, Wallentin L, Alexander JH, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy. Circulation: Arrhythmia and Electrophysiology. 2021 Mar;14(3).Full Text
-
Diener H-C, Chutinet A, Easton JD, Granger CB, Kleine E, Marquardt L, et al. Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. Stroke. 2021 Mar;52(3):1065–8.Full Text Link to Item
-
Harrington JL, Granger CB. Standardizing ST-Segment Elevation Myocardial Infarction Care: Customizing Regionalization to Improve Outcomes. Circ Cardiovasc Qual Outcomes. 2021 Mar;14(3):e007701.Full Text Link to Item
-
Pol T, Hijazi Z, Lindbäck J, Alexander JH, Bahit MC, De Caterina R, et al. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1).Full Text Open Access Copy Link to Item
-
Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. Circulation. 2021 Feb 9;143(6):583–96.Full Text Open Access Copy Link to Item
-
Pocock S, Brieger DB, Owen R, Chen J, Cohen MG, Goodman S, et al. Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. Open Heart. 2021 Feb;8(1).Full Text Link to Item
-
Redfors B, Mohebi R, Giustino G, Chen S, Selker HP, Thiele H, et al. Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv. 2021 Feb;14(2):e009879.Full Text Link to Item
-
Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. Jama. 2021 Jan 19;325(3):254–64.Full Text Link to Item
-
Nelson AJ, Ardissino M, Haynes K, Shambhu S, Eapen ZJ, McGuire DK, et al. Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2021 Jan 19;10(2):e016835.Full Text Link to Item
-
Hijazi Z, Wallentin L, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984.Full Text Open Access Copy Link to Item
-
Granger CB, Hansen CM. Predicting outcome in cardiac arrest: some progress, but more work needed. Eur Heart J. 2020 Dec 14;41(47):4518–20.Full Text Link to Item
-
Pun PH, Pokorney SD, Granger CB. Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease: If You Are Not Confused, You Are Not Thinking Clearly. Jacc Clin Electrophysiol. 2020 Dec 14;6(13):1669–71.Full Text Link to Item
-
Dalgaard F, Xu H, Matsouaka RA, Russo AM, Curtis AB, Rasmussen PV, et al. Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. J Am Heart Assoc. 2020 Dec;9(23):e017024.Full Text Open Access Copy Link to Item
-
Nicolau JC, Brieger D, Owen R, Furtado RHM, Goodman SG, Cohen MG, et al. Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. Clin Cardiol. 2020 Dec;43(12):1352–61.Full Text Link to Item
-
Sullivan AE, Holder T, Truong T, Green CL, Sofela O, Dahhan T, et al. Use of hospital resources in the care of patients with intermediate risk pulmonary embolism. Eur Heart J Acute Cardiovasc Care. 2020 Nov 27;2048872620921601.Full Text Link to Item
-
Sullivan AE, Holder T, Truong T, Green CL, Sofela O, Dahhan T, et al. Use of hospital resources in the care of patients with intermediate risk pulmonary embolism. Eur Heart J Acute Cardiovasc Care. 2020 Nov 27;Full Text Link to Item
-
Rymer JA, Granger CB. Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete? Eur Heart J. 2020 Nov 7;41(42):4111–3.Full Text Link to Item
-
Al-Khatib SM, Pokorney SD, Al-Khalidi HR, Haynes K, Garcia C, Martin D, et al. Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib). Am Heart J. 2020 Nov;229:110–7.Full Text Link to Item
-
Luoma LM, Westerhout CM, Granger CB, Armstrong PW. Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review. Jama Cardiol. 2020 Nov 1;5(11):1286–97.Full Text Link to Item
-
Wallentin L, Lindbäck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037–46.Full Text Link to Item
-
Nanna MG, Granger CB. In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel. Ann Intern Med. 2020 Oct 20;173(8):JC44.Full Text Link to Item
-
Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindbäck J, Alexander JH, et al. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020 Sep 15;9(18):e017155.Full Text Open Access Copy Link to Item
-
Aulin J, Hijazi Z, Siegbahn A, Andersson U, Alexander JH, Connolly SJ, et al. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost. 2020 Sep;18(9):2287–95.Full Text Link to Item
-
Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Alings M, De Caterina R, et al. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. Jama Netw Open. 2020 Sep 1;3(9):e2015943.Full Text Link to Item
-
Samsky MD, DeVore AD, McIlvennan CK, Granger CB, Granger BB, Hernandez AF, et al. Heart Failure Clinical Trial Operations During the COVID-19 Pandemic: Results From a Multicenter Survey. Circ Heart Fail. 2020 Sep;13(9):e007456.Full Text Link to Item
-
Thulin Å, Lindbäck J, Granger CB, Wallentin L, Lind L, Siegbahn A. Extracellular vesicles in atrial fibrillation and stroke. Thromb Res. 2020 Sep;193:180–9.Full Text Link to Item
-
Fanaroff AC, Califf RM, Harrington RA, Granger CB, McMurray JJV, Patel MR, et al. Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 Aug 4;76(5):580–9.Full Text Open Access Copy Link to Item
-
Garcia CJ, Haynes K, Pokorney SD, Lin ND, McMahill-Walraven C, Nair V, et al. Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial. Clin Trials. 2020 Aug;17(4):360–7.Full Text Link to Item
-
Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D’Andréa Saba Arruda G, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J. 2020 Aug;226:49–59.Full Text Open Access Copy Link to Item
-
Marquis-Gravel G, Mehta SR, Valgimigli M, Levine GN, Neumann F-J, Granger CB, et al. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. Can J Cardiol. 2020 Aug;36(8):1298–307.Full Text Link to Item
-
Røsjø H, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, et al. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020 Aug;288(2):248–59.Full Text Link to Item
-
Berglund E, Wallentin L, Oldgren J, Renlund H, Alexander JH, Granger CB, et al. Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. Eur J Prev Cardiol. 2020 Aug;27(12):1311–9.Full Text Link to Item
-
Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, et al. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020 Aug;96(2):E102–9.Full Text Link to Item
-
American Heart Association’s Mission: Lifeline and Get With The Guidelines Coronary Artery Disease Advisory Work Group and the Council on Clinical Cardiology’s Committees on Acute Cardiac Care and General Cardiology and Interventional Cardiovascular Care*. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA's Mission: Lifeline. Circulation. 2020 Jul 21;142(3):199–202.Full Text Link to Item
-
Brieger D, Pocock SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, et al. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. Int J Cardiol. 2020 Jul 15;311:7–14.Full Text Link to Item
-
Shavadia JS, Granger CB, Alemayehu W, Westerhout CM, Povsic TJ, Van Diepen S, et al. Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention. J Am Heart Assoc. 2020 Jul 7;9(13):e016033.Full Text Link to Item
-
Kragholm K, Hansen CM, Dupre ME, Strauss B, Tyson C, Monk L, et al. Care and outcomes of urban and non-urban out-of-hospital cardiac arrest patients during the HeartRescue Project in Washington state and North Carolina. Resuscitation. 2020 Jul;152:5–15.Full Text Link to Item
-
Zeitouni M, Al-Khalidi HR, Roettig ML, Bolles MM, Doerfler SM, Fordyce CB, et al. Catheterization Laboratory Activation Time in Patients Transferred With ST-Segment-Elevation Myocardial Infarction: Insights From the Mission: Lifeline STEMI Accelerator-2 Project. Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006204.Full Text Link to Item
-
McIlvennan CK, Allen LA, Devore AD, Granger CB, Kaltenbach LA, Granger BB. Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. J Card Fail. 2020 Jul;26(7):635–6.Full Text Link to Item
-
White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, et al. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. Am Heart J. 2020 Jul;225:97–107.Full Text Link to Item
-
Choi AY, Mulvihill MS, Lee H-J, Zhao C, Kuchibhatla M, Schroder JN, et al. Transplant Center Variability in Organ Offer Acceptance and Mortality Among US Patients on the Heart Transplant Waitlist. Jama Cardiol. 2020 Jun 1;5(6):660–8.Full Text Link to Item
-
Diener H-C, Sacco RL, Easton JD, Granger CB, Bar M, Bernstein RA, et al. Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups. Stroke. 2020 Jun;51(6):1758–65.Full Text Link to Item
-
Geurink KR, Granger CB, Liao L, Thomas NG, Lindsey BC, Babin E, et al. A reversal of fortune: A case of cardiovascular collapse following protamine sulfate infusion. Heartrhythm Case Rep. 2020 Jun;6(6):322–4.Full Text Link to Item
-
Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, et al. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. Circulation. 2020 May 19;141(20):1618–27.Full Text Link to Item
-
Hilvo M, Wallentin L, Ghukasyan Lakic T, Held C, Kauhanen D, Jylhä A, et al. Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. J Am Heart Assoc. 2020 May 18;9(10):e015258.Full Text Link to Item
-
Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D’Andréa Saba Arruda G, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Am Heart J. 2020 May 13;Full Text Open Access Copy Link to Item
-
Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. Jama Cardiol. 2020 May 1;5(5):582–9.Full Text Link to Item
-
Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020 Apr 28;141(17):1384–92.Full Text Link to Item
-
Redfors B, Furer A, Selker HP, Thiele H, Patel MR, Chen S, et al. Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. J Am Coll Cardiol. 2020 Apr 21;75(15):1743–54.Full Text Link to Item
-
Granger CB, Mahaffey KW. Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. Circulation. 2020 Apr 14;141(15):1235–7.Full Text Link to Item
-
Ehrlich ME, Kolls BJ, Roettig M, Monk L, Shah S, Xian Y, et al. Implementation of Best Practices-Developing and Optimizing Regional Systems of Stroke Care: Design and Methodology. Am Heart J. 2020 Apr;222:105–11.Full Text Link to Item
-
Pokorney SD, Black-Maier E, Hellkamp AS, Friedman DJ, Vemulapalli S, Granger CB, et al. Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Am Coll Cardiol. 2020 Mar 24;75(11):1299–308.Full Text Link to Item
-
Rubini Giménez M, Miller PE, Alviar CL, van Diepen S, Granger CB, Montalescot G, et al. Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial. J Clin Med. 2020 Mar 20;9(3).Full Text Link to Item
-
Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, et al. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020 Mar 17;75(10):1145–55.Full Text Link to Item
-
Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, et al. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. 2020 Mar 10;141(10):843–62.Full Text Link to Item
-
Seligman WH, Das-Gupta Z, Jobi-Odeneye AO, Arbelo E, Banerjee A, Bollmann A, et al. Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. Eur Heart J. 2020 Mar 7;41(10):1132–40.Full Text Link to Item
-
Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation. 2020 Mar 3;141(9):781–3.Full Text Link to Item
-
Bahit MC, Granger CB, Alexander JH, Mulder H, Wojdyla DM, Hanna M, et al. Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. Int J Cardiol. 2020 Mar 1;302:53–8.Full Text Link to Item
-
Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020 Mar;221:1–8.Full Text Link to Item
-
Zeymer U, Bueno H, Granger CB, Hochman J, Huber K, Lettino M, et al. Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care. 2020 Mar;9(2):183–97.Full Text Link to Item
-
Lopes RD, de Barros E Silva PGM, Damiani LP, Santos RHN, Alexander JH, Granger CB, et al. Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI. Jama. 2020 Feb 25;323(8):787–9.Full Text Link to Item
-
DeVore AD, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Lewis EF, et al. Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. Am Heart J. 2020 Feb;220:41–50.Full Text Link to Item
-
Shavadia JS, Granger CB, Alemayehu W, Westerhout CM, Povsic TJ, Brener SJ, et al. High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction. Am Heart J. 2020 Feb;220:137–44.Full Text Link to Item
-
Sutter JS, Lokhnygina Y, Daubert JP, Bahnson T, Jackson K, Koontz JI, et al. Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation. American Heart Journal. 2020 Feb;220:89–96.Full Text
-
Carnicelli AP, Granger CB. In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG. Ann Intern Med. 2020 Jan 21;172(2):JC3.Full Text Link to Item
-
Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, et al. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10–20.Full Text Link to Item
-
Kamath DY, Bhuvana KB, Dhiraj RS, Xavier D, Varghese K, Salazar LJ, et al. Patient and caregiver reported facilitators of self-care among patients with chronic heart failure: report from a formative qualitative study. Wellcome Open Research. 2020 Jan;5:10.Full Text
-
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, et al. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clin Cardiol. 2020 Jan;43(1):24–32.Full Text Link to Item
-
Vora AN, Alexander JH, Wojdyla DM, Aronson R, Granger CB, Darius H, et al. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. Circulation. 2019 Dec 3;140(23):1960–3.Full Text Link to Item
-
Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation. 2019 Dec 3;140(23):1921–32.Full Text Link to Item
-
Black-Maier E, Piccini JP, Granger CB. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2019 Dec;30(12):2968–76.Full Text Link to Item
-
Brennan JM, Wruck L, Pencina MJ, Clare RM, Lopes RD, Alexander JH, et al. Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. Am Heart J. 2019 Dec;218:110–22.Full Text Link to Item
-
Dewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS, et al. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2019 Dec;12(12):e006539.Full Text Link to Item
-
Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909–17.Full Text Open Access Copy Link to Item
-
Berg DD, Barnett CF, Kenigsberg BB, Papolos A, Alviar CL, Baird-Zars VM, et al. Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Circ Heart Fail. 2019 Nov;12(11):e006635.Full Text Link to Item
-
Goldstein SA, Green J, Huber K, Wojdyla DM, Lopes RD, Alexander JH, et al. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). Am J Cardiol. 2019 Nov 1;124(9):1406–12.Full Text Link to Item
-
Bohula EA, Katz JN, van Diepen S, Alviar CL, Baird-Zars VM, Park J-G, et al. Demographics, Care Patterns, and Outcomes of Patients Admitted to Cardiac Intensive Care Units: The Critical Care Cardiology Trials Network Prospective North American Multicenter Registry of Cardiac Critical Illness. Jama Cardiol. 2019 Sep 1;4(9):928–35.Full Text Link to Item
-
Pokorney SD, Granger CB. Continuous anticoagulation with catheter ablation: answers and questions. European Heart Journal. 2019 Sep;40(36):3022–5.Full Text
-
Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, et al. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2019 Aug 6;74(5):601–12.Full Text Link to Item
-
Verheugt FWA, Ten Berg JM, Storey RF, Cuisset T, Granger CB. Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). J Am Coll Cardiol. 2019 Aug 6;74(5):699–711.Full Text Link to Item
-
Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. Jama Cardiol. 2019 Aug 1;4(8):747–55.Full Text Link to Item
-
Shen L, Rørth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, et al. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail. 2019 Aug;21(8):974–84.Full Text Link to Item
-
Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jul 9;74(1):83–99.Full Text Link to Item
-
Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, et al. International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. J Thromb Thrombolysis. 2019 Jul;48(1):27–34.Full Text Link to Item
-
Sabin JE, Cocoros NM, Garcia CJ, Goldsack JC, Haynes K, Lin ND, et al. Bystander Ethics and Good Samaritanism: A Paradox for Learning Health Organizations. Hastings Cent Rep. 2019 Jul;49(4):18–26.Full Text Link to Item
-
Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, et al. Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients. Circ Cardiovasc Qual Outcomes. 2019 Jul;12(7):e005103.Full Text Link to Item
-
Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, et al. Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. J Am Coll Cardiol. 2019 Jun 11;73(22):2819–28.Full Text Link to Item
-
Granger CB, Nelson AJ, Pagidipati NJ. Risk of Total Events With Icosapent Ethyl: Can We Reduce It? J Am Coll Cardiol. 2019 Jun 11;73(22):2803–5.Full Text Link to Item
-
Shavadia JS, Sharma A, Gu X, Neaton J, DeLeve L, Holmes D, et al. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. Clin Trials. 2019 Jun;16(3):253–62.Full Text Link to Item
-
Pun PH, Dupre ME, Tyson C, Al-Khatib SM, Granger CB. Authors' Reply. J Am Soc Nephrol. 2019 Jun;30(6):1137–8.Full Text Link to Item
-
Diener H-C, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019 May 16;380(20):1906–17.Full Text Link to Item
-
Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019 May 14;139(20):2292–300.Full Text Link to Item
-
Guimarães PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol. 2019 May;42(5):568–71.Full Text Link to Item
-
Harskamp RE, Granger TM, Clare RM, White KR, Lopes RD, Pieper KS, et al. Peripheral blood metabolite profiles associated with new onset atrial fibrillation. Am Heart J. 2019 May;211:54–9.Full Text Link to Item
-
Shen L, Jhund PS, Docherty KF, Petrie MC, Anand IS, Carson PE, et al. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. Jacc Heart Fail. 2019 May;7(5):418–27.Full Text Link to Item
-
Killu AM, Granger CB, Gersh BJ. Risk stratification for stroke in atrial fibrillation: a critique. Eur Heart J. 2019 Apr 21;40(16):1294–302.Full Text Link to Item
-
Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509–24.Full Text Link to Item
-
Pokorney SD, Bloom D, Granger CB, Thomas KL, Al-Khatib SM, Roettig ML, et al. Exploring patient-provider decision-making for use of anticoagulation for stroke prevention in atrial fibrillation: Results of the INFORM-AF study. Eur J Cardiovasc Nurs. 2019 Apr;18(4):280–8.Full Text Link to Item
-
Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, et al. Stroke prevention in atrial fibrillation: Closing the gap. Am Heart J. 2019 Apr;210:29–38.Full Text Link to Item
-
Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, et al. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr;47(3):345–52.Full Text Link to Item
-
Al-Khatib SM, Granger CB. The changing epidemiology of ventricular arrhythmias and sudden cardiac death: Is it a reality? Heart Rhythm. 2019 Mar;16(3):367–8.Full Text Link to Item
-
Pun PH, Dupre ME, Starks MA, Tyson C, Vellano K, Svetkey LP, et al. Outcomes for Hemodialysis Patients Given Cardiopulmonary Resuscitation for Cardiac Arrest at Outpatient Dialysis Clinics. J Am Soc Nephrol. 2019 Mar;30(3):461–70.Full Text Link to Item
-
Nelson AJ, Granger CB. In middle-aged adults, Astro-CHARM was better than a standard risk factor model for predicting 10-year ASCVD risk. Ann Intern Med. 2019 Feb 19;170(4):JC23.Full Text Link to Item
-
Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, et al. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019 Feb;105(3):235–42.Full Text Open Access Copy Link to Item
-
Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb;208:123–31.Full Text Link to Item
-
Cocoros NM, Pokorney SD, Haynes K, Garcia C, Al-Khalidi HR, Al-Khatib SM, et al. FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. Clin Trials. 2019 Feb;16(1):90–7.Full Text Link to Item
-
Kochar A, Al-Khalidi HR, Doerfler S, Granger CB. Reply: Delays From First Medical Contact to Revascularization in Patients With ST-Segment Elevation Myocardial Infarction Presenting With Cardiogenic Shock. Jacc Cardiovasc Interv. 2019 Jan 14;12(1):107.Full Text Link to Item
-
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019 Jan 14;40(3):237–69.Full Text Link to Item
-
Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, et al. Association of the PHACTR1/EDN1 Genetic Locus With Spontaneous Coronary Artery Dissection. J Am Coll Cardiol. 2019 Jan 8;73(1):58–66.Full Text Link to Item
-
Granger CB, Bates ER, Jollis JG, Antman EM, Nichol G, O’Connor RE, et al. Improving Care of STEMI in the United States 2008 to 2012. J Am Heart Assoc. 2019 Jan 8;8(1):e008096.Full Text Link to Item
-
Turakhia MP, Desai M, Hedlin H, Rajmane A, Talati N, Ferris T, et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. Am Heart J. 2019 Jan;207:66–75.Full Text Link to Item
-
Limkakeng AT, Granger CB. In patients with chest pain, HEART Pathway-guided and usual care did not differ for MACE or health care use. Ann Intern Med. 2018 Dec 18;169(12):JC69.Full Text Link to Item
-
Fordyce CB, Chen AY, Wang TY, Lucas J, Goyal A, Wong GC, et al. Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry. Am Heart J. 2018 Dec;206:131–3.Full Text Link to Item
-
Hansen SM, Hansen CM, Fordyce CB, Dupre ME, Monk L, Tyson C, et al. Association Between Driving Distance From Nearest Fire Station and Survival of Out-of-Hospital Cardiac Arrest. J Am Heart Assoc. 2018 Nov 6;7(21):e008771.Full Text Link to Item
-
Lopes RD, de Barros E Silva PGM, de Andrade Jesuíno I, Santucci EV, Barbosa LM, Damiani LP, et al. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial. Jama Cardiol. 2018 Nov 1;3(11):1113–8.Full Text Link to Item
-
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–29.Full Text Link to Item
-
Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, et al. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16;138(16):1666–76.Full Text Link to Item
-
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):1677–749.Full Text Link to Item
-
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):e91–220.Full Text Link to Item
-
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018 Oct;15(10):e190–252.Full Text Link to Item
-
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018 Oct;15(10):e73–189.Full Text Link to Item
-
Luo N, Xu H, Jneid H, Fonarow GC, Lopes RD, Piccini JP, et al. Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. Circ Heart Fail. 2018 Oct;11(10):e005356.Full Text Link to Item
-
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272–391.Full Text Link to Item
-
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e210–71.Full Text Link to Item
-
Kochar A, Al-Khalidi HR, Hansen SM, Shavadia JS, Roettig ML, Fordyce CB, et al. Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. Jacc Cardiovasc Interv. 2018 Sep 24;11(18):1824–33.Full Text Link to Item
-
Shavadia JS, Roe MT, Chen AY, Lucas J, Fanaroff AC, Kochar A, et al. Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Report From the ACTION Registry. Jacc Cardiovasc Interv. 2018 Sep 24;11(18):1837–47.Full Text Link to Item
-
Malta Hansen C, Kragholm K, Dupre ME, Pearson DA, Tyson C, Monk L, et al. Association of Bystander and First-Responder Efforts and Outcomes According to Sex: Results From the North Carolina HeartRescue Statewide Quality Improvement Initiative. J Am Heart Assoc. 2018 Sep 18;7(18):e009873.Full Text Link to Item
-
Rymer J, Granger CB. Optimal care for patients with st-elevation myocardial infarction and non'st-elevation acute coronary syndrome in the cardiac catheterization laboratory and coronary care unit. Critical Pathways in Cardiology. 2018 Sep 1;17(3):129–32.
-
Green JB, Hernandez AF, D’Agostino RB, Granger CB, Janmohamed S, Jones NP, et al. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. Am Heart J. 2018 Sep;203:30–8.Full Text Link to Item
-
Friedman DJ, Granger CB. Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions? Eur Heart J. 2018 Aug 21;39(32):2956–8.Full Text Link to Item
-
Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, et al. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 Aug 14;72(7):721–33.Full Text Link to Item
-
Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman S, Nicholls SJ, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018 Aug;202:89–96.Full Text Link to Item
-
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 Aug;20(8):1230–9.Full Text Link to Item
-
Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018 Aug;104(15):1292–9.Full Text Link to Item
-
Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. Circulation. 2018 Jul 31;138(5):527–36.Full Text Link to Item
-
Granger CB, Kochar A. Understanding and Targeting Inflammation in Acute Myocardial Infarction: An Elusive Goal. J Am Coll Cardiol. 2018 Jul 10;72(2):199–201.Full Text Link to Item
-
Filgueiras Filho NM, Feitosa Filho GS, Solla DJF, Argôlo FC, Guimarães PO, Paiva Filho IDM, et al. Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). J Am Heart Assoc. 2018 Jul 6;7(14).Full Text Link to Item
-
Rymer JA, Tempelhof MW, Clare RM, Pieper KS, Granger CB, Van de Werf F, et al. Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. Am Heart J. 2018 Jul;201:103–10.Full Text Link to Item
-
Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018 Jun;200:17–23.Full Text Link to Item
-
McCarthy JJ, Carr B, Sasson C, Bobrow BJ, Callaway CW, Neumar RW, et al. Out-of-Hospital Cardiac Arrest Resuscitation Systems of Care: A Scientific Statement From the American Heart Association. Circulation. 2018 May 22;137(21):e645–60.Full Text Link to Item
-
Pokorney SD, Granger CB. Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation. Eur Heart J. 2018 May 14;39(19):1706–8.Full Text Link to Item
-
Madhavan MV, Gersh BJ, Alexander KP, Granger CB, Stone GW. Coronary Artery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018 May 8;71(18):2015–40.Full Text Link to Item
-
Berwanger O, Nicolau JC, Carvalho AC, Jiang L, Goodman SG, Nicholls SJ, et al. Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial. Jama Cardiol. 2018 May 1;3(5):391–9.Full Text Link to Item
-
Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuíno IDA, Damiani LP, Barbosa LM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. Jama. 2018 Apr 3;319(13):1331–40.Full Text Link to Item
-
Berwanger O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, de Castro Bienert IR, Bosso CE, et al. Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. Am Heart J. 2018 Apr;198:129–34.Full Text Link to Item
-
Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, et al. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75–81.Full Text Link to Item
-
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. Digoxin and Mortality in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063–74.Full Text Link to Item
-
Bahit MC, Kochar A, Granger CB. Post-Myocardial Infarction Heart Failure. Jacc Heart Fail. 2018 Mar;6(3):179–86.Full Text Link to Item
-
Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, et al. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J. 2018 Mar;197:133–41.Full Text Link to Item
-
Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018 Mar;131(3):269-275.e2.Full Text Link to Item
-
Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, et al. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail. 2018 Mar;20(3):504–10.Full Text Link to Item
-
Carnicelli AP, Granger CB. Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography. Ann Intern Med. 2018 Feb 20;168(4):JC22.Full Text Link to Item
-
Granger CB, Xavier D. Improving Evidence for Implementation of Guideline-Based Care in Low- and Middle-Income Countries. Jama. 2018 Feb 13;319(6):554–6.Full Text Link to Item
-
Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477–85.Full Text Link to Item
-
Platz E, Jhund PS, Claggett BL, Pfeffer MA, Swedberg K, Granger CB, et al. Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. Eur J Heart Fail. 2018 Feb;20(2):295–303.Full Text Link to Item
-
Pol T, Held C, Westerbergh J, Lindbäck J, Alexander JH, Alings M, et al. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018 Feb 1;7(3).Full Text Link to Item
-
Jollis JG, Al-Khalidi HR, Roettig ML, Berger PB, Corbett CC, Doerfler SM, et al. Impact of Regionalization of ST-Segment-Elevation Myocardial Infarction Care on Treatment Times and Outcomes for Emergency Medical Services-Transported Patients Presenting to Hospitals With Percutaneous Coronary Intervention: Mission: Lifeline Accelerator-2. Circulation. 2018 Jan 23;137(4):376–87.Full Text Link to Item
-
Hagström E, Norlund F, Stebbins A, Armstrong PW, Chiswell K, Granger CB, et al. Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. J Intern Med. 2018 Jan;283(1):83–92.Full Text Link to Item
-
Mehta S, Granger C, Grines CL, Jacobs A, Henry TD, Rokos I, et al. Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India. Indian Heart J. 2018;70(1):185–90.Full Text Link to Item
-
Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, et al. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018;5(2):e000908.Full Text Link to Item
-
de Waha S, Patel MR, Granger CB, Ohman EM, Maehara A, Eitel I, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017 Dec 14;38(47):3502–10.Full Text Link to Item
-
Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, et al. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017 Dec;48(12):3266–73.Full Text Link to Item
-
Hirji SA, Stevens SR, Shaw LK, Campbell EC, Granger CB, Patel MR, et al. Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease. Am Heart J. 2017 Dec;194:116–24.Full Text Link to Item
-
Kristensen SL, Jhund PS, Lee MMY, Køber L, Solomon SD, Granger CB, et al. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovasc Drugs Ther. 2017 Dec;31(5–6):545–9.Full Text Link to Item
-
Westermann D, Goodman SG, Nicolau JC, Requena G, Maguire A, Chen JY, et al. Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study. Clin Cardiol. 2017 Dec;40(12):1197–204.Full Text Link to Item
-
Bossard M, Granger CB, Tanguay J-F, Montalescot G, Faxon DP, Jolly SS, et al. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2017 Nov 3;6(11).Full Text Link to Item
-
Ebinger J, Granger CB, Zhu A, Chang A, Henry TD. Idarucizumab since FDA approval: Use in the real-world. Am Heart J. 2017 Nov;193:93–4.Full Text Link to Item
-
Fordyce CB, Hansen CM, Kragholm K, Dupre ME, Jollis JG, Roettig ML, et al. Association of Public Health Initiatives With Outcomes for Out-of-Hospital Cardiac Arrest at Home and in Public Locations. Jama Cardiol. 2017 Nov 1;2(11):1226–35.Full Text Link to Item
-
Kochar A, Granger CB. Q Waves at Presentation in Patients With ST-Segment-Elevation Myocardial Infarction: An Underappreciated Marker of Risk. Circ Cardiovasc Interv. 2017 Nov;10(11).Full Text Link to Item
-
Hinohara TT, Al-Khalidi HR, Fordyce CB, Gu X, Sherwood MW, Roettig ML, et al. Impact of Regional Systems of Care on Disparities in Care Among Female and Black Patients Presenting With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc. 2017 Oct 24;6(10).Full Text Link to Item
-
Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet. 2017 Oct 14;390(10104):1737–46.Full Text Link to Item
-
Kragholm K, Lu D, Chiswell K, Al-Khalidi HR, Roettig ML, Roe M, et al. Improvement in Care and Outcomes for Emergency Medical Service-Transported Patients With ST-Elevation Myocardial Infarction (STEMI) With and Without Prehospital Cardiac Arrest: A Mission: Lifeline STEMI Accelerator Study. J Am Heart Assoc. 2017 Oct 11;6(10).Full Text Link to Item
-
Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. J Am Coll Cardiol. 2017 Oct 3;70(14):1689–700.Full Text Link to Item
-
Vinereanu D, Al-Khalidi HR, Rao MP, He W, Lopes RD, Bahit CM, et al. Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). Am Heart J. 2017 Oct;192:38–47.Full Text Link to Item
-
HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017 Sep 28;377(13):1217–27.Full Text Link to Item
-
van Diepen S, Girotra S, Abella BS, Becker LB, Bobrow BJ, Chan PS, et al. Multistate 5-Year Initiative to Improve Care for Out-of-Hospital Cardiac Arrest: Primary Results From the HeartRescue Project. J Am Heart Assoc. 2017 Sep 22;6(9).Full Text Link to Item
-
Guimarães PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, et al. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017 Sep 14;6(9).Full Text Link to Item
-
Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, et al. Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol. 2017 Aug 15;70(7):813–26.Full Text Link to Item
-
Rymer JA, Granger CB. Review: A single hs-cTnT with a cutpoint < limit of detection plus a nonischemic ECG can rule out acute MI. Ann Intern Med. 2017 Aug 15;167(4):JC23.Full Text Link to Item
-
Auer J, Huber K, Granger CB. Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? Eur Heart J. 2017 Aug 14;38(31):2440–3.Full Text Link to Item
-
van Diepen S, Fordyce CB, Wegermann ZK, Granger CB, Stebbins A, Morrow DA, et al. Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States: An American Heart Association Acute Cardiac Care Committee and American College of Cardiology Critical Care Cardiology Working Group Cross-Sectional Survey. Circ Cardiovasc Qual Outcomes. 2017 Aug;10(8):e003864.Full Text Link to Item
-
Bernstein RA, Kamel H, Granger CB, Kowal RC, Ziegler PD, Schwamm LH. Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale. Am Heart J. 2017 Aug;190:19–24.Full Text Link to Item
-
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining Risk of Sudden Death in Heart Failure. N Engl J Med. 2017 Jul 6;377(1):41–51.Full Text Link to Item
-
Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017 Jul;189:137–45.Full Text Link to Item
-
Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindbäck J, Granger CB, et al. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6).Full Text Link to Item
-
Selker HP, Udelson JE, Ruthazer R, D’Agostino RB, Nichols M, Ben-Yehuda O, et al. Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials. Am Heart J. 2017 Jun;188:18–25.Full Text Link to Item
-
Goodman SG, Nicolau JC, Requena G, Maguire A, Blankenberg S, Chen JY, et al. Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. Int J Cardiol. 2017 Jun 1;236:54–60.Full Text Link to Item
-
Guimarães PO, Lopes RD, Wojdyla DM, Abdul-Rahim AH, Connolly SJ, Flaker GC, et al. Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovasc Drugs Ther. 2017 Jun;31(3):295–301.Full Text Link to Item
-
Guimarães PO, Sun J-L, Kragholm K, Shah SH, Pieper KS, Kraus WE, et al. Corrigendum to 'Association of Standard Clinical and Laboratory Variables with Red Blood Cell Distribution Width (RDW)'[Am. Heart J. (2016) 22-28]. Am Heart J. 2017 Jun;188:196.Full Text Link to Item
-
Kosmidou I, Redfors B, Selker HP, Thiele H, Patel MR, Udelson JE, et al. Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials. Eur Heart J. 2017 Jun 1;38(21):1656–63.Full Text Link to Item
-
Kragholm K, Malta Hansen C, Dupre ME, Xian Y, Strauss B, Tyson C, et al. Direct Transport to a Percutaneous Cardiac Intervention Center and Outcomes in Patients With Out-of-Hospital Cardiac Arrest. Circ Cardiovasc Qual Outcomes. 2017 Jun;10(6).Full Text Link to Item
-
Lopes RD, Guimarães PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 1;129(22):2980–7.Full Text Link to Item
-
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017 May 18;376(20):1933–42.Full Text Link to Item
-
Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, et al. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. Jama Cardiol. 2017 May 1;2(5):525–34.Full Text Link to Item
-
REVEAL Collaborative Group, Bowman L, Chen F, Sammons E, Hopewell JC, Wallendszus K, et al. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017 May;187:182–90.Full Text Link to Item
-
Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr;103(8):623–8.Full Text Link to Item
-
Fordyce CB, Douglas PS, Roberts RS, Hoffmann U, Al-Khalidi HR, Patel MR, et al. Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial. Jama Cardiol. 2017 Apr 1;2(4):400–8.Full Text Link to Item
-
Mehta S, Granger CB, Henry TD, Grines CL, Lansky A, Rokos I, et al. Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries. Indian Heart J. 2017 Apr;69 Suppl 1(Suppl 1):S1–5.Full Text Link to Item
-
Pagidipati NJ, Granger CB. Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age. Ann Intern Med. 2017 Mar 21;166(6):JC26.Full Text Link to Item
-
Henry TD, Granger CB. Out-of-Hospital Cardiac Arrest: To CT or Not to CT? Jacc Cardiovasc Interv. 2017 Mar 13;10(5):460–1.Full Text Link to Item
-
Peterson BE, Al-Khatib SM, Granger CB. Apixaban to prevent stroke in patients with atrial fibrillation: a review. Ther Adv Cardiovasc Dis. 2017 Mar;11(3):91–104.Full Text Link to Item
-
Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, Alexander JH, et al. The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. Jama Cardiol. 2017 Mar 1;2(3):324–31.Full Text Link to Item
-
Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2017 Mar;185:140–9.Full Text Link to Item
-
Piccini JP, Granger CB. Insulin Therapy and Stroke Risk in Patients With Diabetes and Atrial Fibrillation: Guilty by Association? J Am Coll Cardiol. 2017 Jan 31;69(4):420–2.Full Text Link to Item
-
Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1).Full Text Link to Item
-
Guimarães PO, Wojdyla DM, Alexander JH, Thomas L, Alings M, Flaker GC, et al. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol. 2017 Jan 15;227:443–9.Full Text Link to Item
-
Fordyce CB, Al-Khalidi HR, Jollis JG, Roettig ML, Gu J, Bagai A, et al. Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks. Circ Cardiovasc Interv. 2017 Jan;10(1).Full Text Link to Item
-
Jollis JG, Granger CB. Improving Care of Out-of-Hospital Cardiac Arrest: Next Steps. Circulation. 2016 Dec 20;134(25):2040–2.Full Text Link to Item
-
Kelly JP, Granger CB. More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart Failure. Jama Intern Med. 2016 Dec 1;176(12):1759–60.Full Text Link to Item
-
Damman K, Solomon SD, Pfeffer MA, Swedberg K, Yusuf S, Young JB, et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. Eur J Heart Fail. 2016 Dec;18(12):1508–17.Full Text Link to Item
-
Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697–707.Full Text Link to Item
-
Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016 Nov;9(11).Full Text Link to Item
-
Garvey JL, Granger C, Peacock WF. Pushing the Envelope on STEMI Response. Ed Manag. 2016 Nov;28(11):121–6.Link to Item
-
Granger CB, Ohman EM. Enhancing the value of clinical trials: the role of data sharing. Nat Rev Cardiol. 2016 Nov;13(11):629–30.Full Text Link to Item
-
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016 Nov;152(5):1243–75.Full Text Link to Item
-
Loley C, Alver M, Assimes TL, Bjonnes A, Goel A, Gustafsson S, et al. No Association of Coronary Artery Disease with X-Chromosomal Variants in Comprehensive International Meta-Analysis. Sci Rep. 2016 Oct 12;6:35278.Full Text Link to Item
-
Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, et al. The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016 Oct 7;37(38):2869–78.Full Text Link to Item
-
van Diepen S, Alemayehu WG, Zheng Y, Theroux P, Newby LK, Mahaffey KW, et al. Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. J Thromb Thrombolysis. 2016 Oct;42(3):376–85.Full Text Link to Item
-
Fordyce CB, Henry TD, Granger CB. Implementation of Regional ST-Segment Elevation Myocardial Infarction Systems of Care: Successes and Challenges. Interv Cardiol Clin. 2016 Oct;5(4):415–25.Full Text Link to Item
-
Le May M, van Diepen S, Liszkowski M, Schnell G, Tanguay J-F, Granger CB, et al. From Coronary Care Units to Cardiac Intensive Care Units: Recommendations for Organizational, Staffing, and Educational Transformation. Can J Cardiol. 2016 Oct;32(10):1204–13.Full Text Link to Item
-
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 Sep 6;68(10):1082–115.Full Text Link to Item
-
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6;134(10):e123–55.Full Text Link to Item
-
Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. Jama Cardiol. 2016 Sep 1;1(6):673–81.Full Text Link to Item
-
Arbel Y, FitzGerald G, Yan AT, Tan MK, Fox KAA, Gore JM, et al. Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. Int J Cardiol. 2016 Sep 1;218:291–7.Full Text Link to Item
-
Calenda BW, Fuster V, Halperin JL, Granger CB. Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. Nat Rev Cardiol. 2016 Sep;13(9):549–59.Full Text Link to Item
-
Hawkins NM, Jhund PS, Pozzi A, O’Meara E, Solomon SD, Granger CB, et al. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J Heart Fail. 2016 Sep;18(9):1162–71.Full Text Link to Item
-
Granger CB, Thomas KL. Stroke Prediction in Atrial Fibrillation: Is it Black and White? J Am Coll Cardiol. 2016 Aug 2;68(5):471–2.Full Text Link to Item
-
Jollis JG, Al-Khalidi HR, Roettig ML, Berger PB, Corbett CC, Dauerman HL, et al. Regional Systems of Care Demonstration Project: American Heart Association Mission: Lifeline STEMI Systems Accelerator. Circulation. 2016 Aug 2;134(5):365–74.Full Text Link to Item
-
Pearson DA, Darrell Nelson R, Monk L, Tyson C, Jollis JG, Granger CB, et al. Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: Results from a statewide quality improvement initiative. Resuscitation. 2016 Aug;105:165–72.Full Text Link to Item
-
Rajan S, Folke F, Kragholm K, Hansen CM, Granger CB, Hansen SM, et al. Prolonged cardiopulmonary resuscitation and outcomes after out-of-hospital cardiac arrest. Resuscitation. 2016 Aug;105:45–51.Full Text Link to Item
-
Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. Jama Cardiol. 2016 Jul 1;1(4).Full Text Link to Item
-
Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. Jama Cardiol. 2016 Jul 1;1(4):451–60.Full Text Link to Item
-
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, et al. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 Jun 21;5(6).Full Text Link to Item
-
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. Bmj. 2016 Jun 15;353:i2868.Full Text Link to Item
-
Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302–11.Full Text Link to Item
-
Berry C, Poppe KK, Gamble GD, Earle NJ, Ezekowitz JA, Squire IB, et al. Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. Qjm. 2016 Jun;109(6):377–82.Full Text Link to Item
-
Rao MP, Ciobanu AO, Lopes RD, Fox KA, Xian Y, Pokorney SD, et al. A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. Am Heart J. 2016 Jun;176:107–13.Full Text Link to Item
-
Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582–90.Full Text Open Access Copy Link to Item
-
Fordyce CB, Wang TY, Chen AY, Thomas L, Granger CB, Scirica BM, et al. Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. J Am Coll Cardiol. 2016 May 3;67(17):1981–90.Full Text Link to Item
-
De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2016 May;175:175–83.Full Text Link to Item
-
Endorsed by the Latin American Society of Interventional Cardiology, PCI WRITING COMMITTEE, Levine GN, Bates ER, Blankenship JC, Bailey SR, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial Infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2016 May;87(6):1001–19.Full Text Link to Item
-
Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, et al. North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med. 2016 May;129(5 Suppl):S1–29.Full Text Link to Item
-
van Diepen S, Lin M, Bakal JA, McAlister FA, Kaul P, Katz JN, et al. Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units? Am Heart J. 2016 May;175:184–92.Full Text Link to Item
-
Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016 Apr 12;67(14):1674–83.Full Text Link to Item
-
Pokorney SD, O’Brien EC, Granger CB. Assessing generalizability of trial results in general practice. Eur Heart J. 2016 Apr 7;37(14):1154–7.Full Text Link to Item
-
Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, et al. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr;102(7):508–17.Full Text Link to Item
-
Guimarães PO, Sun J-L, Kragholm K, Shah SH, Pieper KS, Kraus WE, et al. Association of standard clinical and laboratory variables with red blood cell distribution width. Am Heart J. 2016 Apr;174:22–8.Full Text Link to Item
-
Albers GW, Bernstein RA, Brachmann J, Camm J, Easton JD, Fromm P, et al. Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. J Am Heart Assoc. 2016 Mar 15;5(3):e002944.Full Text Link to Item
-
Bosworth HB, Zullig LL, Mendys P, Ho M, Trygstad T, Granger C, et al. Health Information Technology: Meaningful Use and Next Steps to Improving Electronic Facilitation of Medication Adherence. Jmir Med Inform. 2016 Mar 15;4(1):e9.Full Text Link to Item
-
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2016 Mar 15;67(10):1235–50.Full Text Link to Item
-
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2016 Mar 15;133(11):1135–47.Full Text Link to Item
-
Vavalle JP, van Diepen S, Clare RM, Hochman JS, Weaver WD, Mehta RH, et al. Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. Am Heart J. 2016 Mar;173:57–66.Full Text Link to Item
-
Shah RU, de Lemos JA, Wang TY, Chen AY, Thomas L, Sutton NR, et al. Post-Hospital Outcomes of Patients With Acute Myocardial Infarction With Cardiogenic Shock: Findings From the NCDR. J Am Coll Cardiol. 2016 Feb 23;67(7):739–47.Full Text Link to Item
-
Calenda BW, Granger CB. ACP Journal Club. In atrial fibrillation, the ATRIA risk score better predicted stroke than CHADS2 and CHA2DS2-VASc scores. Ann Intern Med. 2016 Feb 16;164(4):JC23.Full Text Link to Item
-
Diener H-C, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2016 Feb 4;Full Text Link to Item
-
Diener H-C, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2016 Feb 4;Full Text Link to Item
-
Pesaro AEP, Granger CB, Lopes RD. Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects? Am Heart J. 2016 Feb;172:42–4.Full Text Link to Item
-
Durheim MT, Cyr DD, Lopes RD, Thomas LE, Tsuang WM, Gersh BJ, et al. Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol. 2016 Jan 1;202:589–94.Full Text Link to Item
-
Easton JD, Diener HC, Sacco RL, Granger CB, Brueckmann M, Cronin L, et al. RE-SPECT ESUS* Trial: Rationale and Design. Cerebrovascular Diseases. 2016 Jan 1;42:117–117.Link to Item
-
Rao MP, Dupre ME, Pokorney SD, Hansen CM, Tyson C, Monk L, et al. Therapeutic Hypothermia for Patients with Out-of-Hospital Cardiac Arrest in North Carolina. Prehosp Emerg Care. 2016;20(5):630–6.Full Text Link to Item
-
Malta Hansen C, Jollis JG, Granger CB. Initial Interventions for Out-of-Hospital Cardiac Arrest--Reply. Jama. 2015 Dec 8;314(22):2414.Full Text Link to Item
-
Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, et al. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7;36(46):3268–75.Full Text Link to Item
-
Diener H-C, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke. 2015 Dec;10(8):1309–12.Full Text Link to Item
-
Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1;4(12).Full Text Link to Item
-
Hansen CM, Kragholm K, Granger CB, Pearson DA, Tyson C, Monk L, et al. The role of bystanders, first responders, and emergency medical service providers in timely defibrillation and related outcomes after out-of-hospital cardiac arrest: Results from a statewide registry. Resuscitation. 2015 Nov;96:303–9.Full Text Link to Item
-
Kraus WE, Granger CB, Sketch MH, Donahue MP, Ginsburg GS, Hauser ER, et al. A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience. J Cardiovasc Transl Res. 2015 Nov;8(8):449–57.Full Text Link to Item
-
Verheugt FWA, Granger CB. Intracerebral haemorrhage, atrial fibrillation, and anticoagulation - Authors' reply. Lancet. 2015 Oct 31;386(10005):1737.Full Text Link to Item
-
Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015 Oct;47(10):1121–30.Full Text Link to Item
-
Fordyce CB, Granger CB. Adding ezetimibe to simvastatin improved cardiovascular outcomes in stable acute coronary syndrome. Ann Intern Med. 2015 Sep 15;163(6):JC7.Full Text Link to Item
-
Fordyce CB, Gersh BJ, Stone GW, Granger CB. Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends Pharmacol Sci. 2015 Sep;36(9):605–16.Full Text Link to Item
-
Anderson LL, French WJ, Peng SA, Vora AN, Henry TD, Roe MT, et al. Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2015 Sep;8(9):e002477.Full Text Link to Item
-
Malta Hansen C, Kragholm K, Pearson DA, Tyson C, Monk L, Myers B, et al. Association of Bystander and First-Responder Intervention With Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010-2013. Jama. 2015 Jul 21;314(3):255–64.Full Text Link to Item
-
Verheugt FWA, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015 Jul 18;386(9990):303–10.Full Text Link to Item
-
Alnasser SMA, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA, et al. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. Am J Med. 2015 Jul;128(7):766–75.Full Text Link to Item
-
Ghosh S, Vivar J, Nelson CP, Willenborg C, Segrè AV, Mäkinen V-P, et al. Systems Genetics Analysis of Genome-Wide Association Study Reveals Novel Associations Between Key Biological Processes and Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1712–22.Full Text Link to Item
-
Pokorney SD, Granger CB. Should patients on vitamin K antagonists be treated differently? Eur Heart J. 2015 Jun 14;36(23):1431–3.Full Text Link to Item
-
Bahit MC, Granger C. Anticoagulation for atrial fibrillation in argentina: Progress and opportunity. Revista Argentina De Cardiologia. 2015 Jun 1;83(3):183–4.Full Text
-
Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264–72.Full Text Link to Item
-
Steinberg BA, Schulte PJ, Hofmann P, Ersbøll M, Alexander JH, Broderick-Forsgren K, et al. Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. Am J Cardiol. 2015 May 15;115(10):1407–14.Full Text Link to Item
-
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015 May;169(5):631-638.e7.Full Text Link to Item
-
Segall N, Hobbs G, Granger CB, Anderson AE, Bonifacio AS, Taekman JM, et al. Patient load effects on response time to critical arrhythmias in cardiac telemetry: a randomized trial. Crit Care Med. 2015 May;43(5):1036–42.Full Text Link to Item
-
James S, Rao SV, Granger CB. Registry-based randomized clinical trials--a new clinical trial paradigm. Nat Rev Cardiol. 2015 May;12(5):312–6.Full Text Link to Item
-
Kovacs RJ, Flaker GC, Saxonhouse SJ, Doherty JU, Birtcher KK, Cuker A, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2015 Apr 7;65(13):1340–60.Full Text Link to Item
-
Ezekowitz JA, Lewis BS, Lopes RD, Wojdyla DM, McMurray JJV, Hanna M, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):86–94.Full Text Link to Item
-
Pokorney SD, Granger CB. Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):146–7.Full Text Link to Item
-
Rohla M, Vennekate CK, Tentzeris I, Freynhofer MK, Farhan S, Egger F, et al. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. Int J Cardiol. 2015 Apr 1;184:108–14.Full Text Link to Item
-
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Erratum: Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (American Heart Journal (2014) 169:1 (2530) DOI: 10.1016/j.ahj.2014.09.006). American Heart Journal. 2015 Apr 1;169(4):594.Full Text
-
Roger VL, Boerwinkle E, Crapo JD, Douglas PS, Epstein JA, Granger CB, et al. Strategic transformation of population studies: recommendations of the working group on epidemiology and population sciences from the National Heart, Lung, and Blood Advisory Council and Board of External Experts. Am J Epidemiol. 2015 Mar 15;181(6):363–8.Full Text Link to Item
-
Roger VL, Boerwinkle E, Crapo JD, Douglas PS, Epstein JA, Granger CB, et al. Roger et al. respond to "future of population studies". Am J Epidemiol. 2015 Mar 15;181(6):372–3.Full Text Link to Item
-
Vazir A, Claggett B, Jhund P, Castagno D, Skali H, Yusuf S, et al. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. Eur Heart J. 2015 Mar 14;36(11):669–75.Full Text Link to Item
-
Granger CB, Gersh BJ. Potential relief for refractory angina. N Engl J Med. 2015 Feb 5;372(6):566–7.Full Text Link to Item
-
Al-Khatib SM, Daubert JP, Anstrom KJ, Daoud EG, Gonzalez M, Saba S, et al. Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. 2015 Feb;26(2):151–7.Full Text Link to Item
-
Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, et al. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb;61(2):368–78.Full Text Link to Item
-
Vora AN, Holmes DN, Rokos I, Roe MT, Granger CB, French WJ, et al. Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. Jama Intern Med. 2015 Feb;175(2):207–15.Full Text Link to Item
-
Badar AA, Perez-Moreno AC, Hawkins NM, Brunton APT, Jhund PS, Wong CM, et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. Eur J Heart Fail. 2015 Feb;17(2):196–204.Full Text Link to Item
-
Halim SA, Neely ML, Pieper KS, Shah SH, Kraus WE, Hauser ER, et al. Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events. Circ Cardiovasc Genet. 2015 Feb;8(1):168–77.Full Text Link to Item
-
Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation. 2015 Jan 6;131(1):43–53.Full Text Link to Item
-
Granger CB, Gersh BJ. Potential relief for refractory Angina. New England Journal of Medicine. 2015 Jan 1;372(6):566–7.Full Text
-
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2015 Jan;169(1):25–30.Full Text Link to Item
-
van Diepen S, Granger CB, Jacka M, Gilchrist IC, Morrow DA, Katz JN. The unmet need for addressing cardiac issues in intensive care research. Crit Care Med. 2015 Jan;43(1):128–34.Full Text Link to Item
-
Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the ARISTOTLE trial (vol 169, pg 25, 2014). American Heart Journal. 2015;169(4):594–594.Link to Item
-
Magee MF, Tamis-Holland JE, Lu J, Bittner VA, Brooks MM, Lopes N, et al. Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D trial. International Journal of Endocrinology. 2015 Jan 1;2015.Full Text
-
Zullig LL, Gellad WF, Moaddeb J, Crowley MJ, Shrank W, Granger BB, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139–49.Full Text Link to Item
-
Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11;124(25):3692–8.Full Text Link to Item
-
Steinberg BA, Schulte P, Hofmann P, Ersboll M, Alexander JH, Broderick-Forsgren K, et al. Contemporary Use and Clinical Outcomes Following Non-Emergent Electrical Cardioversion for Atrial Fibrillation. Circulation. 2014 Nov 25;130.Link to Item
-
Park D-W, Clare RM, Schulte PJ, Pieper KS, Shaw LK, Califf RM, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. Jama. 2014 Nov 19;312(19):2019–27.Full Text Link to Item
-
Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18;130(21):1847–58.Full Text Link to Item
-
Desai AS, Claggett B, Pfeffer MA, Bello N, Finn PV, Granger CB, et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circ Heart Fail. 2014 Nov;7(6):895–902.Full Text Link to Item
-
Fosbøl EL, Dupre ME, Strauss B, Swanson DR, Myers B, McNally BF, et al. Association of neighborhood characteristics with incidence of out-of-hospital cardiac arrest and rates of bystander-initiated CPR: implications for community-based education intervention. Resuscitation. 2014 Nov;85(11):1512–7.Full Text Link to Item
-
Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, et al. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? Am Heart J. 2014 Nov;168(5):611–21.Full Text Link to Item
-
Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JLL, Granger CB, et al. How can we optimize the processes of care for acute coronary syndromes to improve outcomes? Am Heart J. 2014 Nov;168(5):622–31.Full Text Link to Item
-
Granger CB, Povsic TJ. Another biomarker for risk assessment in acute myocardial infarction? J Am Coll Cardiol. 2014 Oct 21;64(16):1708–10.Full Text Link to Item
-
Kelly J, Granger CB. Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Ann Intern Med. 2014 Oct 21;161(8):JC6.Full Text Link to Item
-
Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014 Oct 14;64(15):1541–50.Full Text Link to Item
-
Bagai A, Schulte PJ, Granger CB, Mahaffey KW, Christenson RH, Bell G, et al. Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Am Heart J. 2014 Oct;168(4):503-511.e2.Full Text Link to Item
-
Diener HC, Easton JD, Granger CB, Kreuzer J, Duffy C, Cotton D, et al. Rationale, objectives and design of a secondary stroke prevention study of dabigatran etexilate versus acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT-ESUS). International Journal of Stroke. 2014 Oct 1;9:216–216.Link to Item
-
Vinereanu D, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M, Cinteza M, et al. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am Heart J. 2014 Oct;168(4):446–56.Full Text Link to Item
-
Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet. 2014 Sep 27;384(9949):1187–95.Full Text Link to Item
-
Karlsson LIM, Wissenberg M, Fosbøl EL, Hansen CM, Lippert FK, Bagai A, et al. Diurnal variations in incidence and outcome of out-of-hospital cardiac arrest including prior comorbidity and pharmacotherapy: a nationwide study in Denmark. Resuscitation. 2014 Sep;85(9):1161–8.Full Text Link to Item
-
Steinberg BA, Broderick SH, Lopes RD, Shaw LK, Thomas KL, DeWald TA, et al. Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease. Europace. 2014 Sep;16(9):1284–90.Full Text Link to Item
-
Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost. 2014 Sep;12(9):1401–12.Full Text Link to Item
-
Hess PL, Mirro MJ, Diener H-C, Eikelboom JW, Al-Khatib SM, Hylek EM, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J. 2014 Sep;168(3):239-247.e1.Full Text Link to Item
-
Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv. 2014 Aug;7(4):585–93.Full Text Link to Item
-
Diener H-C, Granger CB, Patel MR. Is there a period of liability with initiation of warfarin in patients with atrial fibrillation? Eur Heart J. 2014 Jul 21;35(28):1834–5.Full Text Link to Item
-
Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21;35(28):1864–72.Full Text Link to Item
-
Bello NA, Claggett B, Desai AS, McMurray JJV, Granger CB, Yusuf S, et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail. 2014 Jul;7(4):590–5.Full Text Link to Item
-
Huber K, Gersh BJ, Goldstein P, Granger CB, Armstrong PW. The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions. Eur Heart J. 2014 Jun 14;35(23):1526–32.Full Text Link to Item
-
Bagai A, Dangas GD, Stone GW, Granger CB. Reperfusion strategies in acute coronary syndromes. Circ Res. 2014 Jun 6;114(12):1918–28.Full Text Link to Item
-
Bainey KR, Gafni A, Rao-Melacini P, Tong W, Steg PG, Faxon DP, et al. The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study. J Med Econ. 2014 Jun;17(6):415–22.Full Text Link to Item
-
Granger CB, Rao MP. Assessing oral beta-blocker therapy after percutaneous coronary intervention for ST-segment elevation myocardial infarction: the role of observational data. Jacc Cardiovasc Interv. 2014 Jun;7(6):602–3.Full Text Link to Item
-
Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014 May 27;63(20):2141–7.Full Text Link to Item
-
STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 1;370(18):1702–11.Full Text Link to Item
-
Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014 Apr;13(4):429–38.Full Text Link to Item
-
Rao MP, Granger CB. Improving integrated care in low- and middle-income countries: the final STEMI frontier? J Interv Cardiol. 2014 Apr;27(2):167–70.Full Text Link to Item
-
Nelson JA, Vavalle JP, May CH, Zhang A, Newby LK, Shaw LK, et al. Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. J Thromb Thrombolysis. 2014 Apr;37(3):331–7.Full Text Link to Item
-
Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63(11):1082–7.Full Text Link to Item
-
Granger CB, Chertow GM. A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease. Circulation. 2014 Mar 18;129(11):1190–2.Full Text Link to Item
-
Bagai A, Jollis JG, Dauerman HL, Peng SA, Rokos IC, Bates ER, et al. Response to letter regarding article, "Emergency department bypass for ST-segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline Program". Circulation. 2014 Mar 4;129(9):e372.Full Text Link to Item
-
Calvo G, McMurray JJV, Granger CB, Alonso-García Á, Armstrong P, Flather M, et al. Large streamlined trials in cardiovascular disease. Eur Heart J. 2014 Mar;35(9):544–8.Full Text Link to Item
-
Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625–34.Full Text Link to Item
-
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". Circulation. 2014 Jan 14;129(2):e21–2.Full Text Link to Item
-
Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014 Jan;35(4):224–32.Full Text Link to Item
-
Bagai A, Al-Khalidi HR, Sherwood MW, Muñoz D, Roettig ML, Jollis JG, et al. Regional systems of care demonstration project: Mission: Lifeline STEMI Systems Accelerator: design and methodology. Am Heart J. 2014 Jan;167(1):15-21.e3.Full Text Link to Item
-
Granger CB, Becker LB. Randomized clinical trial progress to inform care for out-of-hospital cardiac arrest. Jama. 2014 Jan 1;311(1):31–2.Full Text Link to Item
-
Rao MP, Pokorney SD, Granger CB. Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute. Scientifica (Cairo). 2014;2014:901586.Full Text Link to Item
-
Rogers JK, Pocock SJ, McMurray JJV, Granger CB, Michelson EL, Östergren J, et al. Corrigendum to 'Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-Preserved' [ Eur J Heart Fail 2014;16:33-40]. European Journal of Heart Failure. 2014 Jan 1;16(5):592.Full Text
-
Bao MH, Zheng Y, Westerhout CM, Fu Y, Wagner GS, Chaitman B, et al. Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. J Electrocardiol. 2014;47(4):465–71.Full Text Link to Item
-
Bhattacharya S, Granger CB, Craig D, Haynes C, Bain J, Stevens RD, et al. Validation of the association between a branched chain amino acid metabolite profile and extremes of coronary artery disease in patients referred for cardiac catheterization. Atherosclerosis. 2014 Jan;232(1):191–6.Full Text Link to Item
-
Rogers JK, Pocock SJ, McMurray JJV, Granger CB, Michelson EL, Östergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014 Jan;16(1):33–40.Full Text Link to Item
-
Bagai A, McNally BF, Al-Khatib SM, Myers JB, Kim S, Karlsson L, et al. Temporal differences in out-of-hospital cardiac arrest incidence and survival. Circulation. 2013 Dec 17;128(24):2595–602.Full Text Link to Item
-
Bahit MC, Lopes RD, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013 Dec 10;170(2):215–20.Full Text Link to Item
-
Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, et al. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845–54.Full Text Link to Item
-
Bagai A, Armstrong PW, Stebbins A, Mahaffey KW, Hochman JS, Weaver WD, et al. Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. Am Heart J. 2013 Nov;166(5):913–9.Full Text Link to Item
-
Fosbøl EL, Granger CB. Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction. Eur Heart J. 2013 Nov;34(41):3171–2.Full Text Link to Item
-
Stewart R, Held C, Brown R, Vedin O, Hagstrom E, Lonn E, et al. Physical activity in patients with stable coronary heart disease: an international perspective. Eur Heart J. 2013 Nov;34(42):3286–93.Full Text Link to Item
-
Hijazi Z, Granger CB, Wallentin L. Reply: Higher N-terminal Pro-B-type natriuretic peptide may be related to very different conditions. J Am Coll Cardiol. 2013 Oct 22;62(17):1635–6.Full Text Link to Item
-
van Diepen S, Newby LK, Stebbins A, Armstrong PW, Granger CB. Response to letter "associations of inflammatory biomarkers to body mass index among patients with acute coronary syndrome". Int J Cardiol. 2013 Oct 9;168(4):4543.Full Text Link to Item
-
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, et al. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol. 2013 Oct 3;168(3):2127–33.Full Text Link to Item
-
van Diepen S, Abella BS, Bobrow BJ, Nichol G, Jollis JG, Mellor J, et al. Multistate implementation of guideline-based cardiac resuscitation systems of care: description of the HeartRescue project. Am Heart J. 2013 Oct;166(4):647-653.e2.Full Text Link to Item
-
Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206–14.Full Text Link to Item
-
Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, et al. Randomized clinical trials--removing unnecessary obstacles. N Engl J Med. 2013 Sep 12;369(11):1061–5.Full Text Link to Item
-
Alonso A, Gore JM, Awad HH, Quill AL, Montalescot G, van de Werf F, et al. Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. Eur Heart J Acute Cardiovasc Care. 2013 Sep;2(3):280–91.Full Text Link to Item
-
Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549–58.Full Text Link to Item
-
Hess CN, Al-Khatib SM, Granger CB, Lopes R. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1105–14.Full Text Link to Item
-
van Diepen S, Vavalle JP, Newby LK, Clare R, Pieper KS, Ezekowitz JA, et al. The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. Crit Care Med. 2013 Sep;41(9):2080–7.Full Text Link to Item
-
Alexander JH, Levy E, Lawrence J, Hanna M, Waclawski AP, Wang J, et al. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. Am Heart J. 2013 Sep;166(3):559–65.Full Text Link to Item
-
Fullwood JE, Mostaghimi Z, Granger CB, Washam JB, Bride W, Zhao Y, et al. Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study. Am J Crit Care. 2013 Sep;22(5):398–406.Full Text Link to Item
-
Henry TD, Jacobs AK, Granger CB. Regional systems of care for ST-elevation myocardial infarction: do they save lives? Am Heart J. 2013 Sep;166(3):389–91.Full Text Link to Item
-
Cannon C, Ezekowitz MD, Granger C. Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. Am J Cardiol. 2013 Aug 15;112(4):S3.Full Text Link to Item
-
Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013 Aug;34(31):2464–71.Full Text Link to Item
-
Alherbish A, Westerhout CM, Fu Y, White HD, Granger CB, Wagner G, et al. The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients? Am Heart J. 2013 Aug;166(2):333–9.Full Text Link to Item
-
Bagai A, Al-Khalidi HR, Muñoz D, Monk L, Roettig ML, Corbett CC, et al. Bypassing the emergency department and time to reperfusion in patients with prehospital ST-segment-elevation: findings from the reperfusion in acute myocardial infarction in Carolina Emergency Departments project. Circ Cardiovasc Interv. 2013 Aug;6(4):399–406.Full Text Link to Item
-
Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc. 2013 Aug;78(2):227–39.Full Text Link to Item
-
Bagai A, Jollis JG, Dauerman HL, Peng SA, Rokos IC, Bates ER, et al. Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation. 2013 Jul 23;128(4):352–9.Full Text Link to Item
-
Lopes RD, Becker RC, Newby LK, Peterson ED, Hylek EM, Giugliano R, et al. Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. J Thromb Thrombolysis. 2013 Jul;36(1):115–30.Full Text Link to Item
-
O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013 Jul 1;82(1):E1-27.Full Text Link to Item
-
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4;127(22):2166–76.Full Text Link to Item
-
Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4;61(22):2274–84.Full Text Link to Item
-
Bagai A, Granger CB. Acute coronary syndromes. STREAMlining care for patients with STEMI. Nat Rev Cardiol. 2013 Jun;10(6):304–6.Full Text Link to Item
-
Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, et al. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. Jacc Heart Fail. 2013 Jun;1(3):223–9.Full Text Link to Item
-
Eapen ZJ, Vavalle JP, Granger CB, Harrington RA, Peterson ED, Califf RM. Rescuing clinical trials in the United States and beyond: a call for action. Am Heart J. 2013 Jun;165(6):837–47.Full Text Link to Item
-
Nicolau JC, Corbalan R, Diaz R, Bahit C, Armstrong PW, Granger CB, et al. Cardiovascular clinical research in South America. Am Heart J. 2013 Jun;165(6):848–53.Full Text Link to Item
-
Lopes RD, Lokhnygina Y, Hasselblad V, Newby KL, Yow E, Granger CB, et al. Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. Trials. 2013 May 2;14:123.Full Text Open Access Copy Link to Item
-
McMurray JJV, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013 May;6(3):451–60.Full Text Link to Item
-
Wong C, Hawkins NM, Jhund P, Solomon SD, Granger CB, Yusuf S, et al. Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme. European Journal of Heart Failure. 2013 May 1;12:S110–S110.Link to Item
-
Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013 May;34(20):1475–80.Full Text Link to Item
-
Lopes RD, Granger CB, Alexander KP. The reply. Am J Med. 2013 May;126(5):e21.Full Text Link to Item
-
Rose JJ, Newby LK, Broderick S, Chiswell K, Van de Werf F, Armstrong PW, et al. Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. J Am Coll Cardiol. 2013 Apr 2;61(13):1461–3.Full Text Link to Item
-
Guptill JT, Mehta RH, Armstrong PW, Horton J, Laskowitz D, James S, et al. Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes. Circ Cardiovasc Interv. 2013 Apr;6(2):176–83.Full Text Link to Item
-
Fosbøl EL, Granger CB, Peterson ED, Lin L, Lytle BL, Shofer FS, et al. Prehospital system delay in ST-segment elevation myocardial infarction care: a novel linkage of emergency medicine services and in hospital registry data. Am Heart J. 2013 Mar;165(3):363–70.Full Text Link to Item
-
van Diepen S, Cook DJ, Jacka M, Granger CB. Critical care cardiology research: a call to action. Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):237–42.Full Text Link to Item
-
Westerhout CM, Pieper KS, James SK, Mahaffey KW, de Werf FV, Califf RM, et al. Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Am Heart J. 2013 Mar;165(3):354-62.e2.Full Text Link to Item
-
Khazanie P, Granger CB. ACP Journal Club. A 10-year exercise program improved oxygen consumption and quality of life in stable chronic heart failure. Ann Intern Med. 2013 Feb 19;158(4):JC6.Full Text Link to Item
-
Fosbol EL, Granger CB, Jollis JG, Monk L, Lin L, Lytle BL, et al. The impact of a statewide pre-hospital STEMI strategy to bypass hospitals without percutaneous coronary intervention capability on treatment times. Circulation. 2013 Feb 5;127(5):604–12.Full Text Link to Item
-
Patel MR, Westerhout CM, Granger CB, Brener SJ, Fu Y, Siha H, et al. Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J. 2013 Feb;165(2):226–33.Full Text Link to Item
-
Huber K, Goldstein P, Danchin N, Fox KAA, Welsh R, Granger CB, et al. Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. Am Heart J. 2013 Feb;165(2):123–32.Full Text Link to Item
-
O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78–140.Full Text Link to Item
-
O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):485–510.Full Text Link to Item
-
Khazanie P, Granger CB. Commentary. Annals of Internal Medicine. 2013;158(4):JC6.
-
O’malley RG, Olenchock B, Bohula-May E, Barnett C, Fintel DJ, Granger CB, et al. Organization and staffing practices in US cardiac intensive care units: A survey on behalf of the American Heart Association Writing Group on the Evolution of Critical Care Cardiology. European Heart Journal: Acute Cardiovascular Care. 2013 Jan 1;2(1):3–8.Full Text
-
Kaul P, Fu Y, Westerhout CM, Granger CB, Armstrong PW. Relative prognostic value of baseline Q wave and time from symptom onset among men and women with ST-elevation myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2012 Dec 1;110(11):1555–60.Full Text Link to Item
-
Wang TY, Honeycutt EF, Tapson VF, Moll S, Granger CB, Ohman EM. Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. Am J Med. 2012 Dec;125(12):1214–21.Full Text Link to Item
-
Alherbish A, Westerhout CM, Fu Y, Granger CB, Armstrong PW. The Forgotten Lead: Does aVR ST-Deviation Add Insight into STEMI Patients? Circulation. 2012 Nov 20;126(21).Link to Item
-
Bagai A, Iollis JG, Dauerman HL, Peng SA, Bates ER, French WJ, et al. Bypassing the Emergency Department is Associated with Faster Reperfusion in Patients with Pre-Hospital ST-Segment Elevation: Findings from the ACTION Registry (R)-GWTG (TM). Circulation. 2012 Nov 20;126(21).Link to Item
-
Cecilia Bahit M, Lopes RD, Hohnloser SH, Wojdyla D, Alexander JH, Lewis BS, et al. Apixaban in Patients with Atrial Fibrillation and Prior Coronary Artery Disease: Insights from the ARISTOTLE Trial. Circulation. 2012 Nov 20;126(21).Link to Item
-
Vavalle JP, van Diepen S, Lopes R, Clare R, Hochman JS, Weaver D, et al. Worse Renal Function is Associated with Markedly Worse Outcomes Among STEMI Patients Undergoing Primary PCI: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction ( APEX AMI) Trial. Circulation. 2012 Nov 20;126(21).Link to Item
-
van Diepen S, Vavalle IP, Newby LK, Clare R, Pieper KS, Ezekowitz JA, et al. The Systemic Inflammatory Response Syndrome is associated with Worse Outcomes in ST-Elevation Myocardial Infarction Patients: Insights from the CARDINAL Trial. Circulation. 2012 Nov 20;126(21).Link to Item
-
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749–58.Full Text Link to Item
-
Vavalle JP, Lopes RD, Chen AY, Newby LK, Wang TY, Shah BR, et al. Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. Am J Med. 2012 Nov;125(11):1085–94.Full Text Link to Item
-
Bagai A, Granger CB. Regionalization of ST-segment elevation myocardial infarction care: a task unfinished. Am Heart J. 2012 Nov;164(5):633–5.Full Text Link to Item
-
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 Nov;33(22):2821–30.Full Text Link to Item
-
Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J. 2012 Nov;164(5):646-653.e3.Full Text Link to Item
-
Hess CN, Broderick S, Piccini JP, Alexander KP, Newby LK, Shaw LK, et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. Am Heart J. 2012 Oct;164(4):607–15.Full Text Link to Item
-
Turakhia MP, Estes NAM, Drew BJ, Granger CB, Wang PJ, Knight BP, et al. Latency of ECG displays of hospital telemetry systems: a science advisory from the American Heart Association. Circulation. 2012 Sep 25;126(13):1665–9.Full Text Link to Item
-
Morrow DA, Fang JC, Fintel DJ, Granger CB, Katz JN, Kushner FG, et al. Evolution of critical care cardiology: transformation of the cardiovascular intensive care unit and the emerging need for new medical staffing and training models: a scientific statement from the American Heart Association. Circulation. 2012 Sep 11;126(11):1408–28.Full Text Link to Item
-
Ciervo CA, Granger CB, Schaller FA, Engelke KA. A new era of anticoagulation treatment: optimizing outcomes for atrial fibrillation. J Am Osteopath Assoc. 2012 Sep;112(9 Suppl 2):eS9-e21.Link to Item
-
Ciervo CA, Granger CB, Schaller FA. Stroke prevention in patients with atrial fibrillation: disease burden and unmet medical needs. J Am Osteopath Assoc. 2012 Sep;112(9 Suppl 2):eS2–8.Link to Item
-
Johnson RW, Zhao Y, Newby LK, Granger CB, Granger BB. Reasons for noncompletion of advance directives in a cardiac intensive care unit. Am J Crit Care. 2012 Sep;21(5):311–20.Full Text Link to Item
-
Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M, et al. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. Am J Med. 2012 Sep;125(9):897–905.Full Text Link to Item
-
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, et al. 726 Acute Phase Inflammatory Biomarkers Add Little Predictive Value to Clinical Factors Plus NT-proBNP Among Patients With ST-Segment Elevation Myocardial Infarction: An Apex AMI Trial Substudy. Canadian Journal of Cardiology. 2012 Sep;28(5):S378–S378.Full Text
-
Muñoz D, Roettig ML, Monk L, Al-Khalidi H, Jollis JG, Granger CB. Transport time and care processes for patients transferred with ST-segment-elevation myocardial infarction: the reperfusion in acute myocardial infarction in Carolina emergency rooms experience. Circ Cardiovasc Interv. 2012 Aug 1;5(4):555–62.Full Text Link to Item
-
Garcia DA, Granger CB. Anticoagulation, novel agents, and procedures: can we pardon the interruption? Circulation. 2012 Jul 17;126(3):255–7.Full Text Link to Item
-
Jollis JG, Al-Khalidi HR, Monk L, Roettig ML, Garvey JL, Aluko AO, et al. Expansion of a regional ST-segment-elevation myocardial infarction system to an entire state. Circulation. 2012 Jul 10;126(2):189–95.Full Text Link to Item
-
Jollis JG, Granger CB, Henry TD, Antman EM, Berger PB, Moyer PH, et al. Systems of care for ST-segment-elevation myocardial infarction: a report From the American Heart Association's Mission: Lifeline. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):423–8.Full Text Link to Item
-
Martel C, Granger CB, Ghitescu M, Stebbins A, Fortier A, Armstrong PW, et al. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J. 2012 Jul;164(1):43–51.Full Text Link to Item
-
van Diepen S, Widimsky P, Lopes RD, White KR, Weaver WD, Van de Werf F, et al. Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):437–44.Full Text Link to Item
-
Lopes RD, Becker RC, Newby LK, Peterson ED, Hylek EM, Granger CB, et al. Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2012 Jul;34(1):143–63.Full Text Link to Item
-
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012 Jul;33(14):1750–7.Full Text Link to Item
-
Truffa AAM, Granger CB, White KR, Newby LK, Mehta RH, Hochman JS, et al. Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes. Jacc Cardiovasc Interv. 2012 Jul;5(7):769–76.Full Text Link to Item
-
van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, et al. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis. 2012 Jul;34(1):106–13.Full Text Link to Item
-
Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503–11.Full Text Link to Item
-
Steinberg BA, Jollis JG, Winkler A, Granger C, Newby LK. Treatment pathways and quality improvement for patients with acute myocardial infarction at a tertiary care center. Crit Pathw Cardiol. 2012 Jun;11(2):77–80.Full Text Link to Item
-
Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012 Jun;163(6):931-937.e1.Full Text Link to Item
-
Wiggins NB, Granger CB, Alexander JH. Novel oral anticoagulants after acute coronary syndromes. Cardiovasc Drugs Ther. 2012 Jun;26(3):265–71.Full Text Link to Item
-
Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012 May 15;59(20):1785–95.Full Text Link to Item
-
Mehta RH, Kaul P, Lopes RD, Patel MR, Zheng Y, Pieper KS, et al. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. Am Heart J. 2012 May;163(5):797–803.Full Text Link to Item
-
Van de Werf F, Connolly SJ, Kappetein AP, Brueckmann M, Mack MJ, Granger CB, et al. Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". Stroke. 2012 May;43(5):e46–7.Full Text Link to Item
-
Shah SH, Sun J-L, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J. 2012 May;163(5):844-850.e1.Full Text Link to Item
-
Muñoz D, Granger CB. ACP Journal Club. Review: Statins reduce mortality and cardiovascular (CV) morbidity in patients with low CV risk. Ann Intern Med. 2012 Apr 17;156(8):JC4-J07.Full Text Link to Item
-
Davies RW, Wells GA, Stewart AFR, Erdmann J, Shah SH, Ferguson JF, et al. A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet. 2012 Apr 1;5(2):217–25.Full Text Link to Item
-
Glickman SW, Greiner MA, Lin L, Curtis LH, Cairns CB, Granger CB, et al. Assessment of temporal trends in mortality with implementation of a statewide ST-segment elevation myocardial infarction (STEMI) regionalization program. Ann Emerg Med. 2012 Apr;59(4):243-252.e1.Full Text Link to Item
-
Shah AA, Craig DM, Sebek JK, Haynes C, Stevens RC, Muehlbauer MJ, et al. Metabolic profiles predict adverse events after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2012 Apr;143(4):873–8.Full Text Link to Item
-
Glickman SW, Shofer FS, Wu MC, Scholer MJ, Ndubuizu A, Peterson ED, et al. Development and validation of a prioritization rule for obtaining an immediate 12-lead electrocardiogram in the emergency department to identify ST-elevation myocardial infarction. Am Heart J. 2012 Mar;163(3):372–82.Full Text Link to Item
-
Mills JS, Mahaffey KW, Lokhnygina Y, Nicolau JC, Ruzyllo W, Adams PX, et al. Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. Coron Artery Dis. 2012 Mar;23(2):118–25.Full Text Link to Item
-
van Diepen S, Granger CB. Acute coronary syndromes. Challenging accepted post-MI serum potassium targets. Nat Rev Cardiol. 2012 Feb 28;9(5):259–60.Full Text Link to Item
-
Nolan DK, Sutton B, Haynes C, Johnson J, Sebek J, Dowdy E, et al. Fine mapping of a linkage peak with integration of lipid traits identifies novel coronary artery disease genes on chromosome 5. Bmc Genet. 2012 Feb 27;13:12.Full Text Link to Item
-
Guzman LA, Li S, Wang TY, Daviglus ML, Exaire J, Rodriguez CJ, et al. Differences in treatment patterns and outcomes between Hispanics and non-Hispanic Whites treated for ST-segment elevation myocardial infarction: results from the NCDR ACTION Registry-GWTG. J Am Coll Cardiol. 2012 Feb 7;59(6):630–1.Full Text Link to Item
-
Al-Khatib SM, Alexander JH, Lopes RD, Mahaffey KW, Patel MR, Granger CB. Promise of factor Xa inhibition in atrial fibrillation. Curr Cardiol Rep. 2012 Feb;14(1):70–8.Full Text Link to Item
-
Diener H-C, Eikelboom J, Granger CB, Hacke W. The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War? Int J Stroke. 2012 Feb;7(2):139–41.Full Text Link to Item
-
Mehta RH, Stebbins AS, Lopes RD, Califf RM, Pieper KS, Armstrong PW, et al. Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. Am J Cardiol. 2012 Feb 1;109(3):320–6.Full Text Link to Item
-
Hernandez AF, Granger CB. Prediction is very hard, especially about the future: comment on "factors associated with 30-day readmission rates after percutaneous coronary intervention". Arch Intern Med. 2012 Jan 23;172(2):117–9.Full Text Link to Item
-
Garvey JL, Monk L, Granger CB, Studnek JR, Roettig ML, Corbett CC, et al. Rates of cardiac catheterization cancelation for ST-segment elevation myocardial infarction after activation by emergency medical services or emergency physicians: results from the North Carolina Catheterization Laboratory Activation Registry. Circulation. 2012 Jan 17;125(2):308–13.Full Text Link to Item
-
Granger CB. Apixaban reduced stroke and systemic embolism compared with warfarin in atrial fibrillation. Annals of Internal Medicine. 2012 Jan 17;156(2).
-
Granger CB, Hanna M, Wallentin L. The authors reply. New England Journal of Medicine. 2012 Jan 5;366(1):89.
-
Granger CB, Hanna M, Wallentin L. Apixaban versus Warfarin in Atrial Fibrillation REPLY. New England Journal of Medicine. 2012 Jan 5;366(1):89–89.Link to Item
-
Kociol RD, Lopes RD, Clare R, Thomas L, Mehta RH, Kaul P, et al. International variation in and factors associated with hospital readmission after myocardial infarction. Jama. 2012 Jan 4;307(1):66–74.Full Text Link to Item
-
Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012 Jan 3;125(1):159–64.Full Text Link to Item
-
Lofthus DM, Stevens SR, Armstrong PW, Granger CB, Mahaffey KW. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. Coron Artery Dis. 2012 Jan;23(1):22–30.Full Text Link to Item
-
Yancy CW, Granger CB, Nichol G. Systems of health care. 2012 Jan 1;67–74.Full Text
-
Zeymer U, Huber K, fu Y, Ross A, Granger C, Goldstein P, et al. Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: Results from the ASSENT-4 PCI study. European Heart Journal: Acute Cardiovascular Care. 2012 Jan 1;1(2):136–42.Full Text
-
Wang TY, Granger CB. ACP Journal Club. Review: Reduced function CYP2C19 genotypes may increase risk for stent clots in patients receiving clopidogrel. Ann Intern Med. 2011 Dec 20;155(12):JC6-J13.Full Text Link to Item
-
Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268–76.Full Text Link to Item
-
Muñoz D, Granger CB. ST-segment-elevation myocardial infarction treatment and the seductive lure of observational analyses. Circulation. 2011 Dec 6;124(23):2477–9.Full Text Link to Item
-
Brunner MP, Shah SH, Craig DM, Stevens RD, Muehlbauer MJ, Bain JR, et al. Effect of heparin administration on metabolomic profiles in samples obtained during cardiac catheterization. Circ Cardiovasc Genet. 2011 Dec;4(6):695–700.Full Text Link to Item
-
Cecilia Bahit M, Lopes RD, Clare R, Pieper KS, Newby LK, Van de Werf FF, et al. Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes. Circulation. 2011 Nov 22;124(21).Link to Item
-
Guptill JT, Lopes RD, Mehta RH, Horton J, Laskowitz D, Pieper KS, et al. Most Strokes Occur More Than 48 Hours Following Primary Percutaneous Coronary Intervention in STEMI: the Stroke Experience in APEX-AMI Trial. Circulation. 2011 Nov 22;124(21).Link to Item
-
Bhattacharya S, Craig D, Haynes C, Granger CB, Stevens RD, Hauser ER, et al. Peripheral Metabolite Profiles Discriminate Coronary Artery Disease in a Sequential Cohort of Cardiac Catheterization Patients. Circulation. 2011 Nov 22;124(21).Link to Item
-
Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011 Nov;32(22):2781–9.Full Text Link to Item
-
Ariti CA, Cleland JGF, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2011 Nov;162(5):900–6.Full Text Link to Item
-
Mayer SA, Kurtz P, Wyman A, Sung GY, Multz AS, Varon J, et al. Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension registry. Crit Care Med. 2011 Oct;39(10):2330–6.Full Text Link to Item
-
Steg PG, Mehta SR, Jukema JW, Lip GYH, Gibson CM, Kovar F, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011 Oct;32(20):2541–54.Full Text Link to Item
-
Peacock F, Amin A, Granger CB, Pollack CV, Levy P, Nowak R, et al. Hypertensive heart failure: patient characteristics, treatment, and outcomes. Am J Emerg Med. 2011 Oct;29(8):855–62.Full Text Link to Item
-
Lopes RD, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, et al. Diagnosing acute myocardial infarction in patients with left bundle branch block. Am J Cardiol. 2011 Sep 15;108(6):782–8.Full Text Link to Item
-
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–92.Full Text Link to Item
-
Holmes DR, Becker JA, Granger CB, Limacher MC, Page RL, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation. 2011 Sep 13;124(11):1290–310.Full Text Link to Item
-
Holmes DR, Becker JA, Granger CB, Limacher MC, Page RL, Sila C, et al. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. J Am Coll Cardiol. 2011 Sep 13;58(12):1287–307.Full Text Link to Item
-
Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, et al. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. Am J Cardiol. 2011 Sep 1;108(5):617–24.Full Text Link to Item
-
Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, et al. Medication adherence: a call for action. Am Heart J. 2011 Sep;162(3):412–24.Full Text Link to Item
-
Fosbol EL, Granger CB. ACP Journal Club. Meta-analysis: high-dose statin pretreatment prevents periprocedural cardiac events in patients having PCI. Ann Intern Med. 2011 Aug 16;155(4):JC2–8.Full Text Link to Item
-
Vavalle JP, Granger CB. The need for regional integrated care for ST-segment elevation myocardial infarction. Circulation. 2011 Aug 16;124(7):851–6.Full Text Link to Item
-
Granger CB. Who should have a routine early invasive approach after fibrinolytic therapy? Eur Heart J. 2011 Aug;32(16):1961–3.Full Text Link to Item
-
Mehta RH, Kaul P, Lopes RD, Patel MR, Pieper KS, Armstrong PW, et al. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial. European Heart Journal. 2011 Aug 1;32:872–872.Link to Item
-
Mehta RH, Stebbins A, Lopes RD, Califf RM, Alexander JH, Granger CB. Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction. European Heart Journal. 2011 Aug 1;32:166–166.Link to Item
-
Chan MY, Shah BR, Gao F, Sim LL, Chua T, Tan HC, et al. Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population. Am Heart J. 2011 Aug;162(2):291–9.Full Text Link to Item
-
Lopes RD, Becker RC, Alexander JH, Armstrong PW, Califf RM, Chan MY, et al. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. J Thromb Thrombolysis. 2011 Aug;32(2):242–66.Full Text Link to Item
-
French JK, Armstrong PW, Cohen E, Kleiman NS, O’Connor CM, Hellkamp AS, et al. Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". Am Heart J. 2011 Jul;162(1):89–97.Full Text Link to Item
-
Glickman SW, Lytle BL, Ou F-S, Mears G, O’Brien S, Cairns CB, et al. Care processes associated with quicker door-in-door-out times for patients with ST-elevation-myocardial infarction requiring transfer: results from a statewide regionalization program. Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):382–8.Full Text Link to Item
-
Gersh BJ, Freedman JE, Granger CB. Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments. Rev Esp Cardiol (Engl Ed). 2011 Apr;64(4):260–8.Full Text Link to Item
-
Mehta RH, Starr AZ, Lopes RD, Piccini JP, Patel MR, Pieper KS, et al. Relationship of sustained ventricular tachyarrhythmias to outcomes in patients undergoing primary percutaneous coronary intervention with varying underlying baseline risk. Am Heart J. 2011 Apr;161(4):782–9.Full Text Link to Item
-
ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011 Apr;29(4):623–35.Full Text Link to Item
-
Gersh BJ, Freedman JE, Granger CB. [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. Rev Esp Cardiol. 2011 Apr;64(4):260–8.Full Text Link to Item
-
Gharacholou SM, Lopes RD, Alexander KP, Mehta RH, Stebbins AL, Pieper KS, et al. Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial. Arch Intern Med. 2011 Mar 28;171(6):559–67.Full Text Link to Item
-
Szczech LA, Granger CB, Katz JN, Dasta JF, Amin A, Peacock WF, et al. Response to letter regarding article, acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation. 2011 Mar 8;123(9).Full Text
-
Hudson MP, Armstrong PW, O’Neil WW, Stebbins AL, Weaver WD, Widimsky P, et al. Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):183–92.Full Text Link to Item
-
Mahaffey KW, Wampole JL, Stebbins A, Berdan LG, McAfee D, Rorick TL, et al. Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Contemp Clin Trials. 2011 Mar;32(2):178–87.Full Text Link to Item
-
de Boer SPM, Barnes EH, Westerhout CM, Simes RJ, Granger CB, Kastrati A, et al. High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. Am Heart J. 2011 Mar;161(3):500-507.e1.Full Text Link to Item
-
Mehta RH, O’Shea JC, Stebbins AL, Granger CB, Armstrong PW, White HD, et al. Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. J Am Coll Cardiol. 2011 Jan 11;57(2):138–46.Full Text Link to Item
-
Vuylsteke A, Vincent J-L, de La Garanderie DP, Anderson FA, Emery L, Wyman A, et al. Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT). Crit Care. 2011;15(6):R271.Full Text Link to Item
-
Mehta RH, Stebbins A, Lopes RD, Rao SV, Bates ER, Pieper KS, et al. Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. Am J Med. 2011 Jan;124(1):48–57.Full Text Link to Item
-
Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al. Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. Crit Care Med. 2011 Jan;39(1):78–83.Full Text Link to Item
-
Weed J, Finkel K, Beach ML, Granger CB, Gallagher JD, Sites BD. Spinal anesthesia for orthopedic surgery: a detailed video assessment of quality. Reg Anesth Pain Med. 2011;36(1):51–5.Full Text Link to Item
-
Steg PG, Mehta S, Jolly S, Xavier D, Rupprecht H-J, Lopez-Sendon JL, et al. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. Am Heart J. 2010 Dec;160(6):1029-1034.e1.Full Text Link to Item
-
Lopes RD, Li L, Granger CB, Wang TY, Foody JM, Funk M, et al. Discharge Warfarin is Underused in High Risk Atrial Fibrillation Patients With Myocardial Infarction. Circulation. 2010 Nov 23;122(21).Link to Item
-
Patel MR, Westerhout CM, Granger CB, Fu Y, Kim RJ, Armstrong PW. Aborted Myocardial Infarction after Primary PCI: Insights from Magnetic Resonance Imaging in the APEX-AMI Trial. Circulation. 2010 Nov 23;122(21).Link to Item
-
Stewart AF, Dandona S, Fan M, Almontashiri N, Chen L, Davies RW, et al. Identification of a Rare Variant Near Neurexin 1 Associated with Coronary Artery Disease. Circulation. 2010 Nov 23;122(21).Link to Item
-
Assimes TL, Hólm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010 Nov 2;56(19):1552–63.Full Text Link to Item
-
Devlin JW, Dasta JF, Kleinschmidt K, Roberts RJ, Lapointe M, Varon J, et al. Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registry. Pharmacotherapy. 2010 Nov;30(11):1087–96.Full Text Link to Item
-
Mehta SR, Tanguay J-F, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233–43.Full Text Link to Item
-
Stebbins A, Mehta RH, Armstrong PW, Lee KL, Hamm C, Van de Werf F, et al. A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv. 2010 Oct;3(5):414–22.Full Text Link to Item
-
Toma M, Fu Y, Ezekowitz JA, McAlister FA, Westerhout CM, Granger CB, et al. Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. Am Heart J. 2010 Oct;160(4):671–7.Full Text Link to Item
-
Granger CB, Laskowitz DT. Biomarkers in stroke: when will they impact care? J Am Coll Cardiol. 2010 Sep 21;56(13):1054–5.Full Text Link to Item
-
CURRENT-OASIS 7 Investigators, Mehta SR, Bassand J-P, Chrolavicius S, Diaz R, Eikelboom JW, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):930–42.Full Text Link to Item
-
Glickman SW, Granger CB, Ou F-S, O’Brien S, Lytle BL, Cairns CB, et al. Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderly. Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):514–21.Full Text Link to Item
-
Gore JM, Peterson E, Amin A, Anderson FA, Dasta JF, Levy PD, et al. Predictors of 90-day readmission among patients with acute severe hypertension. The cross-sectional observational Studying the Treatment of Acute hyperTension (STAT) study. Am Heart J. 2010 Sep;160(3):521-527.e1.Full Text Link to Item
-
Shah SH, Granger CB, Hauser ER, Kraus WE, Sun J-L, Pieper K, et al. Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. Am Heart J. 2010 Sep;160(3):371-379.e2.Full Text Link to Item
-
Tjandrawidjaja MC, Fu Y, Westerhout CM, Wagner GS, Granger CB, Armstrong PW, et al. Usefulness of the QRS score as a strong prognostic marker in patients discharged after undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol. 2010 Sep 1;106(5):630–4.Full Text Link to Item
-
Ezekowitz JA, Armstrong PW, Granger CB, Theroux P, Stebbins A, Kim RJ, et al. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Am Heart J. 2010 Aug;160(2):272–8.Full Text Link to Item
-
Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries J-PPM, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010 Aug;42(8):692–7.Full Text Link to Item
-
Patel MR, Worthley SG, Stebbins A, Dill T, Rademakers FE, Velleti US, et al. Erratum: Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: A delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial (J Am Coll Cardiol Img (2010) 3 (52-60)). Jacc: Cardiovascular Imaging. 2010 Jul 1;3(7):796.Full Text
-
Chang SM, Granger CB, Johansson PA, Kosolcharoen P, McMurray JJV, Michelson EL, et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2010 Jul;12(7):738–45.Full Text Link to Item
-
Huber K, Holmes DR, van ’t Hof AW, Montalescot G, Aylward PE, Betriu GA, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J. 2010 Jul;31(14):1708–16.Full Text Link to Item
-
Johnson RW, Newby LK, Granger CB, Cook WA, Peterson ED, Echols M, et al. Differences in level of care at the end of life according to race. Am J Crit Care. 2010 Jul;19(4):335–43.Full Text Link to Item
-
Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes DR, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J. 2010 Jul;31(14):1701–7.Full Text Link to Item
-
Eisenstein EL, Honeycutt EF, Anstrom KJ, Becker RC, Granger CB, Rao SV, et al. Economic assessment of thrombocytopenia: CATCH Registry. J Med Syst. 2010 Jun;34(3):379–86.Full Text Link to Item
-
Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010 Jun;12(6):557–65.Full Text Link to Item
-
López-Sendón J, Gurfinkel EP, Lopez de Sa E, Agnelli G, Gore JM, Steg PG, et al. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J. 2010 Jun;31(12):1449–56.Full Text Link to Item
-
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, et al. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart. 2010 Jun;96(11):838–42.Full Text Link to Item
-
Simes RJ, O’Connell RL, Aylward PE, Varshavsky S, Diaz R, Wilcox RG, et al. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. Am Heart J. 2010 Jun;159(6):988–97.Full Text Link to Item
-
Spencer FA, Montalescot G, Fox KAA, Goodman SG, Granger CB, Goldberg RJ, et al. Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. Eur Heart J. 2010 Jun;31(11):1328–36.Full Text Link to Item
-
Szczech LA, Granger CB, Dasta JF, Amin A, Peacock WF, McCullough PA, et al. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation. 2010 May 25;121(20):2183–91.Full Text Link to Item
-
Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J. 2010 May;31(10):1181–7.Full Text Link to Item
-
Alhadramy O, Westerhout CM, Brener SJ, Granger CB, Armstrong PW, APEX AMI Investigators. Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J. 2010 May;159(5):899–904.Full Text Link to Item
-
Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):277–83.Full Text Link to Item
-
Lopes RD, Garcia D, Becker RC, Granger CB, Newby LK, Alexander JH, et al. Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil. J Thromb Thrombolysis. 2010 May;29(4):395–408.Full Text Link to Item
-
Granger CB, Patel CB. Review: statins do not reduce mortality in patients with heart failure. Ann Intern Med. 2010 Apr 20;152(8):JC4–6.Full Text Link to Item
-
Califf RM, Armstrong PW, Granger CB, Harrington RA, Lee K, Simes RJ, et al. Towards a new order in cardiovascular medicine: re-engineering through global collaboration. Eur Heart J. 2010 Apr;31(8):911–7.Full Text Link to Item
-
Granger CB, Gersh BJ. Clinical trials and registries in cardiovascular disease: competitive or complementary? Eur Heart J. 2010 Mar;31(5):520–1.Full Text Link to Item
-
Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010 Mar;159(3):331–9.Full Text Link to Item
-
Fox KAA, Carruthers K, Steg PG, Avezum A, Granger CB, Montalescot G, et al. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. Eur Heart J. 2010 Mar;31(6):667–75.Full Text Link to Item
-
Tjandrawidjaja MC, Fu Y, Westerhout CM, White HD, Todaro TG, Van de Werf F, et al. Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. Eur Heart J. 2010 Mar;31(5):573–81.Full Text Link to Item
-
Welsh RC, Granger CB, Westerhout CM, Blankenship JC, Holmes DR, O’Neill WW, et al. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Jacc Cardiovasc Interv. 2010 Mar;3(3):343–51.Full Text Link to Item
-
de Boer SPM, Westerhout CM, Simes RJ, Granger CB, Zijlstra F, Boersma E, et al. Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. Jacc Cardiovasc Interv. 2010 Mar;3(3):324–31.Full Text Link to Item
-
Granger CB. No difference in peak troponin level in immediate versus delayed (next working day) intervention for acute coronary syndrome without ST-segment elevation. Evid Based Med. 2010 Feb;15(1):26–7.Full Text Link to Item
-
Katz JN, Shah BR, Volz EM, Horton JR, Shaw LK, Newby LK, et al. Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med. 2010 Feb;38(2):375–81.Full Text Link to Item
-
Lopes RD, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH, et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010 Feb;123(2):134–40.Full Text Link to Item
-
Bassand J-P, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, et al. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J. 2010 Jan;31(1):50–8.Full Text Link to Item
-
Lopes RD, Granger CB. Interpreting the TRITON results in light of the event adjudication process. Cardiology. 2010;115(2):89–90.Full Text Link to Item
-
French JK, Hellkamp AS, Armstrong PW, Cohen E, Kleiman NS, O’Connor CM, et al. Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol. 2010 Jan 1;105(1):59–63.Full Text Link to Item
-
Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, et al. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. Am Heart J. 2010 Jan;159(1):131–40.Full Text Link to Item
-
Patel MR, Worthley SG, Stebbins A, Dill T, Rademakers FE, Valeti US, et al. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. Jacc Cardiovasc Imaging. 2010 Jan;3(1):52–60.Full Text Link to Item
-
van Diepen S, Siha H, Fu Y, Westerhout CM, Lopes RD, Granger CB, et al. Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. J Electrocardiol. 2010;43(4):351–8.Full Text Link to Item
-
Lopes RD, Granger CB. β-blockers in myocardial infarction: An overview. Acute Coronary Syndromes. 2009 Dec 1;9(4):141–7.
-
Lopes RD, Granger CB. Highlights from the American Heart Association (AHA) Scientific Sessions 2008. Acute Coronary Syndromes. 2009 Dec 1;9(3):121–4.
-
Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009 Dec;158(6):998-1004.e1.Full Text Link to Item
-
Jolicoeur EM, O’Neill WW, Hellkamp A, Hamm CW, Holmes DR, Al-Khalidi HR, et al. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J. 2009 Nov;30(21):2575–83.Full Text Link to Item
-
Brener SJ, Westerhout CM, Fu Y, Todaro TG, Moliterno DJ, Wagner GS, et al. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Am Heart J. 2009 Nov;158(5):755–60.Full Text Link to Item
-
Granger BB, Ekman I, Granger CB, Ostergren J, Olofsson B, Michelson E, et al. Adherence to medication according to sex and age in the CHARM programme. Eur J Heart Fail. 2009 Nov;11(11):1092–8.Full Text Link to Item
-
Lopes RD, Ohman EM, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, et al. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). Am J Cardiol. 2009 Nov 1;104(9):1285–91.Full Text Link to Item
-
Granger CB. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI. Evid Based Med. 2009 Oct;14(5):154.Full Text Link to Item
-
Katz JN, Gore JM, Amin A, Anderson FA, Dasta JF, Ferguson JJ, et al. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry. Am Heart J. 2009 Oct;158(4):599-606.e1.Full Text Link to Item
-
Ross AM, Huber K, Zeymer U, Armstrong PW, Granger CB, Goldstein P, et al. The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. Jacc Cardiovasc Interv. 2009 Oct;2(10):925–30.Full Text Link to Item
-
Sinnaeve PR, Donahue MP, Grass P, Seo D, Vonderscher J, Chibout S-D, et al. Gene expression patterns in peripheral blood correlate with the extent of coronary artery disease. Plos One. 2009 Sep 14;4(9):e7037.Full Text Link to Item
-
Mehta RH, Armstrong PW, Granger CB. Prognostic Importance of Ventricular Arrhythmia in Patients Treated With Percutaneous Coronary Intervention Reply. Jama Journal of the American Medical Association. 2009 Sep 2;302(9):944–5.Link to Item
-
Mehta RH, Armstrong PW, Granger CB. In reply. Jama. 2009 Sep 2;302(9):944–5.Full Text
-
Jackson CE, Solomon SD, Gerstein HC, Andersson S, Michelson EL, Granger CB, et al. Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme. European Heart Journal. 2009 Sep 1;30:876–876.Link to Item
-
Sinnaeve PR, Ezekowitz JA, Bogaerts K, Droogne W, Jarai R, Huber K, et al. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. Eur Heart J. 2009 Sep;30(18):2213–9.Full Text Link to Item
-
Mehta SR, Yusuf S, Granger C. The authors reply. New England Journal of Medicine. 2009 Aug 27;361(9):926–7.
-
Berger JS, Elliott L, Gallup D, Roe M, Granger CB, Armstrong PW, et al. Sex differences in mortality following acute coronary syndromes. Jama. 2009 Aug 26;302(8):874–82.Full Text Link to Item
-
Granger CB. ACP Journal Club. Concomitant use of proton pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI. Ann Intern Med. 2009 Aug 18;151(4):JC2-J13.Full Text Link to Item
-
Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009 Aug 15;374(9689):543–50.Full Text Link to Item
-
Brieger D, Fitzgerald G, Fox KAA, Eagle KA, Budaj A, Avezum A, et al. The authors' reply. Heart. 2009 Aug 1;95(16):1355–6.Full Text
-
Bainey KR, Fu Y, Granger CB, Hamm CW, Holmes DR, O’Neill WW, et al. Benefit of angiographic spontaneous reperfusion in STEMI: does it extend to diabetic patients? Heart. 2009 Aug;95(16):1331–6.Full Text Link to Item
-
Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009 Aug;30(16):2019–28.Full Text Link to Item
-
Ruisi CP, Goldberg RJ, Kennelly BM, Goodman SG, Lopez-Sendon J, Granger CB, et al. Pulmonary artery catheterization in patients with acute coronary syndromes. Am Heart J. 2009 Aug;158(2):170–6.Full Text Link to Item
-
Jolly SS, Faxon DP, Fox KAA, Afzal R, Boden WE, Widimsky P, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol. 2009 Jul 28;54(5):468–76.Full Text Link to Item
-
Jolicoeur EM, Ohman EM, Honeycutt E, Becker RC, Crespo EM, Oliveira GBF, et al. Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. Am J Cardiol. 2009 Jul 15;104(2):292–7.Full Text Link to Item
-
McMurray JJV, Granger CB, Ostergren J, Yusuf S, Pfeffer MA, Swedberg K. Dual renin-angiotensin system blockade in heart failure. J Am Coll Cardiol. 2009 Jul 14;54(3):278.Full Text Link to Item
-
Hoekstra J, Cohen M, Giugliano R, Granger CB, Gurbel PA, Hollander JE, et al. Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. Am J Emerg Med. 2009 Jul;27(6):720–8.Full Text Link to Item
-
Lopes RD, Becker RC, Garcia D, Hylek EM, Granger CB, Lourenço DM, et al. Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. J Thromb Thrombolysis. 2009 Jul;28(1):106–16.Full Text Link to Item
-
Brieger D, Fox KAA, Fitzgerald G, Eagle KA, Budaj A, Avezum A, et al. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. 2009 Jun;95(11):888–94.Full Text Link to Item
-
Pieper KS, Gore JM, FitzGerald G, Granger CB, Goldberg RJ, Steg G, et al. Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events. Am Heart J. 2009 Jun;157(6):1097–105.Full Text Link to Item
-
Mehta SR, Granger CB, Boden WE, Steg PG, Bassand J-P, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009 May 21;360(21):2165–75.Full Text Link to Item
-
Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. Jama. 2009 May 6;301(17):1779–89.Full Text Link to Item
-
Allen LA, Granger CB. Risk assessment in the genomic era: are we missing the low-hanging fruit? Am Heart J. 2009 May;157(5):799–801.Full Text Link to Item
-
Preiss D, Zetterstrand S, McMurray JJV, Ostergren J, Michelson EL, Granger CB, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009 May;32(5):915–20.Full Text Link to Item
-
Armstrong PW, Fu Y, Westerhout CM, Hudson MP, Mahaffey KW, White HD, et al. Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. J Am Coll Cardiol. 2009 Apr 28;53(17):1503–9.Full Text Link to Item
-
Hernandez AF, Granger CB. Advancing care for acute heart failure--no time to relax. Lancet. 2009 Apr 25;373(9673):1401–2.Full Text Link to Item
-
Crespo EM, Oliveira GBF, Honeycutt EF, Becker RC, Berger PB, Moliterno DJ, et al. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J. 2009 Apr;157(4):651–7.Full Text Link to Item
-
Granger CB. Accelerating ST-segment elevation myocardial infarction care: emergency medical services take center stage. Jacc Cardiovasc Interv. 2009 Apr;2(4):347–9.Full Text Link to Item
-
Gore JM, Katz J, Kleinschmidt K, Wyman A, Peacock F, Anderson FA, et al. Readmission in Patients With Acute Severe Hypertension Is Common and Predictable: The Studying the Treatment of Acute hyperTension Registry. Journal of the American College of Cardiology. 2009 Mar 10;53(10):A214–A214.Link to Item
-
Lopes RD, Siha H, Fu Y, Armstrong PW, Granger CB. Left Bundle Branch Block Without Concordant ST-Elevation In Suspected ST-Elevation Myocardial Infarction Identifies Patients With High False Positive Rates: Insights From the APEX-AMI Trial. Journal of the American College of Cardiology. 2009 Mar 10;53(10):A323–A323.Link to Item
-
Lopes RD, Starr A, Al-Khatib SM, Newby LK, Mehta RH, de Werf FV, et al. Warfarin Is Independently Associated With Lower Risk of Six-Month Death or Myocardial Infarction in Patients With Atrial Fibrillation Following Acute Coronary Syndromes. Journal of the American College of Cardiology. 2009 Mar 10;53(10):A354–A354.Link to Item
-
Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand J-P, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2009 Mar;30(6):655–61.Full Text Link to Item
-
Crosslin DR, Shah SH, Nelson SC, Haynes CS, Connelly JJ, Gadson S, et al. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Hum Genet. 2009 Mar;125(2):217–29.Full Text Link to Item
-
Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 2009 Mar;41(3):342–7.Full Text Link to Item
-
Joyner CD, Peters RJG, Afzal R, Chrolavicius S, Mehta SR, Fox KAA, et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J. 2009 Mar;157(3):502–8.Full Text Link to Item
-
Sinnaeve PR, Steg PG, Fox KAA, Van de Werf F, Montalescot G, Granger CB, et al. Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med. 2009 Feb 23;169(4):402–9.Full Text Link to Item
-
Allen LA, Felker GM, Pocock S, McMurray JJV, Pfeffer MA, Swedberg K, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009 Feb;11(2):170–7.Full Text Link to Item
-
Granger CB. Review: an early invasive strategy has similar benefits in men and women with NSTEMI or unstable angina. Evid Based Med. 2009 Feb;14(1):19.Full Text Link to Item
-
Abrahamsson P, Dobson J, Granger CB, McMurray JJV, Michelson EL, Pfeffer M, et al. Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. Eur Heart J. 2009 Feb;30(3):338–45.Full Text Link to Item
-
Patel MR, Pfisterer ME, Betriu A, Widmisky P, Holmes DR, O’Neill WW, et al. Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study). Am J Cardiol. 2009 Jan 15;103(2):181–6.Full Text Link to Item
-
Gore JM, Spencer FA, Gurfinkel EP, López-Sendón J, Steg PG, Granger CB, et al. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). Am J Cardiol. 2009 Jan 15;103(2):175–80.Full Text Link to Item
-
Johanson P, Fu Y, Wagner GS, Goodman SG, Granger CB, Wallentin L, et al. ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. Am J Cardiol. 2009 Jan 15;103(2):154–8.Full Text Link to Item
-
Granger CB. Concomitant use of proton-pump inhibitors with clopidogrel may increase risk for readmission after discharge for acute MI Commentary. Annals of Internal Medicine. 2009;151(4).Link to Item
-
Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C, et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. Plos Genet. 2009 Jan;5(1):e1000318.Full Text Open Access Copy Link to Item
-
Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, et al. High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol. 2009;5:258.Full Text Link to Item
-
Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. J Am Coll Cardiol. 2008 Dec 9;52(24):2000–7.Full Text Link to Item
-
Granger CB, Stockbridge NL, Vogel VG, Cummings SR. Response to letter of Meinert et al. Clinical Trials. 2008 Dec 1;5(5):558.Full Text
-
Cohen-Solal A, McMurray JJV, Swedberg K, Pfeffer MA, Puu M, Solomon SD, et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Eur Heart J. 2008 Dec;29(24):3022–8.Full Text Link to Item
-
Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH. Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis. 2008 Dec;26(3):167–74.Full Text Link to Item
-
Mehta SR, Bassand J-P, Chrolavicius S, Diaz R, Fox KAA, Granger CB, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2008 Dec;156(6):1080-1088.e1.Full Text Link to Item
-
Granger CB. Review: an early invasive strategy has similar benefits in men and women with NSTEMI or unstable angina. Acp J Club. 2008 Nov 18;149(5):7.Link to Item
-
Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, et al. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation. 2008 Nov 11;118(20):2038–46.Full Text Link to Item
-
Aronow HD, Lincoff AM, Quinn MJ, McRae AT, Gurm HS, Houghtaling PL, et al. Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol. 2008 Nov 1;102(9):1119–24.Full Text Link to Item
-
Kim JH-J, Newby LK, Clare RM, Shaw LK, Lodge AJ, Smith PK, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J. 2008 Nov;156(5):886–92.Full Text Link to Item
-
Mahaffey KW, Reist CJ, Fu Y, Brener SJ, Theroux P, Patel MR, et al. Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. Contemp Clin Trials. 2008 Nov;29(6):887–95.Full Text Link to Item
-
Pocock SJ, McMurray JJV, Dobson J, Yusuf S, Granger CB, Michelson EL, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Nov;29(21):2641–50.Full Text Link to Item
-
Shah SH, Hauser ER, Crosslin D, Wang L, Haynes C, Connelly J, et al. ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention. Atherosclerosis. 2008 Nov;201(1):148–54.Full Text Link to Item
-
Armstrong PW, Fu Y, Westerhout CM, White HD, Hudson MP, Mahaffey KW, et al. Baseline Q Trumps Time from Symptom Onset as a Prognostic Marker in STEMI Patients Treated with Primary PCI. Circulation. 2008 Oct 28;118(18):S1076–S1076.Link to Item
-
Ezekowitz JA, Bakal JA, Huber K, Theroux P, James SK, Betriu A, et al. NT-proBNP is an Important Independent Predictor of Clinical Events after Primary PCI for STEMI. Circulation. 2008 Oct 28;118(18):S582–3.Link to Item
-
Granger CB, Sinnaeve P, Bengtsson O, McMurray JJ, Michelson EL, Pfeffer MA, et al. No Clear Association Between Candidate Gene Variants and Outcomes In 3239 Patients with Chronic Heart Failure: Results from the CHARM Program. Circulation. 2008 Oct 28;118(18):S623–4.Link to Item
-
Lopes RD, Granger CB, Honeycutt EF, Crespo EM, Anstrom KJ, Ohman EM, et al. Patients with Thrombocytopenia following Heparin Therapy Have Early but not Late Risk of Death: Results from the CATCH Registry. Circulation. 2008 Oct 28;118(18):S1052–S1052.Link to Item
-
Mehta RH, Starr AZ, Lopes RD, Pieper KS, Armstrong PW, Granger CB. Association of Sustained Ventricular Tachycardia/Fibrillation and the Timing of its Occurrence on Outcomes in Patients Undergoing Primary Percutaneous Coronary Interventions: Insights from the APEX-AMI Trial. Circulation. 2008 Oct 28;118(18):S1058–S1058.Link to Item
-
Tjandrawidjaja MC, Fu Y, Westerhout CM, White HD, Todaro TG, Van de Werf F, et al. Resolution of ST-Segment Depression: A New Prognostic Marker of Clinical Outcome in ST-Segment Elevation Myocardial Infarction. Circulation. 2008 Oct 28;118(18):S1076–S1076.Link to Item
-
Toma M, Buller CE, Westerhout CM, Fu Y, O’Neill WW, Holmes DR, et al. Mortality after Acute Non-Culprit Coronary Intervention in STEMI: Insights from APEX AMI. Circulation. 2008 Oct 28;118(18):S974–S974.Link to Item
-
Berger JS, Elliott LE, Newby LK, Roe M, Granger CB, Armstrong PW, et al. Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes. Circulation. 2008 Oct 28;118(18):S1057–8.Link to Item
-
Granger CB, Ohman EM, Becker RC. Risk factors for thrombocytopenia in patients treated with prolonged heparin therapy - Reply. Archives of Internal Medicine. 2008 Oct 27;168(19):2171.
-
Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, et al. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation. 2008 Sep 23;118(13):1335–46.Full Text Link to Item
-
Flaker G, Pogue J, Pfeffer MA, Goldhaber S, Granger CB, Anand IS, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. European Heart Journal. 2008 Sep 1;29:258–258.Link to Item
-
Fox KA, Carruthers K, Motivala A, Avezum A, Granger CB, Montalescot G, et al. Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry. European Heart Journal. 2008 Sep 1;29:326–326.Link to Item
-
French JK, Mahaffey KW, Hellkamp AS, Cohen E, O’connor CM, Kleiman NS, et al. Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI. European Heart Journal. 2008 Sep 1;29:137–8.Link to Item
-
French JK, Mahaffey KW, Hellkamp AS, O’connor CM, Cohen E, Kleiman NS, et al. Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI. European Heart Journal. 2008 Sep 1;29:447–447.Link to Item
-
Granger CB, Gore J, Katz J, Kleinschmidt K, Wyman A, Peacock F, et al. Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry. European Heart Journal. 2008 Sep 1;29:513–513.Link to Item
-
Bainey KR, Fu Y, Wagner GS, Goodman SG, Ross A, Granger CB, et al. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J. 2008 Aug;156(2):248–55.Full Text Link to Item
-
Cohen M, Hoekstra J, Giugliano R, Granger CB, Gurbel PA, Hollander JE, et al. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. J Interv Cardiol. 2008 Aug;21(4):283–99.Full Text Link to Item
-
Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008 Jul;94(7):867–73.Full Text Link to Item
-
Solomon SD, Pfeffer MA, Pocock S, Marro J, McMurray JJV, Granger CB, et al. Response to letter regarding article, "influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure". Circulation. 2008 Jul 1;118(1).Full Text
-
Wang L, Hauser ER, Shah SH, Seo D, Sivashanmugam P, Exum ST, et al. Polymorphisms of the tumor suppressor gene LSAMP are associated with left main coronary artery disease. Ann Hum Genet. 2008 Jul;72(Pt 4):443–53.Full Text Link to Item
-
Granger CB. In patients with suspected CAD and normal ECG, a nomogram model based on clinical and exercise variables predicted mortality. Acp J Club. 2008 Jun 17;148(4):14.Link to Item
-
Granger CB. In patients with suspected CAD and normal ECG, a nomogram model based on clinical and exercise variables predicted mortality. Annals of Internal Medicine. 2008 Jun 17;148(12):JC4–JC4.Full Text
-
Roberts WC, Granger CB, Patel MR, Rao SV, Sinnaeve PR, Sulkes DJ. The editor's roundtable: management and treatment of non-ST-segment elevation in acute coronary syndromes. Am J Cardiol. 2008 Jun 1;101(11):1580–98.Full Text Link to Item
-
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun;29(11):1377–85.Full Text Link to Item
-
Brener SJ, Moliterno DJ, Aylward PE, van’t Hof AWJ, Ruźyllo W, O’Neill WW, et al. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur Heart J. 2008 May;29(9):1127–35.Full Text Link to Item
-
Jackson K, Gersh BJ, Stockbridge N, Fleming TR, Temple R, Califf RM, et al. Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. Am Heart J. 2008 May;155(5):829–40.Full Text Link to Item
-
Connelly JJ, Shah SH, Doss JF, Gadson S, Nelson S, Crosslin DR, et al. Genetic and functional association of FAM5C with myocardial infarction. Bmc Med Genet. 2008 Apr 22;9:33.Full Text Link to Item
-
McDonald MA, Fu Y, Zeymer U, Wagner G, Goodman SG, Ross A, et al. Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy. Eur Heart J. 2008 Apr;29(7):871–9.Full Text Link to Item
-
Mehta RH, Rao SV, Ohman EM, Bates ER, Marcucci G, Zhang M, et al. Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. Eur Heart J. 2008 Apr;29(7):880–7.Full Text Link to Item
-
Yan RT, Yan AT, Granger CB, Lopez-Sendon J, Brieger D, Kennelly B, et al. Usefulness of quantitative versus qualitative ST-segment depression for risk stratification of non-ST elevation acute coronary syndromes in contemporary clinical practice. Am J Cardiol. 2008 Apr 1;101(7):919–24.Full Text Link to Item
-
Toma M, Fu Y, Wagner G, Goodman SG, Granger C, Wallentin L, et al. Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution. Heart. 2008 Mar;94(3):e6.Full Text Link to Item
-
Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf F, et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J. 2008 Mar;29(5):609–17.Full Text Link to Item
-
Jolicoeur EM, Granger CB, Henry TD, Holmes DJ, Pepine CJ, Mark D, et al. Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies. Am Heart J. 2008 Mar;155(3):418–34.Full Text Link to Item
-
Jolicoeur EM, Ohman EM, Temple R, Stockbridge N, Smith S, Mark D, et al. Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. Am Heart J. 2008 Mar;155(3):435–44.Full Text Link to Item
-
Direct Inhibition of delta-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) Investigators, Bates E, Bode C, Costa M, Gibson CM, Granger C, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008 Feb 19;117(7):886–96.Full Text Link to Item
-
Oldgren J, Wallentin L, Afzal R, Bassand J-P, Budaj A, Chrolavicius S, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J. 2008 Feb;29(3):315–23.Full Text Link to Item
-
Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008 Feb;40(2):217–24.Full Text Link to Item
-
Rao SV, Kaul PR, Liao L, Armstrong PW, Ohman EM, Granger CB, et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Feb;155(2):369–74.Full Text Link to Item
-
Weir RAP, McMurray JJV, Puu M, Solomon SD, Olofsson B, Granger CB, et al. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008 Feb;10(2):157–63.Full Text Link to Item
-
Berger JS, Stebbins A, Granger CB, Ohman EM, Armstrong PW, Van de Werf F, et al. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation. 2008 Jan 15;117(2):192–9.Full Text Link to Item
-
Oliveira GBF, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008 Jan 14;168(1):94–102.Full Text Link to Item
-
Eisenstein EL, Collins R, Cracknell BS, Podesta O, Reid ED, Sandercock P, et al. Sensible approaches for reducing clinical trial costs. Clin Trials. 2008;5(1):75–84.Full Text Link to Item
-
Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, et al. Do we need to adjudicate major clinical events? Clin Trials. 2008;5(1):56–60.Full Text Link to Item
-
Granger CB. Review: Angiotensin II receptor blocker plus angiotensin-converting enzyme inhibitor increases risk for adverse effects. Acp J Club. 2008;148(2):35.Link to Item
-
Rao SV, Chiswell K, Sun J-L, Granger CB, Newby LK, Van de Werf F, et al. International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2008 Jan 1;101(1):25–9.Full Text Link to Item
-
Yusuf S, Bosch J, Devereaux PJ, Collins R, Baigent C, Granger C, et al. Sensible guidelines for the conduct of large randomized trials. Clin Trials. 2008;5(1):38–9.Full Text Link to Item
-
Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation. 2007 Dec 11;116(24):2793–801.Full Text Link to Item
-
Tjandrawidjaja MC, Fu Y, Al-Khalidi H, Todaro TG, Adams P, Van de Werf F, et al. Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI. Eur Heart J. 2007 Dec;28(23):2850–7.Full Text Link to Item
-
Nallamothu B, Fox KAA, Kennelly BM, Van de Werf F, Gore JM, Steg PG, et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart. 2007 Dec;93(12):1552–5.Full Text Link to Item
-
Jollis JG, Roettig ML, Aluko AO, Anstrom KJ, Applegate RJ, Babb JD, et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. Jama. 2007 Nov 28;298(20):2371–80.Full Text Link to Item
-
Desai AS, Swedberg K, McMurray JJV, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007 Nov 13;50(20):1959–66.Full Text Link to Item
-
Mehta SR, Granger CB, Eikelboom JW, Bassand J-P, Wallentin L, Faxon DP, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007 Oct 30;50(18):1742–51.Full Text Link to Item
-
Jolicoeur ME, O’Neil WW, Armstrong PW, Pieper K, Hamm C, Holmes DR, et al. Predictors of transfusion in acute myocardial infarction: Insights from APEX-AMI (Assessment of pexelizumab in acute myocardial infarction) trial. Circulation. 2007 Oct 16;116(16):945–945.Link to Item
-
Lopes RD, Mahaffey K, Harrington RA, Horton J, Armstrong P, Newby K, et al. Atrial fibrillation is independently associated with a high risk of death in patients with acute coronary syndromes. Circulation. 2007 Oct 16;116(16):315–315.Link to Item
-
Mahaffey KW, Wampole JL, Stebbins A, Berdan LG, Mcafee D, Rorick TL, et al. Efficient adjudication of endpoints in an international trial: Strategic lessons from the clinical events committee (CEC) of the assessment of pexelizumab in acute myocardial infarction (APEX AMI) trial. Circulation. 2007 Oct 16;116(16):317–317.Link to Item
-
Westerhout CM, Lee KL, James SK, De Wert FV, O’Neill WW, Nielsen TT, et al. Dynamic mortality modeling in PCI-treated ST-elevation myocardial infarction: Implications for clinical decision making. Circulation. 2007 Oct 16;116(16):710–710.Link to Item
-
Granger CB. Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure. Evid Based Med. 2007 Oct;12(5):141.Full Text Link to Item
-
Mehta RH, Greenbaum AB, Lokhnygina Y, Newby LK, Van De Werf F, Armstrong PW, et al. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. J Interv Cardiol. 2007 Oct;20(5):299–306.Full Text Link to Item
-
Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007 Sep 25;116(13):1482–7.Full Text Link to Item
-
Friedewald VE, Bates ER, Granger CB, Yusuf S, Roberts WC. The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. Am J Cardiol. 2007 Sep 15;100(6):974–80.Full Text Link to Item
-
Boden WE, Eagle K, Granger CB. Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. J Am Coll Cardiol. 2007 Sep 4;50(10):917–29.Full Text Link to Item
-
Bradley EH, Nallamothu BK, Curtis JP, Webster TR, Magid DJ, Granger CB, et al. Summary of evidence regarding hospital strategies to reduce door-to-balloon times for patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Crit Pathw Cardiol. 2007 Sep;6(3):91–7.Full Text Link to Item
-
Brener SJ, Moliterno DJ, Aylward P, Van’T Hof AWJ, Ruzyllo W, Ardissino D, et al. Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI. European Heart Journal. 2007 Sep 1;28:660–660.Link to Item
-
Fox KA, Steg PG, Goldberg RJ, Gore JM, Granger CB, Avezum A, et al. Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events. European Heart Journal. 2007 Sep 1;28:689–689.Link to Item
-
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Obstetrical and Gynecological Survey. 2007 Sep 1;62(9):585–7.Full Text
-
Jolly S, Mehta SR, Wallentin L, Afzal R, Budaj A, Fox KAA, et al. The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial. European Heart Journal. 2007 Sep 1;28:187–187.Link to Item
-
Jolly S, Mehta SR, Widimsky P, Afzal R, Steg PG, Valentin V, et al. Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial. European Heart Journal. 2007 Sep 1;28:516–516.Link to Item
-
Lopes RD, Mahaffey KM, Harrington RH, Lan LL, Armstrong PA, Newby KN, et al. Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes. European Heart Journal. 2007 Sep 1;28:259–60.Link to Item
-
McDonald MA, Fu Y, Zeymer U, Wagner GS, Goodman SG, Ross AM, et al. Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy. European Heart Journal. 2007 Sep 1;28:59–59.Link to Item
-
Patel MR, Pfisterer ME, Betriu A, Widimsky P, Holmes DR, O’ Neill WW, et al. Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI. European Heart Journal. 2007 Sep 1;28:9–9.Link to Item
-
Stebbins AL, Lee K, Armstrong PW, Hamm C, Van de Werf F, James S, et al. A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial. European Heart Journal. 2007 Sep 1;28:59–59.Link to Item
-
Theroux P, Neumann FJ, Hamm CW, Mahaffey KW, Hochman JS, James S, et al. Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab. European Heart Journal. 2007 Sep 1;28:384–5.Link to Item
-
Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LAM, Skali H, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Aug 7;116(6):627–36.Full Text Link to Item
-
Granger CB, Patel MR. The search for myocardial protection: is there still hope? J Am Coll Cardiol. 2007 Jul 31;50(5):406–8.Full Text Link to Item
-
Yan RT, Yan AT, Allegrone J, López-Sendón J, Granger CB, Gore JM, et al. Differences between local hospital and core laboratory interpretation of the admission electrocardiogram in patients with acute coronary syndromes and their relation to outcome. Am J Cardiol. 2007 Jul 15;100(2):169–74.Full Text Link to Item
-
Granger CB, Henry TD, Bates WER, Cercek B, Weaver WD, Williams DO. Development of systems of care for ST-elevation myocardial infarction patients: the primary percutaneous coronary intervention (ST-elevation myocardial infarction-receiving) hospital perspective. Circulation. 2007 Jul 10;116(2):e55–9.Full Text Link to Item
-
Timmer JR, Ottervanger JP, de Boer M-J, Boersma E, Grines CL, Westerhout CM, et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med. 2007 Jul 9;167(13):1353–9.Full Text Link to Item
-
Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJV, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007 Jul 3;50(1):40–7.Full Text Link to Item
-
Barbagelata A, Perna ER, Clemmensen P, Uretsky BF, Canella JPC, Califf RM, et al. Time to reperfusion in acute myocardial infarction. It is time to reduce it!. J Electrocardiol. 2007 Jul;40(3):257–64.Full Text Link to Item
-
Strauss DG, Sprague PQ, Underhill K, Maynard C, Adams GL, Kessenich A, et al. Paramedic transtelephonic communication to cardiologist of clinical and electrocardiographic assessment for rapid reperfusion of ST-elevation myocardial infarction. J Electrocardiol. 2007 Jul;40(3):265–70.Full Text Link to Item
-
O’Meara E, Clayton T, McEntegart MB, McMurray JJV, Piña IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Jun 19;115(24):3111–20.Full Text Link to Item
-
Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007 Jun 8;316(5830):1491–3.Full Text Link to Item
-
Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, et al. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2007 Jun;153(6):960–9.Full Text Link to Item
-
Armstrong PW, Granger CB. Pexelizumab and the APEX AMI trial. Jama. 2007 May 2;297(17):1881.Full Text Link to Item
-
Fox KAA, Steg PG, Eagle KA, Goodman SG, Anderson FA, Granger CB, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. Jama. 2007 May 2;297(17):1892–900.Full Text Link to Item
-
Hawkins NM, Wang D, McMurray JJV, Pfeffer MA, Swedberg K, Granger CB, et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. Eur J Heart Fail. 2007 May;9(5):510–7.Full Text Link to Item
-
Jolicoeur EM, Granger CB, Fakunding JL, Mockrin SC, Grant SM, Ellis SG, et al. Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. Am Heart J. 2007 May;153(5):732–42.Full Text Link to Item
-
Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand J-P. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 May;28(10):1193–204.Full Text Link to Item
-
Oliveira GBF, Avezum A, Anderson FA, Budaj A, Dabbous OH, Goodman SG, et al. Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. Am Heart J. 2007 Apr;153(4):493–9.Full Text Link to Item
-
Wang L, Hauser ER, Shah SH, Pericak-Vance MA, Haynes C, Crosslin D, et al. Peakwide mapping on chromosome 3q13 identifies the kalirin gene as a novel candidate gene for coronary artery disease. Am J Hum Genet. 2007 Apr;80(4):650–63.Full Text Link to Item
-
Mehta RH, Califf RM, Yang Q, Pieper KS, White HD, Ohman EM, et al. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. Am J Cardiol. 2007 Mar 15;99(6):793–6.Full Text Link to Item
-
Granger CB, McMurray JJV. Reply. Journal of the American College of Cardiology. 2007 Feb 13;49(6):729.Full Text
-
Mehta RH, Califf RM, Garg J, White HD, Van de Werf F, Armstrong PW, et al. The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. Eur Heart J. 2007 Feb;28(4):415–24.Full Text Link to Item
-
APEX AMI Investigators, Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. Jama. 2007 Jan 3;297(1):43–51.Full Text Link to Item
-
Hawkins NM, Wang D, McMurray JJV, Pfeffer MA, Swedberg K, Granger CB, et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart. 2007 Jan;93(1):59–64.Full Text Link to Item
-
Lewis EF, Lamas GA, O’Meara E, Granger CB, Dunlap ME, McKelvie RS, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007 Jan;9(1):83–91.Full Text Link to Item
-
Granger CB. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? Circulation. 2006 Dec 5;114(23):2432–3.Full Text Link to Item
-
Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Bmj. 2006 Nov 25;333(7578):1091.Full Text Link to Item
-
Madsen LH, Christensen G, Lund T, Serebruany VL, Granger CB, Hoen I, et al. Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. Circ Res. 2006 Nov 10;99(10):1141–7.Full Text Link to Item
-
Granger CB. Bleeding in acute coronary syndromes. Timely Top Med Cardiovasc Dis. 2006 Nov 1;10:E30.Link to Item
-
Eisenstein EL, Honeycutt EF, Anstrom KJ, Granger CB, Becker RC, Ohman EM. PHM3 HEPARIN-RELATED THROMBOCYTOPENIA ASSOCIATED WITH MAJOR INCREASE IN HOSPITAL COSTS. Value in Health. 2006 Nov;9(6):A248–A248.Full Text
-
Jollis JG, Mehta RH, Roettig ML, Berger PB, Babb JD, Granger CB. Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. Am Heart J. 2006 Nov;152(5):851.e1-851.11.Full Text Link to Item
-
Shah SH, Kraus WE, Crossman DC, Granger CB, Haines JL, Jones CJH, et al. Serum lipids in the GENECARD study of coronary artery disease identify quantitative trait loci and phenotypic subsets on chromosomes 3q and 5q. Ann Hum Genet. 2006 Nov;70(Pt 6):738–48.Full Text Link to Item
-
Gore JM, Spencer FA, Gurfinkel EP, Lopez-Sendon J, Anderson FA, FitzGerald G, et al. Incidence of heparin-induced thrombocytopenia lower than expected patients with acute coronary syndromes. The global registry of acute coronary events. Circulation. 2006 Oct 31;114(18):863–863.Link to Item
-
Lopez-Sendon J, Goodman SG, Steg PG, Brieger D, Eagle KA, Granger CB, et al. Heparin therapy during fibrinolysis in ST-segment elevation myocardial infarction: Registry data support clinical trial results. Circulation. 2006 Oct 31;114(18):863–863.Link to Item
-
Steg PG, Cottin Y, du Bocage C, Montalescot G, Van De Werf F, Gulba DC, et al. Patients on chronic warfarin therapy who present with an acute coronary syndrome are high risk and receive delayed and inadequate treatment. Circulation. 2006 Oct 31;114(18):860–860.Link to Item
-
Rokos IC, Larson DM, Henry TD, Koenig WJ, Eckstein M, French WJ, et al. Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks. Am Heart J. 2006 Oct;152(4):661–7.Full Text Link to Item
-
Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J. 2006 Oct;152(4):684.e1-684.e9.Full Text Link to Item
-
Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout S-D, et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J. 2006 Sep;152(3):478–85.Full Text Link to Item
-
Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, et al. Glucose, insulin, and acute myocardial infarction: Reply [4]. European Heart Journal. 2006 Sep 1;27(17):2142–3.Full Text
-
Armstrong PW, Granger CB. Reflections on early stopping of a clinical trial. Am Heart J. 2006 Sep;152(3):407–9.Full Text Link to Item
-
Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, Shah SH, et al. GATA2 is associated with familial early-onset coronary artery disease. Plos Genet. 2006 Aug 25;2(8):e139.Full Text Link to Item
-
Connelly JJ, Wang T, Cox JE, Haynes C, Wang L, Shah SH, et al. GATA2 is associated with familial early-onset coronary artery disease. Plos Genetics. 2006 Aug 25;2(8).Full Text
-
Granger CB, McMurray JJV. Using measures of disease progression to determine therapeutic effect: a sirens' song. J Am Coll Cardiol. 2006 Aug 1;48(3):434–7.Full Text Link to Item
-
Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, et al. The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. Am Heart J. 2006 Aug;152(2):277–84.Full Text Link to Item
-
Mahaffey KW, Van de Werf F, Shernan SK, Granger CB, Verrier ED, Filloon TG, et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am Heart J. 2006 Aug;152(2):291–6.Full Text Link to Item
-
Mehta RH, Honeycutt E, Peterson ED, Granger CB, Halabi AR, Shaw LK, et al. Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. Circulation. 2006 Jul 4;114(1 Suppl):I396–401.Full Text Link to Item
-
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006 Jul;152(1):86–92.Link to Item
-
Yusuf S, Granger CB, Mehta SR. The Authors Reply [2]. New England Journal of Medicine. 2006 Jun 29;354(26):2830.Full Text
-
Yusuf S, Granger CB, Mehta SR. Fondaparinux versus enoxaparin in acute coronary syndromes - Reply. New England Journal of Medicine. 2006 Jun 29;354(26):2830–2830.Link to Item
-
Viswanathan GN. Facilitated versus primary PCI for acute myocardial infarction. Lancet. 2006 Jun 3;367(9525):1813.Full Text Link to Item
-
Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006 Jun;27(11):1289–97.Full Text Link to Item
-
McMurray JJV, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2006 Jun;27(12):1447–58.Full Text Link to Item
-
Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJV, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006 May 16;47(10):1997–2004.Full Text Link to Item
-
Armstrong PW, Chang W-C, Wallentin L, Goldstein P, Granger CB, Bogaerts K, et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. Cmaj. 2006 May 9;174(10):1421–6.Full Text Link to Item
-
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. American Heart Journal. 2006 May 1;151(5):985–91.
-
LaPointe NMA, DeLong ER, Chen A, Hammill BG, Muhlbaier LH, Califf RM, et al. Multifaceted intervention to promote beta-blocker use in heart failure. Am Heart J. 2006 May;151(5):992–8.Full Text Link to Item
-
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J. 2006 May;151(5):985–91.Full Text Link to Item
-
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 Apr 6;354(14):1464–76.Full Text Link to Item
-
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. Jama. 2006 Apr 5;295(13):1519–30.Full Text Link to Item
-
Ezekowitz JA, Théroux P, Chang W, Mahaffey KW, Granger CB, Weaver WD, et al. N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol. 2006 Apr;22(5):393–7.Full Text Link to Item
-
Armstrong PW, Mahaffey KW, Chang W-C, Weaver WD, Hochman JS, Theroux P, et al. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am Heart J. 2006 Apr;151(4):787–90.Full Text Link to Item
-
Goodman SG, Steg PG, Eagle KA, Fox KAA, López-Sendón J, Montalescot G, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006 Mar;151(3):654–60.Full Text Link to Item
-
Mitchell GF, Arnold JMO, Dunlap ME, O’Brien TX, Marchiori G, Warner E, et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. Eur J Heart Fail. 2006 Mar;8(2):191–7.Full Text Link to Item
-
Orlandini A, Díaz R, Wojdyla D, Pieper K, Van de Werf F, Granger CB, et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006 Mar;27(5):527–33.Full Text Link to Item
-
O’Meara E, Clayton T, McEntegart MB, McMurray JJV, Lang CC, Roger SD, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006 Feb 21;113(7):986–94.Full Text Link to Item
-
Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21;47(4):809–16.Full Text Link to Item
-
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006 Feb 7;113(5):671–8.Full Text Link to Item
-
Chang W-C, Kaul P, Fu Y, Westerhout CM, Granger CB, Mahaffey KW, et al. Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. Eur Heart J. 2006 Feb;27(4):419–26.Full Text Link to Item
-
Patel MR, Meine TJ, Lindblad L, Griffin J, Granger CB, Becker RC, et al. Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. Am Heart J. 2006 Feb;151(2):316–22.Full Text Link to Item
-
Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006 Jan;27(1):65–75.Full Text Link to Item
-
Al-Faleh H, Fu Y, Wagner G, Goodman S, Sgarbossa E, Granger C, et al. Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. Am Heart J. 2006 Jan;151(1):10–5.Full Text Link to Item
-
Donahue MP, Rose K, Hochstrasser D, Vonderscher J, Grass P, Chibout SD, et al. Discovery of proteins related to coronary artery disease using industrial scale proteomics analysis of pooled plasma (vol 152, pg 478, 2006). American Heart Journal. 2006;152(6):1021–1021.Link to Item
-
Galla JM, Mahaffey KW, Sapp SK, Alexander JH, Roe MT, Ohman EM, et al. Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. Am Heart J. 2006 Jan;151(1):16–24.Full Text Link to Item
-
Kauf TL, Velazquez EJ, Crosslin DR, Weaver WD, Diaz R, Granger CB, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J. 2006 Jan;151(1):206–12.Full Text Link to Item
-
Mehta RH, Marks D, Califf RM, Sohn S, Pieper KS, Van de Werf F, et al. Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. Am J Med. 2006 Jan;119(1):70.e1-70.e8.Full Text Link to Item
-
Solomon SD, Anavekar N, Skali H, McMurray JJV, Swedberg K, Yusuf S, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005 Dec 13;112(24):3738–44.Full Text Link to Item
-
Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJV, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005 Dec 10;366(9502):2005–11.Full Text Link to Item
-
Sinnaeve PR, Simes J, Yusuf S, Garg J, Mehta S, Eikelboom J, et al. Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J. 2005 Nov;26(22):2396–403.Full Text Link to Item
-
Welsh RC, Chang W, Goldstein P, Adgey J, Granger CB, Verheugt FWA, et al. Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. Heart. 2005 Nov;91(11):1400–6.Full Text Link to Item
-
Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005 Nov 1;96(9):1200–6.Full Text Link to Item
-
Demers C, McMurray JJV, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. Jama. 2005 Oct 12;294(14):1794–8.Full Text Link to Item
-
Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J. 2005 Oct;26(19):1964–70.Full Text Link to Item
-
Barbagelata A, Di Carli MF, Califf RM, Garg J, Birnbaum Y, Grinfeld L, et al. Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. Am Heart J. 2005 Oct;150(4):659–65.Full Text Link to Item
-
Lim MJ, Eagle KA, Gore JM, Anderson FA, Dabbous OH, Mehta RH, et al. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2005 Oct 1;96(7):917–21.Full Text Link to Item
-
Savonitto S, Cohen MG, Politi A, Hudson MP, Kong DF, Huang Y, et al. Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2005 Oct;26(20):2106–13.Full Text Link to Item
-
Yan AT, Yan RT, Tan M, Eagle KA, Granger CB, Dabbous OH, et al. In-hospital revascularization and one-year outcome of acute coronary syndrome patients stratified by the GRACE risk score. Am J Cardiol. 2005 Oct 1;96(7):913–6.Full Text Link to Item
-
Granger CB, Steg PG, Peterson E, López-Sendón J, Van de Werf F, Kline-Rogers E, et al. Medication performance measures and mortality following acute coronary syndromes. Am J Med. 2005 Aug;118(8):858–65.Full Text Link to Item
-
Nallamothu BK, Bates ER, Hochman JS, Granger CB, Guetta V, Wilcox RG, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J. 2005 Aug;26(15):1506–12.Full Text Link to Item
-
Wong C-K, French JK, Aylward PEG, Stewart RAH, Gao W, Armstrong PW, et al. Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. J Am Coll Cardiol. 2005 Jul 5;46(1):29–38.Full Text Link to Item
-
Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation. 2005 Jul 5;112(1):48–53.Full Text Link to Item
-
Kaul P, Newby LK, Fu Y, Mark DB, Goodman SG, Wagner GS, et al. Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns. Heart. 2005 Jul;91(7):876–81.Full Text Link to Item
-
Armstrong PW, Newby LK, Granger CB, Lee KL, Califf RM, Simes RJ, et al. Letter regarding article by Armstrong et al, "Lessons learned from a clinical trial" - Response. Circulation. 2005 Jun 14;111(23):E393–E393.Link to Item
-
Granger CB. Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease. Evidence Based Medicine. 2005 Jun 1;10(3):78.Full Text
-
Mehta RH, Califf RM, Garg J, Pieper KS, Alexander JH, Moliterno DJ, et al. Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. Am J Cardiol. 2005 Jun 1;95(11):1371–5.Full Text Link to Item
-
O’Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, et al. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2005 Jun;7(4):650–6.Full Text Link to Item
-
Cohen MG, Kelly RV, Kong DF, Menon V, Shah M, Ferreira J, et al. Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med. 2005 May;118(5):482–8.Full Text Link to Item
-
Mehta RH, Alexander JH, Van de Werf F, Armstrong PW, Pieper KS, Garg J, et al. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. Jama. 2005 Apr 13;293(14):1746–50.Full Text Link to Item
-
Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, et al. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Am Heart J. 2005 Apr;149(4):637–44.Full Text Link to Item
-
Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, et al. Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. Am Heart J. 2005 Apr;149(4):670–4.Full Text Link to Item
-
Mehta SR, Steg PG, Granger CB, Bassand J-P, Faxon DP, Weitz JI, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation. 2005 Mar 22;111(11):1390–7.Full Text Link to Item
-
Patel MR, Granger CB. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. Drugs Today (Barc). 2005 Mar;41(3):165–70.Full Text Link to Item
-
Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O’Neill W, et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2005 Mar;149(3):402–7.Full Text Link to Item
-
Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol. 2005 Mar 1;95(5):614–8.Full Text Link to Item
-
Mehta RH, Granger CB, Alexander KP, Bossone E, White HD, Sketch MH. Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol. 2005 Feb 15;45(4):471–8.Full Text Link to Item
-
Ohman EM, Granger CB, Rice L, Abrams CS, Becker RC, Berger PB, et al. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. J Thromb Thrombolysis. 2005 Feb;19(1):11–9.Full Text Link to Item
-
Granger CB. Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease. Acp J Club. 2005;142(3):66.Link to Item
-
Labinaz M, Mathias J, Pieper K, Granger CB, Lincoff AM, Moliterno DJ, et al. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. Eur Heart J. 2005 Jan;26(2):128–36.Full Text Link to Item
-
Armstrong PW, Newby LK, Granger CB, Lee KL, Simes RJ, Van de Werf F, et al. Lessons learned from a clinical trial. Circulation. 2004 Dec 7;110(23):3610–4.Full Text Link to Item
-
Barbagelata A, Califf RM, Sgarbossa EB, Knight D, Mark DB, Granger CB, et al. Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. Am Heart J. 2004 Nov;148(5):795–802.Full Text Link to Item
-
O’Meara E, Solomon S, McMurray J, Pfeffer M, Yusuf S, Michelson E, et al. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2004 Nov;25(21):1920–6.Full Text Link to Item
-
Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004 Oct 26;110(17):2618–26.Full Text Link to Item
-
Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJV, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004 Oct 12;110(15):2180–3.Full Text Link to Item
-
Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. Jama. 2004 Oct 6;292(13):1555–62.Full Text Link to Item
-
Kaul P, Armstrong PW, Chang W-C, Naylor CD, Granger CB, Lee KL, et al. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. Circulation. 2004 Sep 28;110(13):1754–60.Full Text Link to Item
-
Hauser ER, Crossman DC, Granger CB, Haines JL, Jones CJH, Mooser V, et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet. 2004 Sep;75(3):436–47.Full Text Link to Item
-
Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FWA, Armstrong PW, et al. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). Am J Cardiol. 2004 Aug 1;94(3):279–83.Full Text Link to Item
-
Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004 Jul 15;117(2):73–81.Full Text Link to Item
-
Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol. 2004 Jul 7;44(1):38–43.Full Text Link to Item
-
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van De Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. Revista Portuguesa De Cardiologia. 2004 Jul 1;23(7–8):1071–2.
-
Chang W-C, Boersma E, Granger CB, Harrington RA, Califf RM, Simoons ML, et al. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. Am Heart J. 2004 Jul;148(1):62–71.Full Text Link to Item
-
Waters RE, Singh KP, Roe MT, Lotfi M, Sketch MH, Mahaffey KW, et al. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Jun 16;43(12):2153–9.Full Text Link to Item
-
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. Jama. 2004 Jun 9;291(22):2727–33.Full Text Link to Item
-
Kaul P, Armstrong PW, Fu Y, Knight JD, Clapp-Channing NE, Sutherland W, et al. Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. Can J Cardiol. 2004 Jun;20(8):760–6.Link to Item
-
Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KAA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004 Jun 1;140(11):857–66.Full Text Link to Item
-
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J. 2004 Jun;147(6):993–8.Full Text Link to Item
-
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, et al. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response. Circulation. 2004 Apr 27;109(16):E195–6.Link to Item
-
Granger CB, Van Eyk JE, Mockrin SC, Anderson NL, National Heart, Lung, And Blood Institute Clinical Proteomics Working Group. National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. Circulation. 2004 Apr 13;109(14):1697–703.Full Text Link to Item
-
Pfeffer MA, McMurray JJ, Östergren J, Granger CB, Yusuf S, Pitt B. Candesartan reduced mortality and hospital admissions in chronic heart failure. Evidence Based Medicine. 2004 Mar 1;9(2):44–5.Full Text
-
Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, et al. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol. 2004 Feb 15;93(4):458–61.Full Text Link to Item
-
Kaul P, Newby LK, Fu Y, Mark DB, Califf RM, Topol EJ, et al. International differences in evolution of early discharge after acute myocardial infarction. Lancet. 2004 Feb 14;363(9408):511–7.Full Text Link to Item
-
McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J. 2004 Feb;147(2):246–52.Full Text Link to Item
-
Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, et al. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J. 2004 Feb;25(4):313–21.Full Text Link to Item
-
Rebeiz AG, Roe MT, Alexander JH, Mahaffey KW, Granger CB, Peterson ED, et al. Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. Am J Med. 2004 Jan 15;116(2):119–29.Full Text Link to Item
-
Granger CB, Weaver WD. Reducing cardiac events after acute coronary syndromes. Rev Cardiovasc Med. 2004;5 Suppl 5:S39–46.Link to Item
-
Waters RE, Mahaffey KW, Granger CB, Roe MT. Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. Am Heart J. 2003 Dec;146(6):958–68.Full Text Link to Item
-
Kramer JM, Newby LK, Chang WC, Simes RJ, Van de Werf F, Granger CB, et al. International variation in the use of evidence-based medicines for acute coronary syndromes. Eur Heart J. 2003 Dec;24(23):2133–41.Full Text Link to Item
-
Pechlaner C. The CHARM programme. Lancet. 2003 Nov 15;362(9396):1675–6.Full Text Link to Item
-
McMurray JJV, Pfeffer MA, Swedberg K, Granger CB, Yusuf S. The CHARM programme. The Lancet. 2003 Nov;362(9396):1678–9.Full Text
-
Mehta RH, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson FA, et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol. 2003 Nov 1;92(9):1031–6.Full Text Link to Item
-
Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003 Oct 27;163(19):2345–53.Full Text Link to Item
-
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol. 2003 Oct 1;42(7):1178–85.Full Text Link to Item
-
Lockwood E, Fu Y, Wong B, Van de Werf F, Granger CB, Armstrong PW, et al. Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. Am Heart J. 2003 Oct;146(4):640–5.Full Text Link to Item
-
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003 Sep 9;108(10):1184–90.Full Text Link to Item
-
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003 Sep 9;108(10):1176–83.Full Text Link to Item
-
Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep 6;362(9386):772–6.Full Text Link to Item
-
McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 Sep 6;362(9386):767–71.Full Text Link to Item
-
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759–66.Full Text Link to Item
-
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6;362(9386):777–81.Full Text Link to Item
-
Gupta M, Chang W-C, Van de Werf F, Granger CB, Midodzi W, Barbash G, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. Eur Heart J. 2003 Sep;24(18):1640–50.Full Text Link to Item
-
Armstrong PW, Wagner G, Goodman SG, Van de Werf F, Granger C, Wallentin L, et al. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. Eur Heart J. 2003 Aug;24(16):1515–22.Full Text Link to Item
-
Fox KAA, Goodman SG, Anderson FA, Granger CB, Moscucci M, Flather MD, et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003 Aug;24(15):1414–24.Full Text Link to Item
-
Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AAJ, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003 Jul 15;108(2):135–42.Full Text Link to Item
-
McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003 Jun;5(3):261–70.Full Text Link to Item
-
Tjandrawidjaja MC, Fu Y, Goodman SG, Van de Werf F, Granger CB, Armstrong PW, et al. The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. Eur Heart J. 2003 Jun;24(11):1024–34.Full Text Link to Item
-
Wallentin L, Bergstrand L, Dellborg M, Fellenius C, Granger CB, Lindahl B, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J. 2003 May;24(10):897–908.Full Text Link to Item
-
Rao SV, Ohman EM, Granger CB, Armstrong PW, Gibler WB, Christenson RH, et al. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol. 2003 Apr 15;91(8):936–40.Full Text Link to Item
-
Serebruany VL, Malinin AI, Callahan KP, Binbrek A, Van De Werf F, Alexander JH, et al. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Am Heart J. 2003 Apr;145(4):636–42.Full Text Link to Item
-
Hauser ER, Mooser V, Crossman DC, Haines JL, Jones CH, Winkelmann BR, et al. Design of the Genetics of Early Onset Cardiovascular Disease (GENECARD) study. Am Heart J. 2003 Apr;145(4):602–13.Full Text Link to Item
-
Khadour FH, Fu Y, Chang W-C, Ma X, Mark D, Granger CB, et al. Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromes. Can J Cardiol. 2003 Mar 15;19(3):257–63.Link to Item
-
Al-Khatib SM, Stebbins AL, Califf RM, Lee KL, Granger CB, White HD, et al. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. Am Heart J. 2003 Mar;145(3):515–21.Full Text Link to Item
-
Batchelor WB, Mark DB, Knight JD, Granger CB, Armstrong PW, Califf RM, et al. Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada. Am Heart J. 2003 Feb;145(2):349–55.Full Text Link to Item
-
Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003 Jan;145(1):73–9.Full Text Link to Item
-
Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003 Jan;145(1):47–57.Full Text Link to Item
-
O’Shea JC, Wilcox RG, Skene AM, Stebbins AL, Granger CB, Armstrong PW, et al. Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. Am J Cardiol. 2002 Dec 15;90(12):1374–7.Full Text Link to Item
-
Donahue M, Kraus W, Granger C. Genetics in heart failure: practical incorporation of this new biologic dimension. Am Heart J. 2002 Dec;144(6):938–40.Full Text Link to Item
-
Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf RM, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis. 2002 Oct;14(2):91–101.Full Text Link to Item
-
Mehta RH, Criger DA, Granger CB, Pieper KK, Califf RM, Topol EJ, et al. Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. J Am Coll Cardiol. 2002 Sep 18;40(6):1034–40.Full Text Link to Item
-
Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002 Aug 20;106(8):974–80.Full Text Link to Item
-
Bahit MC, Criger DA, Ohman EM, Granger CB, Wagner GS. Thresholds for the electrocardiographic change range of biochemical markers of acute myocardial infarction (GUSTO-IIa data). Am J Cardiol. 2002 Aug 1;90(3):233–7.Full Text Link to Item
-
Kottke-Marchant K, Bahit MC, Granger CB, Zoldhelyi P, Ardissino D, Brooks L, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J. 2002 Aug;23(15):1202–12.Full Text Link to Item
-
Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB, et al. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002 Aug;14(1):33–42.Full Text Link to Item
-
Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation. 2002 Jul 16;106(3):309–12.Full Text Link to Item
-
Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. Am Heart J. 2002 Jul;144(1):73–80.Full Text Link to Item
-
Newby LK, Califf RM, White HD, Harrington RA, Van de Werf F, Granger CB, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med. 2002 Jun 1;112(8):647–58.Full Text Link to Item
-
Goldberg RJ, Steg PG, Sadiq I, Granger CB, Jackson EA, Budaj A, et al. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol. 2002 Apr 1;89(7):791–6.Full Text Link to Item
-
Zijlstra F, Patel A, Jones M, Grines CL, Ellis S, Garcia E, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J. 2002 Apr;23(7):550–7.Full Text Link to Item
-
Granger CB, Alexander JH, Lesaffre E, Wallentin L, Armstrong PW, Van de Werf F. Differential impact of antithrombotic treatments combined with tenecteplase in the elderly with acute myocardial infarction: Results from ASSENT-3. Journal of the American College of Cardiology. 2002 Mar 6;39(5):306A-306A.Link to Item
-
McGuire DK, Rao SV, Joski PJ, Barsness GW, Peterson ED, Jollis JG, et al. Diabetes is associated with a higher risk of death than is prior myocardial infarction in the setting of coronary disease: Results from the Duke cardiovascular database. Journal of the American College of Cardiology. 2002 Mar 6;39(5):329A-329A.Link to Item
-
Bahit MC, Granger CB, Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. Am Heart J. 2002 Feb;143(2):205–16.Full Text Link to Item
-
Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol. 2002 Jan 2;39(1):22–9.Full Text Link to Item
-
Birnbaum Y, Mahaffey KW, Criger DA, Gates KB, Barbash GI, Barbagelata A, et al. Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. Cardiology. 2002;97(3):166–74.Full Text Link to Item
-
Roe MT, Granger CB, Puma JA, Hellkamp AS, Hochman JS, Ohman EM, et al. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Am J Cardiol. 2001 Dec 15;88(12):1403-A6.Full Text Link to Item
-
Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2001 Dec 4;104(23):2772–7.Full Text Link to Item
-
Angeja BG, Alexander JH, Chin R, Li X, Barron HV, Armstrong PW, et al. Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. Am J Cardiol. 2001 Dec 1;88(11):1240–5.Full Text Link to Item
-
Callahan KP, Malinin AI, Gurbel PA, Alexander JH, Granger CB, Atar D, et al. Platelets and thrombolysis: Cooperation or contrariety? Heartdrug. 2001 Dec 1;1(5):281–90.Full Text
-
Sekaran NK, Moliterno DJ, Ferguson JJ, Every N, Anderson HV, Aguirre FV, et al. "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. J Thromb Thrombolysis. 2001 Dec;12(3):207–16.Full Text Link to Item
-
Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001 Dec;22(24):2253–61.Full Text Link to Item
-
White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001 Dec 1;358(9296):1855–63.Full Text Link to Item
-
Fu Y, Goodman S, Chang WC, Van De Werf F, Granger CB, Armstrong PW. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation. 2001 Nov 27;104(22):2653–9.Full Text Link to Item
-
Bahit MC, Alexander JH, She L, Armstrong PW, White HD, Van de Werf F, et al. Increased risk of ICH with standard contraindications to fibrinolytic therapy: Results from ASSENT-2. Circulation. 2001 Oct 23;104(17):539–539.Link to Item
-
Hasdai D, Topol EJ, Kilaru R, Battler A, Simoons ML, Harrington RA, et al. Frequency, patient characteristics, and outcomes of mild to moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from four international fibrinolytic therapy trials. Circulation. 2001 Oct 23;104(17):483–483.Link to Item
-
Rao SV, Newby LK, Ohman EM, Granger CB, Hasselblad V, Gibler BB, et al. Elevated cardiac markers across a spectrum of patients with ACS: Defining the role of isolated troponin or CK-MB elevation. Circulation. 2001 Oct 23;104(17):708–9.Link to Item
-
Serebruany VL, Malinin AI, Callahan KP, Binbreck AS, Van de Werf F, Alexander JH, et al. Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction (the ASSENT-2 platelet substudy). Circulation. 2001 Oct 23;104(17):539–539.Link to Item
-
Birnbaum Y, Goodman S, Barr A, Gates KB, Barbash GI, Battler A, et al. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. Am J Cardiol. 2001 Oct 15;88(8):842–7.Full Text Link to Item
-
Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation. 2001 Sep 11;104(11):1229–35.Full Text Link to Item
-
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001 Aug 25;358(9282):605–13.Full Text Link to Item
-
Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med. 2001 Jul 17;2(4):180–6.Full Text Link to Item
-
Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med. 2001 Jul 17;2(4):187–94.Full Text Link to Item
-
Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, et al. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol. 2001 Jul;38(1):64–71.Full Text Link to Item
-
Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselbad V, et al. Erratum: Reactivation of ischemic events in acute coronary syndromes: Results from GUSTO-IIb (Journal of American College of Cardiology (2001) 37 (1001-1007)) [1]. Journal of the American College of Cardiology. 2001 Jun 1;37(7):2012.
-
Birnbaum Y, Criger DA, Wagner GS, Strasberg B, Mager A, Gates K, et al. Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. Am Heart J. 2001 Jun;141(6):915–24.Full Text Link to Item
-
Bahit MC, Topol EJ, Califf RM, Armstrong PW, Criger DA, Hasselblad V, et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. J Am Coll Cardiol. 2001 Mar 15;37(4):1001–7.Full Text Link to Item
-
Armstrong PW, Granger C, Van de Werf F. Bolus fibrinolysis: risk, benefit, and opportunities. Circulation. 2001 Feb 27;103(8):1171–3.Full Text Link to Item
-
Barbash GI, Birnbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. Circulation. 2001 Feb 20;103(7):954–60.Full Text Link to Item
-
Al-Khatib SM, Ohman EM, White HD, Granger CB, Califf RM, Kilaru R, et al. Atrioventricular nodal block in acute myocardial infarction treated with thrombolytic therapy is common and portends poor prognosis: Results from large trials of thrombolytic therapy. Journal of the American College of Cardiology. 2001 Feb 1;37(2):341S-341S.Link to Item
-
Alexander JH, Li X, Chin R, Barron H, Granger CB, Armstrong PW, et al. Risk of major bleeding in patients treated with PTCA early following thrombolysis with TNK vs. t-PA. Journal of the American College of Cardiology. 2001 Feb 1;37(2):349A-350A.Link to Item
-
Bahit MC, Alexander JH, Tasissa G, Armstrong PW, Califf RM, Granger CB. Higher coronary intervention following acute MI associated with lower rates of evidence-based medical therapy in regions of North America: Results from ASSENT II. Journal of the American College of Cardiology. 2001 Feb 1;37(2):351A-351A.Link to Item
-
Bahit MC, Criger DA, Granger CB, Ohman EM, Wagner GS. Elevation of CK-MB greater than 2 fold and troponin greater than 3 fold are the best thresholds for identifying MI associated with ECG evolution. Journal of the American College of Cardiology. 2001 Feb 1;37(2):115A-116A.Link to Item
-
Mahaffey KW, Roe MT, Sparapani R, Dyke CB, Alexander JH, Berdan LG, et al. Cardiac enzyme elevations after coronary artery bypass grafting associated with increased risk of death: Results from PARAGON-B. Journal of the American College of Cardiology. 2001 Feb 1;37(2):359A-359A.Link to Item
-
GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J. 2001 Feb;141(2):190–9.Full Text Link to Item
-
Callahan KP, Malinin AI, Gurbel PA, Alexander JH, Granger CB, Serebruany VL. Platelet function and fibrinolytic agents: two sides of a coin? Cardiology. 2001;95(2):55–60.Full Text Link to Item
-
Granger C. Acute coronary syndromes: introducing new therapies into established guidelines. Md Med. 2001;Suppl:12–5.Link to Item
-
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001 Jan;119(1 Suppl):64S-94S.Full Text Link to Item
-
Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001 Jan;37(1):9–18.Full Text Link to Item
-
Savonitto S, Fusco R, Granger CB, Cohen MG, Thompson TD, Ardissino D, et al. Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes. Ann Noninvasive Electrocardiol. 2001 Jan;6(1):64–77.Full Text Link to Item
-
Granger CB. Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. Am J Cardiol. 2000 Dec 28;86(12B):4M-9M.Full Text Link to Item
-
Chang WC, Fu Y, Ohman EM, Gupta M, Morris A, Roth SN, et al. Temporal evolution in the management of acute ST elevation myocardial infarction: The seven-year GUSTO experience from Canada and the United States. Canadian Journal of Cardiology. 2000 Dec 12;16(10):1231–9.
-
Collen D, Sobel B. Intracranial haemorrhage with bolus thrombolytic agents. Lancet. 2000 Nov 25;356(9244):1848.Full Text Link to Item
-
Armstrong PW, Granger C, Van de Werf F. Intracranial haemorrhage with bolus thrombolytic agents. Lancet. 2000 Nov 25;356(9244):1849.Full Text Link to Item
-
McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J. 2000 Nov;21(21):1750–8.Full Text Link to Item
-
Alexander JH, Poku MB, Card TL, Gibler WB, Granger CB. Randomization in a clinical trial only modestly delays time to treatment in acute myocardial infarction patients undergoing thrombolysis - Results from the ASSENT-2 Emergency Department Registry. Circulation. 2000 Oct 31;102(18):796–796.Link to Item
-
Bahit MC, Granger CB, Alexander KP, Kramer J, Lapointe NMA, Califf RM. Applying the evidence: Opportunity in US for 80,000 additional lives saved per year. Circulation. 2000 Oct 31;102(18):873–873.Link to Item
-
Fu YL, Chang WC, Alexander JH, Granger CB, Newby LK, Betriu A, et al. Contemporary changes in early discharge and outcomes in acute myocardial infarction in ASSENT-2. Circulation. 2000 Oct 31;102(18):434–434.Link to Item
-
Granger CB, Alexander JH, Armstrong PW. Caution needed in interpreting the impact of dosing errors: A case study from ASSENT-2. Circulation. 2000 Oct 31;102(18):590–590.Link to Item
-
Gupta M, Chang WC, Van de Werf F, Granger CB, Barbash G, Pehrsson K, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction (AMI) in ASSENT-2. Circulation. 2000 Oct 31;102(18):434–434.Link to Item
-
O’Shea JC, Wilcox RG, Granger CB, Skene AM, Stebbins AL, Aylward PE, et al. Neither education level nor social isolation is an independent predictor of short-term mortality after acute myocardial infarction: Results from the GUSTO III trial. Circulation. 2000 Oct 31;102(18):511–511.Link to Item
-
Birnbaum Y, Wagner GS, Gates KB, Thompson TD, Barbash GI, Siegel RJ, et al. Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction. Am J Cardiol. 2000 Oct 15;86(8):830–4.Full Text Link to Item
-
Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL, et al. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Am J Med. 2000 Oct 15;109(6):489–92.Full Text Link to Item
-
Granger CB, Keavney B, Francomano C, Olsson G, Yusuf S. Recommendations for national and local regulatory authorities concerning research in genetic markers of disease. Am Heart J. 2000 Oct;140(4):S3–5.Full Text Link to Item
-
Hauser ER, Mooser V, Schmidt S, Crossman DC, Haines JL, Jones C, et al. Concordance for cardiovascular risk factors in affected sib pairs (ASPs) with early-onset coronary artery disease (CAD). American Journal of Human Genetics. 2000 Oct 1;67(4):212–212.Link to Item
-
Chang WC, Fu Y, Ohman EM, Gupta M, Morris A, Roth SN, et al. Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. Can J Cardiol. 2000 Oct;16(10):1231–9.Link to Item
-
Granger CB. Genetics of coronary heart disease: current understanding and future prospects. Am Heart J. 2000 Oct;140(4):S1–2.Full Text Link to Item
-
Winkelmann BR, Hager J, Kraus WE, Merlini P, Keavney B, Grant PJ, et al. Genetics of coronary heart disease: current knowledge and research principles. Am Heart J. 2000 Oct;140(4):S11–26.Full Text Link to Item
-
Fu Y, Chang WC, Mark D, Califf RM, Mackenzie B, Granger CB, et al. Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. Circulation. 2000 Sep 19;102(12):1375–81.Full Text Link to Item
-
Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. Jama. 2000 Aug 16;284(7):876–8.Full Text Link to Item
-
O’Shea JC, Wilcox RG, Granger CB, Skene AM, Stebbins AL, Aylward PE, et al. Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial. European Heart Journal. 2000 Aug 1;21:223–223.Link to Item
-
O’Shea JC, Wilcox RG, Granger CB, Skene AM, Stebbins AL, Bode C, et al. Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial. European Heart Journal. 2000 Aug 1;21:213–213.Link to Item
-
Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight D, Mark DB, et al. Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). Am J Cardiol. 2000 Jul 1;86(1):24–9.Full Text Link to Item
-
Granger CB. When is angina good? Preconditioning in acute myocardial infarction. Am Heart J. 2000 May;139(5):771–2.Full Text Link to Item
-
Hasdai D, Granger CB, Srivatsa SS, Criger DA, Ellis SG, Califf RM, et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. J Am Coll Cardiol. 2000 May;35(6):1502–12.Full Text Link to Item
-
Granger CB, Skene A. Acute ischemic heart disease. Am Heart J. 2000 Apr;139(4):S189–92.Full Text Link to Item
-
Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000 Apr;139(4):609–17.Full Text Link to Item
-
Batchelor WB, Granger CB, Kleiman NS, Phillips HR, Ellis SG, Betriu A, et al. A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. Am J Cardiol. 2000 Mar 15;85(6):692–7.Full Text Link to Item
-
Brener SJ, Ellis SG, Sapp SK, Betriu A, Granger CB, Burchenal JE, et al. Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. Am Heart J. 2000 Mar;139(3):476–81.Full Text Link to Item
-
Shah A, Wagner GS, Granger CB, O’Connor CM, Green CL, Trollinger KM, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. J Am Coll Cardiol. 2000 Mar 1;35(3):666–72.Full Text Link to Item
-
Alexander JH, Granger CB, Califf RM, White HD, Hochman J, Topol EJ, et al. Higher aPTTs associated with worse outcomes after thrombolytic therapy with reduced-dose heparin: Results from ASSENT-2. Journal of the American College of Cardiology. 2000 Feb 1;35(2):372A-372A.Link to Item
-
Cohen MG, Hudson MP, Granger CB, Kong DF, Gardner LH, Wagner GS, et al. Quantitative electrocardiographic variables predict adverse outcomes in Non-ST elevation acute coronary syndromes: Results from GUSTO IIb. Journal of the American College of Cardiology. 2000 Feb 1;35(2):410A-411A.Link to Item
-
Hudson MP, Barbash GI, Granger CB, Birnbaum Y, Houbracken K, Pieper KS, et al. Temporal and regional differences in therapy for reinfarction following thrombolysis: Results from GUSTO I and ASSENT II. Journal of the American College of Cardiology. 2000 Feb 1;35(2):386A-386A.Link to Item
-
Roe MT, Alexander JH, Pacchiana CM, Harrington RA, Granger CB, Califf RM, et al. Elevated CK-MB following coronary intervention in patients with acute coronary syndromes is associated with a four-fold increase in mortality: Results from the GUSTO-IIb and PURSUIT trials. Journal of the American College of Cardiology. 2000 Feb 1;35(2):40A-40A.Link to Item
-
Roe MT, Granger CB, Ohman EM, Califf RM, Hellkamp A, Topol EJ, et al. Hirudin significantly reduces ischemic events following coronary intervention for acute coronary syndromes. Journal of the American College of Cardiology. 2000 Feb 1;35(2):39A-40A.Link to Item
-
Shah MR, Bahit MC, Granger CB, Beasley D, White HD, Topol EJ, et al. Clinical features of patients with heart failure after an acute coronary syndrome: Findings from GUSTO-IIb. Journal of the American College of Cardiology. 2000 Feb 1;35(2):212A-213A.Link to Item
-
Crenshaw BS, Granger CB, Birnbaum Y, Pieper KS, Morris DC, Kleiman NS, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. Circulation. 2000 Jan 4;101(1):27–32.Full Text Link to Item
-
O’Connor CM, Gattis WA, Gheorghiade M, Granger CB, Gilbert J, McKenney JM, et al. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J. 1999 Dec;138(6 Pt 1):1140–8.Full Text Link to Item
-
Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, Weaver WD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol. 1999 Dec 1;84(11):1281–6.Full Text Link to Item
-
Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, et al. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. 1999 Dec;138(6 Pt 1):1065–72.Full Text Link to Item
-
Holmes DR, Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation. 1999 Nov 16;100(20):2067–73.Full Text Link to Item
-
Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999 Nov 15;84(10):1145–50.Full Text Link to Item
-
Cohen MG, Granger CB, Ohman EM, Stebbins AL, Grinfeld LR, Cagide AM, et al. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1999 Nov 15;34(6):1729–37.Full Text Link to Item
-
Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999 Nov 15;34(6):1711–20.Full Text Link to Item
-
Armstrong PW, Fu YL, Chang WC, Kaul P, Granger CB, Ohman EM. Increased early discharge does not compromise mortality: Insights from GUSTO I and GUSTO III. Circulation. 1999 Nov 2;100(18):499–499.Link to Item
-
Chetcuti SJ, Silva S, Granger CB, Berger PB, Bates ER. The effect of infarct location in cardiogenic shock: The GUSTO experience. Circulation. 1999 Nov 2;100(18):302–3.Link to Item
-
Goldmann BU, Ohman EM, Hamm CW, Bastos E, Newby K, Granger CB, et al. Is the adverse outcome with positive troponin T neutralized by revascularization? Results from GUSTO-IIa. Circulation. 1999 Nov 2;100(18):810–810.Link to Item
-
Hudson MP, Granger CB, Stebbins AL, White HD, Bates ER, Greenbaum AB, et al. Cardiogenic shock survival and use of intraaortic balloon counterpulsation: Results from the GUSTO I and III trials. Circulation. 1999 Nov 2;100(18):370–370.Link to Item
-
Mahaffey KW, Lee KL, White HD, Gore JM, Weaver WD, Granger CB, et al. Intracranial hemorrhage on the increase and beyond predicted levels: Serial results from two large thrombolysis trials. Circulation. 1999 Nov 2;100(18):182–182.Link to Item
-
McGuire DK, Emanuelsson H, Charnwood A, Granger CB, White HD. Diabetes mellitus is associated with worse clinical outcomes across the spectrum of acute coronary syndromes: Results from GUSTO-IIb. Circulation. 1999 Nov 2;100(18):432–432.Link to Item
-
Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Tudor GE, et al. Women are more likely to have adverse effects from angiotensin-converting enzyme inhibitors: Results from the SPICE registry. Circulation. 1999 Nov 2;100(18):537–537.Link to Item
-
Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail. 1999 Sep;5(3):276–82.Full Text Link to Item
-
Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J. 1999 Sep;138(3 Pt 1):493–9.Full Text Link to Item
-
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999 Aug 28;354(9180):716–22.Full Text Link to Item
-
Bart BA, Ertl G, Held P, Kuch J, Maggioni AP, McMurray J, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J. 1999 Aug;20(16):1182–90.Full Text Link to Item
-
Berger PB, Ellis SG, Holmes DR, Granger CB, Criger DA, Betriu A, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation. 1999 Jul 6;100(1):14–20.Full Text Link to Item
-
Batchelor WB, Peterson ED, Mark DB, Knight JD, Granger CB, Armstrong PW, et al. A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol. 1999 Jul;34(1):12–9.Full Text Link to Item
-
Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation. 1999 May 11;99(18):2371–7.Full Text Link to Item
-
Sadowski ZP, Alexander JH, Skrabucha B, Dyduszynski A, Kuch J, Nartowicz E, et al. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J. 1999 May;137(5):792–8.Full Text Link to Item
-
Alexander JH, Granger CB, Sadowski Z, Aylward PE, White HD, Thompson TD, et al. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. Am Heart J. 1999 May;137(5):799–805.Full Text Link to Item
-
Hasdai D, Lerman A, Rihal CS, Criger DA, Garratt KN, Betriu A, et al. Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. Am Heart J. 1999 Apr;137(4 Pt 1):612–20.Full Text Link to Item
-
Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. Jama. 1999 Feb 24;281(8):707–13.Full Text Link to Item
-
Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, et al. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. Circulation. 1999 Jan 26;99(3):370–6.Full Text Link to Item
-
Birnbaum Y, Wagner GS, Barbash GI, Gates K, Criger DA, Sclarovsky S, et al. Correlation of angiographic findings and right (V1 to V3) versus left (V4 to V6) precordial ST-segment depression in inferior wall acute myocardial infarction. Am J Cardiol. 1999 Jan 15;83(2):143–8.Full Text Link to Item
-
Mahaffey KW, Toth CA, White HD, Stebbins AL, Granger CB, Chatterjee K. Thrombolytic therapy for acute MI in diabetics with retinopathy. Cardiology Review. 1999 Jan 1;16(11):27–32.
-
Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, et al. Racial differences in the management of unstable angina: Results from the multicenter GUARANTEE registry. American Heart Journal. 1999;138(6 I):1065–72.
-
Barbagelata A, Di Carli MF, Sgarbossa EB, Califf RM, Clemmensen P, Criger DA, et al. The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. J Electrocardiol. 1999;32 Suppl:111–3.Full Text Link to Item
-
Granger CB, Califf RM. The gusto trials. Journal of Interventional Cardiology. 1999 Jan 1;12(1):13–31.Full Text
-
Kleiman NS, Granger CB, White HD, Armstrong P, Ardissino D, de Werf FV, et al. Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. Am Heart J. 1999 Jan;137(1):12–23.Full Text Link to Item
-
Mahaffey KW, Granger CB, Sloan MA. Assessing risk factors for nonhemorrhagic stroke after acute myocardial infarction. Cardiology Review. 1998 Dec 1;15(11):46–50.
-
Alexander KP, Peterson ED, Granger CB, Casas AC, Van de Werf F, Armstrong PW, et al. Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. J Am Coll Cardiol. 1998 Dec;32(7):2023–30.Full Text Link to Item
-
Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation. 1998 Nov 3;98(18):1860–8.Full Text Link to Item
-
Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, Lee KL, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. 1998 Nov 3;98(18):1853–9.Full Text Link to Item
-
Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, et al. Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Am Heart J. 1998 Nov;136(5):868–76.Full Text Link to Item
-
Armstrong PW, Fu YL, Chang WC, Granger CB, Betriu A, Van de Werf F, et al. Acute coronary syndromes: Prognostic insights from GUSTO IIb. Circulation. 1998 Oct 27;98(17):630–630.Link to Item
-
Armstrong PW, Fu YL, Chang WC, MacKenzie M, Mark DB, Granger CB, et al. Canadian-American differences in management and outcome of non ST elevation acute coronary syndromes: 6 month follow up from the GUSTO IIb study. Circulation. 1998 Oct 27;98(17):479–80.Link to Item
-
Batchelor WB, Peterson ED, Knight DJ, Armstrong PW, Granger CB. The use of a clinical predictive model for severe coronary artery disease improves the efficiency of cardiac catheterization in both the US and Canada. Circulation. 1998 Oct 27;98(17):135–135.Link to Item
-
Di Carli MF, Barbagelata A, Mahaffey KW, Casas CA, Puma JA, Granger CB. Does preinfarction angina reduce infarct size? An ancillary study from the controlled, randomized AMISTAD trial. Circulation. 1998 Oct 27;98(17):630–630.Link to Item
-
Fu YL, Armstrong PW, Chang WC, Ohman EM, Gupta M, Morris A, et al. Impact of temporal trends in management on outcomes of acute myocardial infarction in Canada versus US. Circulation. 1998 Oct 27;98(17):479–479.Link to Item
-
Miller JM, Ohman EM, Hasselblad V, Granger CB, Sketch MH, Kong DF, et al. Can TIMI grade 3 flow at 60 minutes after thrombolysis substitute as a new angiographic standard? A meta-analytic approach. Circulation. 1998 Oct 27;98(17):784–784.Link to Item
-
Roe MT, Bhatt DL, Houghtaling P, Granger CB. A three-fold subsequent risk of death or reinfarction among patients with creatine kinase elevation after percutaneous coronary intervention: Results of the GUSTO IIb study of acute coronary syndromes. Circulation. 1998 Oct 27;98(17):496–496.Link to Item
-
Sloan MA, Sila CA, Mahaffey KW, Granger CB, Longstreth WT, Koudstaal P, et al. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation. 1998 Oct 6;98(14):1376–82.Full Text Link to Item
-
Ardissino D, Merlini PA, Eisenberg PR, Kottke-Marchant K, Crenshaw BS, Granger CB. Coagulation markers and outcomes in acute coronary syndromes. Am Heart J. 1998 Oct;136(4 Pt 2 Su):S7-18.Full Text Link to Item
-
Harrington RA, Kleiman NS, Granger CB, Ohman EM, Berkowitz SD. Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J. 1998 Oct;136(4 Pt 2 Su):S43–50.Full Text Link to Item
-
Gebel JM, Sila CA, Sloan MA, Granger CB, Weisenberger JP, Green CL, et al. Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke. 1998 Sep;29(9):1799–801.Full Text Link to Item
-
Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol. 1998 Sep;32(3):634–40.Full Text Link to Item
-
Every NR, Cannon CP, Granger C, Moliterno DJ, Aguirre FV, Talley JD, et al. Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. J Am Coll Cardiol. 1998 Aug;32(2):387–92.Full Text Link to Item
-
Granger CB. Heparin management in acute myocardial infarction (AMI). Aust N Z J Med. 1998 Aug;28(4):541–7.Full Text Link to Item
-
Straznicky I, White HD, Granger CB, Aylward PE, Barbash GI, Topol EJ, et al. Effects of four thrombolytic regimens in elderly patients. Cardiology Review. 1998 Jul 13;15(1):22–8.
-
Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. J Am Coll Cardiol. 1998 Jun;31(7):1493–8.Full Text Link to Item
-
Hochrein J, Sun F, Pieper KS, Lee KL, Gates KB, Armstrong PW, et al. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. Am J Cardiol. 1998 May 1;81(9):1078–84.Full Text Link to Item
-
Califf RM, Granger CB. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. Diabetes Care. 1998 Apr;21(4):655–7.Full Text Link to Item
-
Langer A, Krucoff MW, Klootwijk P, Simoons ML, Granger CB, Barr A, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol. 1998 Mar 15;31(4):783–9.Full Text Link to Item
-
Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD, et al. Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation. 1998 Mar 3;97(8):757–64.Full Text Link to Item
-
Esposito GA, Dunham G, Granger BB, Tudor GE, Granger CB. Converting i.v. nitroglycerin therapy to nitroglycerin ointment therapy: a comparison of two methods. Am J Crit Care. 1998 Mar;7(2):123–30.Link to Item
-
Christenson RH, Duh SH, Newby LK, Ohman EM, Califf RM, Granger CB, et al. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem. 1998 Mar;44(3):494–501.Link to Item
-
Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Stroke. 1998 Mar;29(3):563–9.Full Text Link to Item
-
Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1998 Mar 1;31(3):497–505.Full Text Link to Item
-
Goodman SG, Langer A, Ross AM, Wildermann NM, Barbagelata A, Sgarbossa EB, et al. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. Circulation. 1998 Feb 10;97(5):444–50.Full Text Link to Item
-
Hathaway WR, Peterson ED, Wagner GS, Granger CB, Zabel KM, Pieper KS, et al. Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Jama. 1998 Feb 4;279(5):387–91.Full Text Link to Item
-
Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998 Feb;31(2):241–51.Full Text Link to Item
-
Gilchrist I. Heparin Dosing and Outcome in Acute Coronary Syndromes: The GUSTO-IIb Experience. Journal of the American College of Cardiology. 1998 Feb;31(2):78A-78A.Full Text
-
Granger C. Hirudin Reduces Death and Myocardial (Re)infarction at 6-Months: Follow-up Results of the GUSTO IIb Trial. Journal of the American College of Cardiology. 1998 Feb;31(2):79A-79A.Full Text
-
Krucoff M. A Comparison of Static Serial vs Continuous ST-Segment Recovery to Predict Outcome After Lytics for MI. Journal of the American College of Cardiology. 1998 Feb;31(2):228A-229A.Full Text
-
Mahaffey K. Comparison of Stroke Rates in Patients With Acute Coronary Syndromes and Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology. 1998 Feb;31(2):406A-406A.Full Text
-
Mahaffrey K. Disagreement Between Site Investigators and Clinical Event Committees is Common and Can Affect Trial Results. Journal of the American College of Cardiology. 1998 Feb;31(2):184A-185A.Full Text
-
Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: Mechanisms of action, Pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998 Jan 1;114(5 SUPPL.):489S-510S.
-
Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, et al. Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol. 1998 Jan;31(1):105–10.Full Text Link to Item
-
Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, et al. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997 Dec;30(7):1606–10.Full Text Link to Item
-
Aylward PE, Sadowski Z, Granger CB, Ardissino D, Wilcox RG, Armstrong PW, et al. International differences in outcomes: Results from the GUSTO-III trial. Circulation. 1997 Oct 21;96(8):1118–1118.Link to Item
-
Batchelor WB, Granger CB, Phillips HR, Kleinman NS, Stebbins AL. Ionic, low osmolar contrast is associated with better outcome following direct PTCA: Results from GUSTO-IIb. Circulation. 1997 Oct 21;96(8):2978–2978.Link to Item
-
Cannon CP, Scirica BM, Every NR, Anderson HV, Aguirre FV, Granger CB, et al. Racial differences in the management of unstable angina: Results from the GUARANTEE registry. Circulation. 1997 Oct 21;96(8):3329–3329.Link to Item
-
Granger CB, Betriu A, Phillips HR, Stebbins AL, Califf RM. Nearly half of early benefit of direct angioplasty lost in longer term follow-up: 6-month results from the GUSTO-IIb direct angioplasty substudy. Circulation. 1997 Oct 21;96(8):1137–1137.Link to Item
-
Mahaffey KW, Puma JA, Barbagelata A, Casas CA, Lambe L, Orlandi C, et al. Does adenosine in conjunction with thrombolysis reduce infarct size? Results from the controlled, randomized AMISTAD trial. Circulation. 1997 Oct 21;96(8):1144–1144.Link to Item
-
Miller JM, Phillips HR, Barness GW, Wildermann N, Betriu AB, Garcia EL, et al. TIMI grade 3 flow after primary coronary angioplasty predicts both early and late survival following acute myocardial infarction. Circulation. 1997 Oct 21;96(8):2236–2236.Link to Item
-
Newby K, Harrington RA, Bhapkar M, Granger CB, Rames A, Moliterno D. Tight control of aPTT in acute coronary syndrome patients using an automated strategy for bedside heparin adjustment: Results from the PARAGON A trial. Circulation. 1997 Oct 21;96(8):4200–4200.Link to Item
-
Anderson RD, Ohman EM, Holmes DR, Col I, Stebbins AL, Bates ER, et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997 Sep;30(3):708–15.Full Text Link to Item
-
Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997 Aug;30(2):406–13.Full Text Link to Item
-
Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997 Jul;30(1):171–9.Full Text Link to Item
-
Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. Circulation. 1997 Jul 1;96(1):116–21.Full Text Link to Item
-
Granger CB. Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol. 1997 Jun 19;79(12A):44–8.Full Text Link to Item
-
Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation. 1997 Jun 3;95(11):2508–16.Full Text Link to Item
-
Berkowitz SD, Granger CB, Pieper KS, Topol EJ, Califf RM. Incidence and predictors of bleeding after antithrombin therapy for acute coronary syndromes: The GUSTO II trials. Thrombosis and Haemostasis. 1997 Jun 1;PS963–PS963.Link to Item
-
Berkowitz SD, Granger CB, Thompson T, Kleiman NS, Topol EJ, Califf RM. Thombocytopenia was associated with greater hemorrhage and higher mortality in GUSTO IIb trial. Thrombosis and Haemostasis. 1997 Jun 1;PS962–PS962.Link to Item
-
Alberts MJ, Davis JP, Graffagnino C, McClenny C, Delong D, Granger C, et al. Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage. Ann Neurol. 1997 May;41(5):683–6.Full Text Link to Item
-
Califf RM, Lee KL, Granger CB, Ohman EM. Predictors of outcome of reperfusion therapy. Eur Heart J. 1997 May;18(5):728–35.Full Text Link to Item
-
Jelesoff NE, Feinglos M, Granger CB, Califf RM. Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. J Cardiovasc Risk. 1997 Apr;4(2):100–11.Link to Item
-
Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, et al. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. J Am Coll Cardiol. 1997 Mar 15;29(4):770–7.Full Text Link to Item
-
Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, et al. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J. 1997 Mar;133(3):273–82.Full Text Link to Item
-
Alexander KP, Peterson ED, Hellkamp AS, Granger CB, Topol EJ, Califf RM. Early catheterization is standard strategy in unstable angina/NQWMI: Results from GUSTO IIb. Journal of the American College of Cardiology. 1997 Feb 1;29(2):5614–5614.Link to Item
-
Alexander KP, Peterson ED, Mahaffey KW, Casas AC, Granger CB, VandeWerf F, et al. Medical interventions in unstable angina: Does international clinical practice match evidence-based guidelines? Journal of the American College of Cardiology. 1997 Feb 1;29(2):23138–23138.Link to Item
-
Amsterdam PB, Hafley GE, Harrington RA, Granger CB, Topol EJ, Califf RM. Is the ECG adequate to identify patients with left circumflex occlusion in acute coronary syndromes? Journal of the American College of Cardiology. 1997 Feb 1;29(2):78128–78128.Link to Item
-
Barbagelata A, Califf RM, Sgarbossa EB, Goodman S, Knight D, Mark DB, et al. Mortality, morbidity, resource use and quality of life following Q- vs non-Q-wave infarction and thrombolytic therapy: A GUSTO-I substudy. Journal of the American College of Cardiology. 1997 Feb 1;29(2):78106–78106.Link to Item
-
Granger CB, Phillips HR, Betriu A, Ellis SG, Weaver WD, Aylward P, et al. Direct angioplasty may be less advantageous in patients presenting early after symptom onset: Results from GUSTO IIb. Journal of the American College of Cardiology. 1997 Feb 1;29(2):7811–7811.Link to Item
-
Krucoff MW, Green CL, Troliinger KM, Pope JE, Harrington RA, Granger CB, et al. Temporal distribution of important ECG information in patients with MI: When should you take the next ECG after lytics? Journal of the American College of Cardiology. 1997 Feb 1;29(2):9466–9466.Link to Item
-
Krucoff MW, Green CL, Trollinger KM, Pope JE, Granger CB, Ohman EM, et al. ST-segment recovery parameters predictive of outcome in AMI: Variability with infarct artery location and implications for therapeutic targets. Journal of the American College of Cardiology. 1997 Feb 1;29(2):3455–3455.Link to Item
-
Mahaffey KW, Granger CB, Tardiff BE, Woodlief L, Lee KL, Weaver WD, et al. Endpoint adjudication by a clinical events committee can impact the statistical outcome of a clinical trial: Results from GUSTO-IIb. Journal of the American College of Cardiology. 1997 Feb 1;29(2):3339–3339.Link to Item
-
Vorchheimer DA, Baruch L, Deperalta ET, Guzman IC, Hayes RM, Hellkamp AS, et al. Weight adjusted antithrombotic regimens eliminate the nitroglycerin-antithrombotic interaction. Journal of the American College of Cardiology. 1997 Feb 1;29(2):3453–3453.Link to Item
-
Berdan LG, Kleiman NS, Woodlief LH, Harrington RA, Granger CB, Califf RM. Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective. J Thromb Thrombolysis. 1997;4(3/4):415–23.Full Text Link to Item
-
Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, et al. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. Ann Intern Med. 1996 Dec 1;125(11):891–900.Full Text Link to Item
-
Granger CB. Diet and secondary prevention of coronary disease: is it time to stop chewing the fat? J Am Coll Cardiol. 1996 Nov 1;28(5):1109–10.Full Text Link to Item
-
Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996 Oct 31;335(18):1333–41.Full Text Link to Item
-
Alexander JH, Granger CB, Thompson TD, Sadowski Z, Aylward PE. Prophylactic lidocaine use in GUSTO-I and GUSTO-II: Incidence and outcomes. Circulation. 1996 Oct 15;94(8):1143–1143.Link to Item
-
Armstrong PW, Califf RM, Granger CB, Woodlief LH, Topol EJ. Recurrent ischemia in the GUSTO IIb trial. Circulation. 1996 Oct 15;94(8):2225–2225.Link to Item
-
Armstrong PW, Granger CB, Knight D, Sutherland W, ClappChanning N, Hlatky M, et al. Temporal trends in the process of myocardial infarction management; Canadian/US GUSTO experience. Circulation. 1996 Oct 15;94(8):158–158.Link to Item
-
Armstrong PW, Granger CB, Knight D, Sutherland W, ClappChanning N, Hlatky M, et al. Practice patterns and outcomes amongst non ST elevation patients with acute coronary syndromes. Circulation. 1996 Oct 15;94(8):160–160.Link to Item
-
Granger CB, Woodlief LH. Lack of rebound recurrence of reinfarction after discontinuation of antithrombin therapy: Results from the GUSTO IIb trial. Circulation. 1996 Oct 15;94(8):2516–2516.Link to Item
-
Mark DB, Granger CB, Ellis SG, Phillips HR, Knight D, DavidsonRay L, et al. Costs of direct angioplasty versus thrombolysis for acute myocardial infarction: Results from the GUSTO II randomized trial. Circulation. 1996 Oct 15;94(8):973–973.Link to Item
-
Metz BK, Granger CB, White HD, Simes J, Topol EJ. Streptokinase and hirudin reduces death and reinfarction in acute myocardial infarction compared with streptokinase and heparin: Results from GUSTO IIb. Circulation. 1996 Oct 15;94(8):2509–2509.Link to Item
-
Moliterno DJ, Aguirre FV, Cannon CP, Every NR, Granger CB, Sapp SK, et al. The global unstable angina registry and treatment evaluation (GUARANTEE) study. Circulation. 1996 Oct 15;94(8):1136–1136.Link to Item
-
Simes RJ, Granger CB, Antman EM, Califf RM, Braunwald E, Topol EJ. Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes: A prospective meta-analysis of the GUSTO-IIb and TIMI 9b trials. Circulation. 1996 Oct 15;94(8):2507–2507.Link to Item
-
White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation. 1996 Oct 15;94(8):1826–33.Full Text Link to Item
-
Jelesoff NE, Feinglos M, Granger CB, Califf RM. Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. Coron Artery Dis. 1996 Oct;7(10):732–43.Full Text Link to Item
-
Peterson ED, Hathaway WR, Zabel KM, Pieper KS, Granger CB, Wagner GS, et al. Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. J Am Coll Cardiol. 1996 Aug;28(2):305–12.Full Text Link to Item
-
Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Journal of Intravenous Nursing. 1996 May 1;19(3):147–56.
-
Mahaffey KW, Granger CB, Collins R, O’Connor CM, Ohman EM, Bleich SD, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol. 1996 Mar 15;77(8):551–6.Full Text Link to Item
-
Chang YC, Patz EF, Goodman PC, Granger CB. Significance of hemoptysis following thrombolytic therapy for acute myocardial infarction. Chest. 1996 Mar;109(3):727–9.Full Text Link to Item
-
Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation. 1996 Mar 1;93(5):870–8.Full Text Link to Item
-
Sloan MA, Sila CA, Mahaffey KW, Granger CB, Longstreth WT, Green CL, et al. Clinical and radiographic factors associated with mortality following intracranial hemorrhage after thrombolysis for acute myocardial infarction. Stroke. 1996 Jan 1;27(1):90–90.Link to Item
-
Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J Am Coll Cardiol. 1995 Dec;26(7):1651–6.Full Text Link to Item
-
Barbagelata A, Granger CB, Topol EJ, Worley SJ, Kereiakes DJ, George BS, et al. Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. Am J Cardiol. 1995 Nov 15;76(14):1007–13.Full Text Link to Item
-
Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation. 1995 Nov 15;92(10):2811–8.Full Text Link to Item
-
ANDERSON RD, STEBBINS AL, BATES E, STOMEL R, GRANGER CB, OHMAN EM. UNDERUTILIZATION OF AORTIC COUNTERPULSATION IN PATIENTS WITH CARDIOGENIC-SHOCK - OBSERVATIONS FROM THE GUSTO-1 STUDY. Circulation. 1995 Oct 15;92(8):658–658.Link to Item
-
BERKOWITZ SD, GRANGER CB, PIEPER KS, CALIFF RM. HEMORRHAGIC NON-CNS COMPLICATIONS ASSOCIATED WITH 4 THROMBOLYTIC STRATEGIES FOR ACUTE MYOCARDIAL-INFARCTION. Circulation. 1995 Oct 15;92(8):2197–2197.Link to Item
-
CRENSHAW BS, WARD SR, STEBBINS AL, GRANGER CB. RISK-FACTORS AND OUTCOMES IN PATIENTS WITH ATRIAL-FIBRILLATION FOLLOWING ACUTE MYOCARDIAL-INFARCTION. Circulation. 1995 Oct 15;92(8):3740–3740.Link to Item
-
GOODMAN SG, LANGER A, WILDERMANN NM, BARBAGELATA A, SGARBOSSA EB, WAGNER GS, et al. NON-Q VS Q-WAVE MYOCARDIAL-INFARCTION POST-THROMBOLYSIS - ANGIOGRAPHIC INSIGHTS. Circulation. 1995 Oct 15;92(8):2529–2529.Link to Item
-
GRANGER CB, ARMSTRONG PW. REINFARCTION FOLLOWING DISCONTINUATION OF INTRAVENOUS HEPARIN OR HIRUDIN FOR UNSTABLE ANGINA AND ACUTE MYOCARDIAL-INFARCTION. Circulation. 1995 Oct 15;92(8):2196–2196.Link to Item
-
GRANGER CB, CALIFF RM, VANDEWERF F, WHITE HD, TOPOL EJ. ACTIVATED PARTIAL THROMBOPLASTIN TIME AND CLINICAL OUTCOME AMONG PATIENTS WITH UNSTABLE ANGINA OR NON-Q-WAVE MI TREATED WITH INTRAVENOUS HEPARIN. Circulation. 1995 Oct 15;92(8):1985–1985.Link to Item
-
MAHAFFEY KW, GRANGER CB, STEBBINS AL, CALIFF RM. DIABETIC-RETINOPATHY SHOULD NOT BE A CONTRAINDICATION TO THROMBOLYTIC THERAPY - QUANTIFICATION OF RISK IN 6011 PATIENTS. Circulation. 1995 Oct 15;92(8):1986–1986.Link to Item
-
PETERSON ED, MARK DB, ARMSTRONG PW, KNIGHT D, GRANGER CB. DOES A CONSERVATIVE POST-MI CATHETERIZATION STRATEGY MISS SEVERE CORONARY-DISEASE - COMPARISONS OF USE AND DIAGNOSTIC YIELD IN CANADA AND THE US. Circulation. 1995 Oct 15;92(8):565–565.Link to Item
-
TARDIFF BE, GRANGER CB, WOODLIEF L, MAHAFFEY KW, HARRINGTON RA, CALIFF RM. PROGNOSTIC-SIGNIFICANCE OF POST-INTERVENTION ISOZYME ELEVATIONS. Circulation. 1995 Oct 15;92(8):2599–2599.Link to Item
-
Langer A, Krucoff MW, Klootwijk P, Veldkamp R, Simoons ML, Granger C, et al. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1995 Jun;25(7):1552–7.Full Text Link to Item
-
Pilote L, Granger C, Armstrong PW, Mark DB, Hlatky MA. Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial. Med Care. 1995 Jun;33(6):598–610.Full Text Link to Item
-
Van de Werf F, Topol EJ, Lee KL, Woodlief LH, Granger CB, Armstrong PW, et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Jama. 1995 May 24;273(20):1586–91.Full Text Link to Item
-
Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995 Apr 1;91(7):1929–35.Full Text Link to Item
-
Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 1994 Dec 15;74(12):1220–8.Full Text Link to Item
-
Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, et al. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med. 1994 Oct 27;331(17):1130–5.Full Text Link to Item
-
KRUCOFF MW, GREEN CL, TROLLINGER KM, SAWCHAK ST, WILDERMAN NM, SHAH A, et al. UNIVARIATE RELATIONSHIPS BETWEEN MORTALITY AND PARAMETERS OF CONTINUOUS 12-LEAD ST-SEGMENT DEVIATION AND RECOVERY AFTER THROMBOLYTIC THERAPY FOR ACUTE INFARCTION. Circulation. 1994 Oct 1;90(4):501–501.Link to Item
-
ZABEL KM, GRANGER CB, BECKER RC, WOODLIEF LH, CHESEBRO JH, CALIFF RM. BEDSIDE APTT MONITORING IS ASSOCIATED WITH LESS BLEEDING AMONG GUSTO PATIENTS RECEIVING IV HEPARIN FOLLOWING THROMBOLYTIC ADMINISTRATION. Circulation. 1994 Oct 1;90(4):553–553.Link to Item
-
Califf RM, Granger CB. Trials of new antithrombin agents. Journal of Myocardial Ischemia. 1994 Aug 8;6(6):10–4.
-
Hillegass WB, Jollis JG, Granger CB, Ohman EM, Califf RM, Mark DB. Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. Am J Cardiol. 1994 Mar 1;73(7):444–9.Full Text Link to Item
-
MARK DB, NAYLOR CD, HLATKY MA, TOPOL EJ, KNIGHT JD, CLAPPCHANNING N, et al. PATIENT SATISFACTION WITH HEALTH-CARE IS INSENSITIVE TO VARIATIONS IN CARE RECEIVED AND QUALITY-OF-LIFE - UNITED-STATES CANADA GUSTO SUBSTUDY RESULTS. Journal of the American College of Cardiology. 1994 Feb 1;A166–A166.Link to Item
-
Krucoff MW, Green CL, Harrell FE, Simoons ML, Wilderman NM, Trollinger KM, et al. From signal/noise to information content/noise. Reconsidering the statistical analysis of continuous ST-segment data streams with gaps: potential optimization of application-specific information content using left, right, and interval censoring. J Electrocardiol. 1994;27 Suppl:233–7.Full Text Link to Item
-
Krucoff MW, Croll MA, Pope JE, Granger CB, O’Connor CM, Sigmon KN, et al. Continuous 12-lead ST-segment recovery analysis in the TAMI 7 study. Performance of a noninvasive method for real-time detection of failed myocardial reperfusion. Circulation. 1993 Aug;88(2):437–46.Full Text Link to Item
-
HILLEGASS WB, JOLLIS JG, GRANGER CB, CALIFF RM, MARK DB. HOW MANY LIVES DOES A NEW MORE POTENT THROMBOLYTIC AGENT HAVE TO SAVE TO JUSTIFY ADDITIONAL INTRACRANIAL HEMORRHAGES. Clinical Research. 1993 Apr 1;41(2):A122–A122.Link to Item
-
Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol. 1993 Mar 15;21(4):920–5.Full Text Link to Item
-
Krucoff MW, Croll MA, Pope JE, Pieper KS, Kanani PM, Granger CB, et al. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. Am J Cardiol. 1993 Jan 15;71(2):145–51.Full Text Link to Item
-
Krucoff MW, Green CL, Langer A, Klootwijk LJ, Trollinger KM, Sawchak ST, et al. Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations. J Electrocardiol. 1993;26 Suppl:249–55.Link to Item
-
Ross AM, Lundergan C, Thompson M, Reiner J, Deychak Y, Rohrbeck S, et al. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. New England Journal of Medicine. 1993;329(22):1615–22.Full Text
-
GRANGER CB, CALIFF RM, HIRSH J, WOODLIEF LH, TOPOL EJ. APTTS AFTER THROMBOLYSIS AND STANDARD INTRAVENOUS HEPARIN ARE OFTEN LOW AND CORRELATE WITH BODY-WEIGHT, AGE AND SEX - EXPERIENCE FROM THE GUSTO TRIAL. Circulation. 1992 Oct 1;86(4):258–258.Link to Item
-
GRANGER CB, OCONNOR CM, BLEICH SD, COL JJ, KEELER GP, OHMAN EM. AN OVERVIEW OF THE EFFECT OF INTRAVENOUS HEPARIN ON CLINICAL END-POINTS FOLLOWING THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION. Circulation. 1992 Oct 1;86(4):259–259.Link to Item
-
GRANGER CB, OHMAN EM, BATES E. POOLED ANALYSIS OF ANGIOGRAPHIC PATENCY RATES FROM THROMBOLYTIC THERAPY TRIALS. Circulation. 1992 Oct 1;86(4):269–269.Link to Item
-
KLINE EM, SMITH DD, MARTIN JS, DRACUP K, WOODLIEF LH, GRANGER CB, et al. IN-HOSPITAL TREATMENT DELAYS IN PATIENTS TREATED WITH THROMBOLYTIC THERAPY - A REPORT OF THE GUSTO TIME TO TREATMENT SUBSTUDY. Circulation. 1992 Oct 1;86(4):702–702.Link to Item
-
OHMAN EM, CHRISTENSON RH, GRANGER CB, BERRIOS E, WORLEY S, OCONNOR CM, et al. NONINVASIVE DETECTION OF REPERFUSION AFTER THROMBOLYSIS BASED ON CLINICAL-ASSESSMENT AND RAPID CK-MB ANALYSIS. Circulation. 1992 Oct 1;86(4):268–268.Link to Item
-
Granger CB, Califf RM, Topol EJ. Thrombolytic Therapy for Acute Myocardial Infarction : A Review. Drugs. 1992 Sep;44(3):293–325.Full Text Link to Item
-
Granger CB, Gabriel DA, Reece NS, Boothroyd E, Harding MB, Harrison JK, et al. Fibrin modification by ionic and nonionic contrast media during cardiac catheterization. Am J Cardiol. 1992 Mar 15;69(8):821–3.Full Text Link to Item
-
Califf RM, Granger C. TIMI IIB follow-up. Lessons for clinicians and investigators. Circulation. 1992 Feb;85(2):839–41.Full Text Link to Item
-
KRUCOFF MW, CROLL MA, GRANGER CB, OCONNOR CM, SIGMON KN, POPE JE, et al. PROSPECTIVE BLINDED NONINVASIVE DETECTION OF FAILED THROMBOLYSIS USING DIGITAL TRENDING FROM CONTINUOUS 12-LEAD ST-SEGMENT MONITORING. Circulation. 1990 Oct 1;82(4):254–254.Link to Item
-
GRANGER CB, GABRIEL DA, REECE NS, BOOTHROYD E, HARDING MB, HARRISON JK, et al. FIBRIN MODIFICATION BY CONTRAST-MEDIA DURING CARDIAC-CATHETERIZATION. Arteriosclerosis. 1990 Sep 1;10(5):A928–A928.Link to Item
-
Weissler AM, Miller BI, Granger CB, Henry TD, Sheikh KH, Kirch DL, et al. Augmentation of mortality risk discriminating power of left ventricular ejection fraction by measures of nonuniformity in systolic emptying on radionuclide ventriculography. J Am Coll Cardiol. 1990 Aug;16(2):387–95.Full Text Link to Item
-
Krucoff MW, Croll MA, Pope JE, Granger CB, Pieper KS, Sigmon KN, et al. Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. J Electrocardiol. 1990;23 Suppl:6–10.Full Text Link to Item
-
Granger CB, Karimeddini MK, Smith VE, Shapiro HR, Katz AM, Riba AL. Rapid ventricular filling in left ventricular hypertrophy: I. Physiologic hypertrophy. J Am Coll Cardiol. 1985 Apr;5(4):862–8.Full Text Link to Item
-
-
Book Sections
-
Manly DA, Granger CB. Anticoagulation Drug Trials for Stroke Prevention in Atrial Fibrillation. In: Stroke Prevention in Atrial Fibrillation. 2018. p. 35–46.Full Text
-
Marc Jolicoeur E, Granger CB. Anticoagulant Agents. In: Reperfusion Therapy for Acute Myocardial Infarction. 2016. p. 195–232.
-
Kuijt WJ, Williams J, Granger CB, Krucoff MW, Roe MT. Current approaches to prevention and management of reperfusion injury. In: Management of Myocardial Reperfusion Injury. 2012. p. 215–38.Full Text
-
Rebeiz AG, Granger CB, Simoons ML. Incidence and management of complications of fibrinolytic, antiplatelet, and anticoagulant therapy. In: Clinical, Interventional and Investigational Thrombocardiology. 2005. p. 375–96.
-
-
Other Articles
-
Mehta RH, Honeycutt E, Peterson ED, Granger CB, Halabi AR, Shaw LK, et al. Response to letter regarding article, "Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft" [2]. Vol. 114, Circulation. 2006.Full Text
-
-
Conference Papers
-
Rikken SAOF, Bor WL, Zheng KL, Gibson CM, Granger CB, Coller BS, et al. Oral Presentation No. 53 Dose-related preprocedural patency of the infarct-related artery after zalunfiban (RUC-4) administration upon arrival at the catheterization laboratory in ST-elevation myocardial infarction: insights from the phase IIa study. In: Cardiovascular Research. Oxford University Press (OUP); 2022.Full Text
-
Chen S, Hellkamp A, Alhanti B, Melloni C, Piccini JPS, Khouri MG, et al. EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS AMONG MEDICARE PATIENTS WITH ATRIAL FIBRILLATION AND CANCER. In: Journal of the American College of Cardiology. 2022. p. 113–113.Link to Item
-
Fudim M, Lopes RD, Wojdyla DM, Mehran R, Khan MS, Granger CB, et al. Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. In: Circulation. 2022.Link to Item
-
Harrington J, Carnicelli A, Hua K, Hong H, Lopes RD, Patel MR, et al. NOAC USE IS SAFE AND EFFECTIVE FOR PATIENTS WITH ATRIAL FIBRILLATION AND REDUCED RENAL FUNCTION: RESULTS FROM COMBINE-AF. In: Journal of the American College of Cardiology. 2022. p. 36–36.Link to Item
-
Jollis JG, Tamis-Holland JE, Goyal A, Henry TD, Zegre-Hemsey JK, French WJ, et al. Processes and Outcomes for 121,576 Patients With ST Elevation Myocardial Infarction in the AHA Get With the Guidelines (R)-Coronary Artery Disease (GWTG-CAD) Registry, 2018-2021. In: Circulation. 2022.Link to Item
-
Keane RR, Kendersky P, Park J-G, Loriaux D, Arps K, Brown K, et al. CHARACTERISTICS AND OUTCOMES OF ADULTS WITH CONGENITAL HEART DISEASE IN THE CARDIAC INTENSIVE CARE UNIT: INSIGHTS FROM THE CRITICAL CARE CARDIOLOGY TRIALS NETWORK REGISTRY. In: Journal of the American College of Cardiology. 2022. p. 1389–1389.Link to Item
-
Lewinski AA, King HA, Blewer AL, Miller J, Oakes M, Granger CB, et al. INCREASING FIT OF A STATE-WIDE PUBLIC HEALTH INTERVENTION TO IMPROVE CARDIAC ARREST OUTCOMES: IMPLEMENTATION LESSONS LEARNED. In: Annals of Behavioral Medicine. 2022. p. S378–S378.Link to Item
-
Starks MA, Chu J, Leung B, Chan T, Blewer AL, Simmons D, et al. Accelerating AED Use In Out-of-Hospital Cardiac Arrest With Combinations Of First Responder And Drone Delivery To Achieve 5-minute AED Deployment. In: Circulation. 2022.Link to Item
-
Wang X, Jering KS, Cikes M, Tokmakova M, Mehran R, Han Y, et al. Sex differences in clinical characteristics and outcomes after acute myocardial infarction: insights from PARADISE-MI. In: European Journal of Heart Failure. 2022. p. 127–8.Link to Item
-
Bahit MC, Sacco RL, Easton JD, Meyerhoff J, Cronin L, Kleine E, et al. Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. In: Circulation. 2021. p. 1738–46.Full Text Link to Item
-
Harrington J, Giczewska A, Wojdyla D, Washam JB, Fudim M, Hijazi Z, et al. Relationship Between Body Weight and Pharmacokinetics of Apixaban in Patients With Atrial Fibrillation: Insights from the ARISTOTLE Trial. In: Circulation. 2021.Link to Item
-
Blewer AL, Starks MA, Malta Hansen C, Ong ME, Viera AJ, Al-Araji R, et al. Abstract 236: Gender Disparities in Bystander CPR and Defibrillation Persist in Black and Hispanic Neighborhoods in the US. In: Circulation. Ovid Technologies (Wolters Kluwer Health); 2020.Full Text
-
Cooper LB, Kaltenbach L, Al-Khalidi H, Cole R, Allen LA, Fonarow GC, et al. SACUBITRIL-VALSARTAN FOLLOWING HOSPITAL DISCHARGE FOR HEART FAILURE. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2020. p. 1063–1063.Link to Item
-
Hijazi Z, Alexander JH, Li Z, Wojdyla D, Mehran R, Granger CB, et al. APIXABAN VERSUS WARFARIN AND ASPIRIN VERSUS PLACEBO ACCORDING TO RENAL FUNCTION AFTER ACUTE CORONARY SYNDROME OR PCI IN ATRIAL FIBRILLATION: INSIGHTS FROM THE AUGUSTUS TRIAL. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2020. p. 298–298.Link to Item
-
Harrington JL, Jollis JG, Patel MR, Joiner A, Granger CB. SARS-CoV-2 Dramatically Decreases Healthcare Access for Patients With Cardiovascular Disease. In: Circulation. 2020.Link to Item
-
Harskamp R, Lopes RD, Li Z, Wojdyla D, Goodman SG, Aronson R, et al. Safety and efficacy of antithrombotic therapy according to stroke and bleeding risk in patients with atrial fibrillation and acute coronary syndrome or PCI: insights from AUGUSTUS. In: European Heart Journal. 2020. p. 645–645.Link to Item
-
McIlvennan CK, Allen LA, DeVore AD, Kaltenbach LA, Granger CB, Granger BB. Changes in Care Delivery for Patients with Heart Failure During the Covid-19 Pandemic: Results of a Multicenter Survey. In: Journal of Cardiac Failure. 2020. p. S74–5.Link to Item
-
Pokorney S, Garonzik S, Chertow GM, Washam JB, Mussina K, Bansal N, et al. Pharmacokinetics of apixaban in patients with end stage renal disease on hemodialysis and atrial fibrillation: results from the RENAL-AF trial. In: European Heart Journal. 2020. p. 3373–3373.Link to Item
-
Storey R, Alexander JH, Wojdyla DM, Mehran R, Vora AN, Goodman SG, et al. Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach. In: European Heart Journal. 2020. p. 1450–1450.Link to Item
-
Welsh RC, Lopes RD, Wojdyla D, Aronson R, Granger CB, Windecker S, et al. Prior Oral Anticoagulant Status and Outcomes in Patients With Atrial Fibrillation With an Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the Augustus Trial. In: Circulation. 2020.Link to Item
-
Lopes RD, Wojdyla D, Granger CB, Goodman SG, Aronson R, Windecker S, et al. Stent Thrombosis After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2019. p. E986–E986.Link to Item
-
Perez MV, Mahaffey K, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Apple Watch App Identifies Clinically Important Arrhythmias Other Than Atrial Fibrillation: Results From the Apple Heart Study. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2019. p. E988–E988.Link to Item
-
Pokorney SD, Chertow GM, Al-Khalidi H, Gallup D, Dignacco P, Mussina K, et al. Apixaban versus Warfarin for Stroke Prevention in Patients With End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results of a Randomized Clinical Trial Assessing Safety. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2019. p. E988–9.Link to Item
-
Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindback J, Alexander JH, et al. Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 2951–2951.Link to Item
-
Kamath D, Bhuvana KB, Salazar L, Varghese K, Umesh S, Immaculate SJ, et al. Patients explanations of self-care in chronic heart failure: a grounded theory analysis of qualitative data from PANACEA-HF Phase 1. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 2629–2629.Link to Item
-
Laaksonen R, Hilvo M, Kauhanen D, Lakic TG, Lindback J, Held C, et al. Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 2243–2243.Link to Item
-
Nicolau JC, Brieger D, Goodman S, Cohen MG, Simon T, Westermann D, et al. Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 3353–3353.Link to Item
-
Rasmussen PV, Hansen ML, Gislason G, Pallisgaard J, Ruwald M, Granger CB, et al. Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 2978–2978.Link to Item
-
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, et al. Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 1222–1222.Link to Item
-
Zeitouni M, Giczewska A, Lopes RD, Wojdyla D, Christersson C, De Caterina R, et al. Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE. In: European Heart Journal. OXFORD UNIV PRESS; 2019. p. 2956–2956.Link to Item
-
Granger CB, Diener H-C, Sacco R, Easton J, Cronin L, Fräßdorf M, et al. MAJOR BLEEDING IN PATIENTS WITH EMBOLIC STROKE OF UNDETERMINED SOURCE TREATED WITH DABIGATRAN VERSUS ACETYLSALICYLIC ACID (RE-SPECT ESUS TRIAL). In: Journal of the American College of Cardiology. Elsevier BV; 2019. p. 1757–1757.Full Text
-
Kochar A, Wojdyla D, Thomas L, Alexander J, Rao S, Held C, et al. TRANSFUSIONS, WITH OR WITHOUT CONCOMITANT BLEEDING, ARE ASSOCIATED WITH HIGH SHORT-TERM MORTALITY IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ORAL ANTICOAGULATION. In: Journal of the American College of Cardiology. Elsevier BV; 2019. p. 399–399.Full Text
-
Pokorney S, House J, Granger CB, Hylek E, Alberts M, Anstrom K, et al. LOW RATES OF ORAL ANTICOAGULATION USE AND POOR OUTCOMES AMONG FRAIL PATIENTS HOSPITALIZED WITH ATRIAL FIBRILLATION. In: Journal of the American College of Cardiology. Elsevier BV; 2019. p. 323–323.Full Text
-
Shavadia J, Granger CB, Alemayehu W, Westerhout C, Povsic T, Brener S, et al. IDENTIFYING BIOMARKERS INDEPENDENTLY ASSOCIATED WITH SPONTANEOUS REPERFUSION IN ST ELEVATION MYOCARDIAL INFARCTION. In: Journal of the American College of Cardiology. Elsevier BV; 2019. p. 234–234.Full Text
-
Choi AY, Mulvihill MS, Lee H-J, Zhao C, Kuchibhatla M, Granger CB, et al. Heart Transplant Candidates Listed at Low First-Rank Organ Acceptance Rate Centers Are More Likely to Die Waiting. In: Circulation. 2019.Link to Item
-
Shavadia JS, Granger CB, Alemayehu WW, Westerhout CM, Van Diepen S, Povsic TJ, et al. High Throughput Targeted Proteomics Discovery Approach to Discover Novel Biomarkers Associated With St-segment Resolution After an St Elevation Myocardial Infarction. In: Circulation. 2019.Link to Item
-
Granger CB, Diener H-C, Sacco RL, Easton JD, Cronin L, Fraessdorf M, et al. Dabigatran vs. Acetylsalicylic Acid For Stroke Prevention In Patients With Embolic Stroke Of Undetermined Source (Re-spect Esus): Arrhythmia Monitoring And Outcomes. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2018. p. E768–E768.Link to Item
-
Diener HC, Sacco RL, Easton JD, Granger CB, Cronin L, Grauer C, et al. RE-SPECT ESUS: DABIGATRAN VERSUS ACETYLSALICYLIC ACID FOR STROKE PREVENTION IN PATIENTS WITH EMBOLIC STROKE OF UNDETERMINED SOURCE. In: International Journal of Stroke. SAGE PUBLICATIONS LTD; 2018. p. 27–27.Link to Item
-
Aulin J, Hijazi Z, Lindback J, Alexander JH, Gersh B, Granger CB, et al. Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2018. p. 196–196.Link to Item
-
Brieger D, Pocock SJ, Goodman SG, Westermann D, Blankenberg S, Nicolau JC, et al. Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study. In: European Heart Journal. OXFORD UNIV PRESS; 2018. p. 1083–4.Link to Item
-
Pokorney SD, Thomas KL, James B, Alberts MJ, Berger PB, Dorsch M, et al. Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation. In: European Heart Journal. OXFORD UNIV PRESS; 2018. p. 818–9.Link to Item
-
Rosjo HR, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, et al. Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2018. p. 897–897.Link to Item
-
Siegbahn A, Hijazi Z, Lindback J, Oldgren J, Pol T, Alexander JH, et al. Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2018. p. 1007–1007.Link to Item
-
Vinereanu D, Wojdyla DM, Alexander JH, Lopes RD, Gersh BJ, Al-Khatib SM, et al. Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE. In: European Heart Journal. OXFORD UNIV PRESS; 2018. p. 1231–1231.Link to Item
-
Al-Khatib SM, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, et al. Nsaid Use is Associated With Worse Outcomes but Similar Benefits of Apixaban Over Warfarin in Patients With Atrial Fibrillation: Results From the ARISTOTLE Trial. In: Circulation. 2018.Link to Item
-
Feng KY, Granger BB, Fonarow GC, Pina IL, Lewis EF, Cooper LB, et al. Strategies for Improving the Care of Patients Hospitalized With Heart Failure: Baseline Data From the CONNECT-HF Trial. In: Circulation. 2018.Link to Item
-
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Alings M, De Caterina R, et al. The Biomarker-Based ABC-Bleeding Risk Score Refines the Risk of Bleeding in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy. In: Circulation. 2018.Link to Item
-
Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, et al. GDF-15 is Associated With Major Bleeding and Death Independent of Geographic Regions in Patients With Atrial Fibrillation. In: Circulation. 2018.Link to Item
-
Tomasdottir M, Hadziosmanovic N, Held C, Aylward PE, Budaj A, Cannon CP, et al. Biomarkers Improve the Prediction of Incident Atrial Fibrillation in Patients With Stable Coronary Heart Disease. In: Circulation. 2018.Link to Item
-
Jollis JG, Al-Khalidi HR, Roettig ML, Monk L, Berger PB, Corbett C, et al. Regional STEMI Systems of Care: Results of the Mission: Lifeline STEMI ACCELERATOR-2 Study. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2017. p. E461–2.Link to Item
-
Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. In: Am J Med. 2017. p. 1440-1448.e1.Full Text Link to Item
-
Luo N, Xu H, Jneid H, Fonarow GC, Lopes RD, Granger CB, et al. High Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation Irrespective of Ejection Fraction: Insights From the AHA Get With The Guidelines- Atrial Fibrillation Program. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2017.Link to Item
-
Aulin J, Hijazi Z, Andersson U, Alexander JH, Gersh B, Granger CB, et al. Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 780–780.Link to Item
-
Guimaraes PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Wallentin L, et al. INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 576–576.Link to Item
-
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, et al. A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 1221–1221.Link to Item
-
Pol T, Hijazi Z, Alexander JH, Alings M, Erol C, Granger CB, et al. Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 760–1.Link to Item
-
Redfors B, Furer A, Selker HP, Thiele H, Patel MR, Udelson JE, et al. Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 997–997.Link to Item
-
Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, De Barros E Silva PGM, et al. Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 776–776.Link to Item
-
Guimaraes PO, Granger CB, Chiswell K, Stebbins A, Held C, Hochman JS, et al. Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial. In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 188–188.Link to Item
-
Vinereanu D, Al-Khalidi HR, Rao MP, Lopes RL, Bahit CM, Ciobanu AO, et al. Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF). In: European Heart Journal. OXFORD UNIV PRESS; 2017. p. 781–2.Link to Item
-
Hijazi Z, Sharma A, Andersson U, Alexander JH, Al-Khatib SM, Hanna M, et al. Biomarkers Predict Cause of Death More Accurately Than Clinical Variables in Patients With Atrial Fibrillation on Oral Anticoagulation Results From the ARISTOTLE Trial. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2016.Link to Item
-
Pokorney SD, Granger CB, Bloom D, Thomas KL, Al-Khatib SM, Anderson J, et al. Provider Rather Than Patient Misperceptions Appear to be the Most Common Barriers to Oral Anticoagulation Use for Stroke Prevention in Atrial Fibrillation. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2016.Link to Item
-
Pokorney SD, Granger CB, Bloom D, Thomas KL, Al-Khatib SM, Anderson J, et al. Provider Rather Than Patient Misperceptions Appear to be the Most Common Barriers to Oral Anticoagulation Use for Stroke Prevention in Atrial Fibrillation. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2016.Link to Item
-
Kragholm K, Lu D, Chiswell K, Al-Khalidi H, Roettig ML, Roe M, et al. Improvement in Care and Outcomes for Ambulance-Transported ST-Elevation Myocardial Infarction Patients With and Without Out-of-Hospital Cardiac Arrest: A Mission: Lifeline STEMI ACCELERATOR Study. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2016.Link to Item
-
Goodman SG, Nicolau JC, Requena G, Maguire A, Blankenberg S, Chen JY, et al. Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study. In: European Heart Journal. OXFORD UNIV PRESS; 2016. p. 30–30.Link to Item
-
Rao P, Alexander JH, Wojdyla D, Atar D, Hylek EM, Hanna M, et al. Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2016. p. 233–4.Link to Item
-
Wolsk E, Claggett B, Køber LV, Pocock S, Yusuf S, Swedberg K, et al. Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction. In: Journal of Cardiac Failure. Elsevier BV; 2016. p. S65–6.Full Text
-
Fordyce CB, Hansen CM, Kragholm K, Jollis JG, Roettig ML, Dupre ME, et al. STATEWIDE INITIATIVES IMPROVE THE CARE AND OUTCOMES OF PATIENTS WITH OUT-OF-HOSPITAL CARDIAC ARREST AT HOME AND IN PUBLIC LOCATIONS: RESULTS FROM THE HEARTRESCUE PROJECT. In: Journal of the American College of Cardiology. Elsevier BV; 2016. p. 806–806.Full Text
-
Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. In: Circulation. 2015. p. 624–32.Full Text Link to Item
-
Alexander J, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz J, et al. Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 345–345.Link to Item
-
Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, et al. Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 338–9.Link to Item
-
Hansen CM, Kragholm K, Pearson DA, Tyson C, Monk L, Nelson D, et al. Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 195–195.Link to Item
-
Hawkins NM, Jhund PS, Pozzi A, Solomon SD, Granger CB, Yusuf S, et al. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 340–340.Link to Item
-
Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Granger CB, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 339–339.Link to Item
-
Hijazi Z, Lindback J, Ostlund O, Siegbahn A, Alexander JH, Granger CB, et al. External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 710–1.Link to Item
-
Rordorf R, De Ferrari GM, Wojdyla D, De Caterina R, Thomas L, Granger CB, et al. Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 1068–1068.Link to Item
-
Wallentin LC, Lindback J, Held C, Granger CB, Koenig W, Stewart RAH, et al. Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy. In: European Heart Journal. OXFORD UNIV PRESS; 2015. p. 1041–2.Link to Item
-
Durheim MT, Cyr DD, Al-Khatib SM, Thomas LE, Lopes RD, Gersh BJ, et al. Chronic Obstructive Pulmonary Disease Is Associated With Increased Risk Of Mortality Among Patients With Atrial Fibrillation: Insights From The Aristotle Trial. In: American Journal of Respiratory and Critical Care Medicine. AMER THORACIC SOC; 2015.Link to Item
-
Sherwood MW, Al-Khalidi HR, Jollis JG, Roettig ML, Berger PB, Corbett CC, et al. Developing Regional STEMI Systems of Care: Final Results of the Mission: Lifeline STEMI ACCELERATOR Study. In: Circulation. 2014. p. 2111–2111.
-
Cowper PA, Sheng S, Anstrom KJ, Stafford JA, Lopes RD, Davidson-Ray L, et al. The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2014.Link to Item
-
Hansen CM, Jollis JG, Dupre M, McNally B, Monk L, Tyson C, et al. Improved Rates of Bystander and First Responder Intervention Are Associated with Improved Survival After Out-of-Hospital Cardiac Arrest Following Statewide Quality Improvement Initiative. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2014.Link to Item
-
Hansen CM, Jollis JG, Dupre M, McNally B, Monk L, Tyson C, et al. Early Defibrillation, Mainly by Bystanders and First Responders, Associated with Higher Survival in Statewide Data. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2014.Link to Item
-
Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, et al. Does Repeat Measurement of High Sensitivity Troponin I Improve Prediction of Cardiovascular Events in Atrial Fibrillation? In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2014.Link to Item
-
Rao MP, Dupre M, Hansen C, Milford-Beland S, Monk L, Tyson C, et al. Pre-Hospital Initiation of Therapeutic Hypothermia Associated With Better Survival and Neurologic Outcome in a Broad Population of Patients in North Carolina. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2014.Link to Item
-
Wallentin L, Hijazi Z, Andersson U, Lindahl B, Granger CB, Alexander JH, et al. Single Measurement of GDF-15 Provides Reliable Prognostication of Stroke and Major Bleeding in Atrial Fibrillation. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2014.Link to Item
-
Asberg S, Hijazi Z, Siegbahn A, Andersson U, Granger CB, Hanna M, et al. Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2014. p. 426–426.Link to Item
-
Christersson C, Wallentin L, Andersson U, Hylek EM, Husted S, De Caterina R, et al. The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment. In: European Heart Journal. OXFORD UNIV PRESS; 2014. p. 866–7.Link to Item
-
Hijazi Z, Lindback J, Siegbahn A, Alexander JH, Held C, Hanna M, et al. A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score. In: European Heart Journal. OXFORD UNIV PRESS; 2014. p. 357–357.Link to Item
-
Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. In: J Am Coll Cardiol. 2014. p. 52–61.Full Text Link to Item
-
Bagai A, Wang Y, Wang TY, Curtis J, Gurm HS, Peterson ED, et al. In-Hospital ADP Receptor Inhibitor Switching in Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry (R). In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2013.Link to Item
-
Granger CB, Bates ER, Jollis JG, Antman E, Nichol G, O’Connor RE, et al. Improving Care of ST Segment Elevation Myocardial Infarction in the United States 2008 to 2012: A Report From Mission: Lifeline. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2013.Link to Item
-
Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, et al. Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2013.Link to Item
-
Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit C, et al. Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex: Results From the ARISTOTLE Trial. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2013.Link to Item
-
Held C, Hylek EB, Alexander JH, Hanna M, Lopes RD, Wojdyla D, et al. Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2013. p. 99–99.Link to Item
-
Horowitz JD, De Caterina R, Heresztyn T, Andersson U, Lopes R, Hylek E, et al. ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy. In: European Heart Journal. OXFORD UNIV PRESS; 2013. p. 1040–1.Link to Item
-
Lopes RD, Garcia DA, Wojdyla D, Dorian P, Alexander JH, Wallentin L, et al. Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE. In: European Heart Journal. OXFORD UNIV PRESS; 2013. p. 98–9.Link to Item
-
Newby LK, Sarov-Blat L, Melloni C, Patel MR, Heitner JF, Hamm CW, et al. Safety and Efficacy of Losmapimod in Non-ST-Segment Elevation Acute Myocardial Infarction: Results of the SOLSTICE Phase 2 Randomized Trial. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2012. p. 2787–8.Link to Item
-
Christersson C, Schollin M, Alexander JH, Bersh BJ, Horowitz J, Hylek EM, et al. Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death. In: European Heart Journal. OXFORD UNIV PRESS; 2012. p. 969–969.Link to Item
-
Granger CB, Alexander JH, Hanna M, Wang J, Mohan P, Lawrence J, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2012. p. 685–6.Link to Item
-
McMurray JJV, Connolly SJ, Hart R, Flaker G, Lopes RD, Wang J, et al. Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis. In: European Heart Journal. OXFORD UNIV PRESS; 2012. p. 52–52.Link to Item
-
McMurray JJV, Lewis B, Ezekowitz J, Gersh B, Lopes RD, Wojdyla D, et al. Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial. In: European Heart Journal. OXFORD UNIV PRESS; 2012. p. 519–519.Link to Item
-
Siegbahn A, Christersson C, Schollin M, Alexander JH, Horowitz J, Hylek EM, et al. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy. In: European Heart Journal. OXFORD UNIV PRESS; 2012. p. 51–51.Link to Item
-
Wallentin LC, Christersson C, Siegbahn A, Schollin M, Alexander JH, Hanna M, et al. NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin. In: European Heart Journal. OXFORD UNIV PRESS; 2012. p. 51–51.Link to Item
-
Gupta DK, Castagno D, Granger CB, Yusuf S, Swedberg K, McMurray JJV, et al. Prognostic Impact of an Ischemic Etiology of Chronic Heart Failure across the Spectrum of Ejection Fractions in the CHARM Program. In: Journal of Cardiac Failure. Elsevier BV; 2012. p. S78–S78.Full Text
-
Brunner MP, Shah SH, Craig DM, Bain JR, Muehlbauer MJ, Newgard CB, et al. EFFECT OF HEPARIN ADMINISTRATION ON METABOLOMIC PROFILES FROM SAMPLES OBTAINED DURING CARDIAC CATHETERIZATION. In: Journal of the American College of Cardiology. Elsevier BV; 2011. p. E1147–E1147.Full Text
-
Truffa AA, Lopes RD, White KR, Mehta RH, Patel MR, Pieper KS, et al. SERIOUS INFECTIONS IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION TREATED WITH PRIMARY PCI ARE RARE, BUT ASSOCIATED WITH HIGHER MORTALITY. In: Journal of the American College of Cardiology. Elsevier BV; 2011. p. E980–E980.Full Text
-
Granger CB, Monk LM, Roettig ML, Al-Khalidi HR, Applegate RJ, Corbett CC, et al. State-Wide Care is Improved in the Reperfusion of Acute MI in Carolina Emergency Department Emergency Response (RACE-ER) Systems Improvement Program. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2010. p. 2223–4.Link to Item
-
Ezekowitz J, Armstrong PW, Granger CB, Theroux P, Stebbins A, Patel MR. Early Prediction of Left Ventricular Ejection Fraction 90 Days After STEMI Using NT-proBNP and Cardiac Magnetic Resonance Imaging. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S826–S826.Link to Item
-
Glaser R, Kaul P, Roberts R, Armstrong PW, Granger CB, Barden LG, et al. Women With ST Elevation Myocardial Infarction Treated With Primary PCI Have Worse Outcomes Than Men in the Modern Era: Results From the APEX-AMI Trial. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S936–S936.Link to Item
-
Glickman S, Cairns CB, Chen AY, Granger CB, Cannon CP, Fraulo ES, et al. Delays in Fibrinolytic Administration for Acute ST-Segment Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry (ACTION-GWTG). In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S423–S423.Link to Item
-
Katz JN, Echols MR, Wyman A, Gore JM, Peacock WF, Anderson FA, et al. African Americans Hospitalized With Acute, Severe Hypertension Receive Less Intense Treatment and Follow-up Than Peers: Results From the STAT Registry. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S421–S421.Link to Item
-
Mehta RH, Lopes RD, Stebbins A, Rao SV, Pieper KS, Califf RM, et al. Differences in Bleeding Rates Accounts for All of the Excess Mortality in African Americans Compared With Caucasians With ST-Elevation Myocardial Infarction treated With Fibrinolysis. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S522–3.Link to Item
-
Piccini JP, Schulte PJ, Pieper KS, Mehta RH, Topol EJ, White HD, et al. Antiarrhythmic Drug Therapy for Sustained Ventricular Arrhythmias Complicating Acute Myocardial Infarction. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S632–3.Link to Item
-
Newby LK, Shah SH, Sun J-L, Pieper K, Hauser ER, Kraus WE, et al. Red Cell Distribution Width (RDW) is a Strong Predictor of Outcome and is Weakly Associated With Clinical Variables in Patients at Risk for Cardiovascular Events. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S1174–S1174.Link to Item
-
Shah SH, Sun J-L, Pieper K, Crosslin DR, Haynes C, Bain JR, et al. Plasma Metabolomic Profiles Predict Future Cardiovascular Events. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2009. p. S466–7.Link to Item
-
Kim JH-J, Newby LK, Clare R, Shaw LK, Lodge A, Smith P, et al. Clopidogrel and CABG-related bleeding: Not as important as currently believed? In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. A223–4.Link to Item
-
Lopes RD, White HD, Hochman J, Horton JR, Van de Werf F, Ardissino D, et al. New onset atrial fibrillation following myocardial infarction is a strong independent predictor of mortality in patients treated with primary percutaneous coronary intervention. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. A11–2.Link to Item
-
Lopez-Sendon J, Gurfinkel EP, de Sa EL, Agnelli G, Gore JM, Steg PG, et al. Factors related to heart rupture in acute coronary syndromes. The global registry of acute coronary events. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. A245–6.Link to Item
-
Therou P, Armstrong PW, Moliterno DJ, Neumann F-J, Stebbins AL, Mahaffey KW, et al. Do selected markers of inflammatory response during the acute phase of ST-segment elevation myocardial infarction relate to outcome? In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. A185–A185.Link to Item
-
Wang TY, Honeycutt EF, Ohman EM, Moll S, Granger CB, Tapson VF. Incidence and management of acquired thrombocytopenia among patients receiving prolonged heparin venous thromboembolism prophylaxis: Insights from the complications after thrombocytopenia caused by heparin (CATCH) registry. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. A310–A310.Link to Item
-
Berger JS, Gallup D, Roe M, Armstrong PW, Simes RJ, White HD, et al. Sex-based differences in mortality following acute coronary syndromes. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. A194–A194.Link to Item
-
Berger JS, Gallup D, Roe M, Granger CB, Armstrong PW, Simes RJ, et al. Sex differences in clinical presentation and angiographic data in acute coronary syndromes. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2008. p. B55–6.Link to Item
-
Granger CB, Babb JD, Bohle DJ, Fletcher SM, Garvey JL, Hathaway WR, et al. The Reperfusion of Acute MI in Carolina Emergency Departments (RACE) systems improvement program: Primary results. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 2629–2629.Link to Item
-
Huber K, Aylward PE, Van’T Hof AW, Montalescot G, Holmes DR, Betriu GA, et al. Glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention of ST-elevation myocardial infarction improve perfusion and outcomes: Insights from APEX-AMI. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 673–673.Link to Item
-
Martel C, Theroux P, Labarthe B, Rivard J, Bonnefoy A, Granger CB, et al. The serum of pexelizumab-treated ST-Segment elevation MI patients reduces complement activation but not cell apoptosis. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 723–723.Link to Item
-
Allen LA, Felker GM, Pocock SJ, McMurray JJV, Pfeffer MA, Swedberg K, et al. Liver function test abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 44A-44A.Link to Item
-
Allen LA, Felker GM, Pocock SJ, Shaw LK, McMurray JJV, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: Data from the CHARM program and the duke databank. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 88A-88A.Link to Item
-
Berger JS, Stebbins A, Granger CB, Armstrong PW, Van de Werf F, White HD, et al. Initial aspirin dose for the treatment of ST elevation myocardial infarction. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 202A-202A.Link to Item
-
Frazier CG, Shah S, Nelson CL, Seo D, Hauser ER, Crosslin D, et al. Variants in genes associated with inflammation and vascular cell function are associated with vulnerable plaque. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 199A-199A.Link to Item
-
Hudson MP, Granger CB, O’Neill WW, Stebbins AL, Widimsky P, Aylward P, et al. Faster times to primary percutaneous coronary intervention are associated with better survival: Insights from the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infraction) trial. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 42B-43B.Link to Item
-
Jolicoeur ME, Ohman ME, Honeycutt EF, Mazon FJN, Beckerd RC, Crespo EM, et al. Bleeding is common among patients treated with heparin experiencing thrombocyllopenia and confers a high mortality risk: Report from the CATCH registry. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 340A-340A.Link to Item
-
O’Neill WW, Armstrong PW, Alkhalidi HR, Hamm CW, Holmes DR, Todaro TG, et al. Blood transfusion is independently associated with death in acute myocardial infarction: Insights from APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 36B-36B.Link to Item
-
Rao SV, Kaul P, Liao L, Mark DB, Eisenstein EL, Armstrong PW, et al. Bleeding complications are a major driver of resource use among patients with acute coronary syndromes. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 252A-252A.Link to Item
-
Roe MT, Grimes K, Bates E, Kleiman N, Bode C, Huber K, et al. Inhibition of 8 delta-protein kinase C to ameliorate reperfusion injury during primary percutaneous coronary intervention for acute ST-elevation myocardial infarction - Preliminary results from the DELTA MI trial. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 215A-215A.Link to Item
-
Widimsky P, Weaver WD, Van de Werf F, Neumann F-J, Ardissino D, Stebbins A, et al. Patients transferred for primary PCI in APEX-AMI (Assessment of pexelizumab in acute myocardial infarction) trial have only modest symptom onset to PCI delays and good outcomes. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 241A-241A.Link to Item
-
Shah SH, Hauser ER, Nelson C, Gregory S, Crosslin D, Haynes C, et al. ALOX5AP genetic variants are associated with in-stent restenosis after percutaneous coronary intervention. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 211A-211A.Link to Item
-
Shah SH, Nelson C, Stafford JA, Granger CB, Kraus WE, Hauser ER. Clinical predictors of presence of left main coronary artery disease on angiography in a large cohort. In: Journal of the American College of Cardiology. ELSEVIER SCIENCE INC; 2007. p. 218A-218A.Link to Item
-
Armstrong PW, Adams PX, Hamm CW, O’Neill WW, Vahanian AS, Granger CB, et al. Assessment of pexelizumab in acute myocardial infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2006. p. 2425–2425.Link to Item
-
Chang SM, Kosolcharoen P, Murray D, Pfeffer MA, Yusuf S, Swedberg K, et al. Lack of interaction between angiotensin receptor blocker and aspirin in patients with heart failure. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2006. p. 767–767.Link to Item
-
Wallentin LC, Mehta SR, Afzal R, Chrolavicius S, Granger CB, Budaj A, et al. Effects of fondaparinux in patients with ST-Segment elevation acute myocardial infarction non-eligible for reperfusion treatment. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2006. p. 699–700.Link to Item
-
Wang L, Hauser ER, Shah SH, Haynes C, Rose JM, Harris M, et al. Identification of kalirin gene as a novel coronary artery disease gene through peak-wide association mapping on chromosome 3q13-21. In: Circulation. LIPPINCOTT WILLIAMS & WILKINS; 2006. p. 887–887.Link to Item
-
Goldstein P, Wiel E, van de Werf F, Steg G, Armstrong P, Ross AM, et al. ASSENT-4 in "French" perspective. Outcomes of STEMI patients treated with pre-hospital thrombolysis in mobile intensive care units in France across trials and registries. In: American Journal of Cardiology. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC; 2006. p. 80M-80M.Link to Item
-
Granger CB, Wallentin L, Avezum A, Mehta S, Diaz R, Ruda M, et al. Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes. In: European Heart Journal. OXFORD UNIV PRESS; 2006. p. 448–448.Link to Item
-
-